

AC451	Multiple organ condyloma acuminatum tissue array, 45 cases 45 cores		331-Eur	US Biomax	tissue
AC451	Multiple organ condyloma acuminatum tissue array, 45 cases 45 cores; ihc Anti-Human Papilloma Virus (HPV) confirmed		210-Eur	US Biomax	tissue
AD2081	Adrenal gland disease spectrum (adrenal cancer progression) tissue array, 100 cases 200 cores		456-Eur	US Biomax	tissue
AD2081	Adrenal gland disease spectrum (adrenal cancer progression) tissue array, 100 cases 200 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
AG801	Adrenal tumor tissue array, 80 cases 80 cores		266-Eur	US Biomax	tissue
AG801	Adrenal tumor tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
AMS541	Mouse(FBV strain) normal tissue array, cover 22 organs anatomic sites, 3 cases 54 cores		225-Eur	US Biomax	tissue
AMS541	Mouse(FBV strain) normal tissue array, cover 22 organs anatomic sites, 3 cases 54 cores; ihc H&E		238-Eur	US Biomax	tissue
AMS542	Mouse(KM strain) normal tissue array, cover 22 organs anatomic sites, 3 cases 54 cores		225-Eur	US Biomax	tissue
AMS542	Mouse(KM strain) normal tissue array, cover 22 organs anatomic sites, 3 cases 54 cores; ihc H&E		238-Eur	US Biomax	tissue
AMS543	Skin squamous cell carcinoma (SCC) tissue array, 80 cases 80 cores, no overlaps with SK801; ihc Anti-Cytokeratin (High MW) confirmed		215-Eur	US Biomax	tissue
AMS544	Mouse normal tissue array, covering 22 organ anatomic sites, 3 cases 54 cores		225-Eur	US Biomax	tissue
AMS544	Mouse normal tissue array, covering 22 organ anatomic sites, 3 cases 54 cores; ihc H&E		238-Eur	US Biomax	tissue
ART661	Rat(Wistar strain) normal tissue array, covering all major organs, non-overlapping with ART662, 22 cases 66 cores		225-Eur	US Biomax	tissue
ART661	Rat(Wistar strain) normal tissue array, covering all major organs, non-overlapping with ART662, 22 cases 66 cores; ihc H&E, IHC anti-Vimentin Cytokeratin		238-Eur	US Biomax	tissue
ASM221	Cyno monkey normal tissue array, 22 cases 22 cores		225-Eur	US Biomax	tissue
ASM221	Cyno monkey normal tissue array, 22 cases 22 cores; ihc H&E, IHC anti-Vimentin Cytokeratin		238-Eur	US Biomax	tissue
BB01011	Gastric ulcer tissue array, 14 cases 24 cores		160-Eur	US Biomax	tissue
BB01011	Gastric ulcer tissue array, 14 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
BC000110	Colorectal cancer tissue array, 85 cases 170 cores		397-Eur	US Biomax	recombinant

BC000110	Colorectal cancer tissue array, 85 cases 170 cores; ihc Anti-Actin confirmed		382-Eur	US Biomax	recombinant
BC000111	Multiple organ cancer tissue array, 39 cases 39 cores		189-Eur	US Biomax	tissue
BC000111	Multiple organ cancer tissue array, 39 cases 39 cores; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
BC000119	Multi-organ carcinoma tissue array, including TNM, clinical stage and pathology grade, 200 cases 200 cores		456-Eur	US Biomax	tissue
BC000119	Multi-organ carcinoma tissue array, including TNM, clinical stage and pathology grade, 200 cases 200 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BC00012	Multiple organ diseased tissue array, 30 cases 60 cores, replaced by MC801		160-Eur	US Biomax	tissue
BC00012	Multiple organ diseased tissue array, 30 cases 60 cores, replaced by MC801; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
BC000120	Multi-organ carcinoma tissue array, including TNM, clinical stage and pathology grade, 200 cases 200 cores		456-Eur	US Biomax	tissue
BC000120	Multi-organ carcinoma tissue array, including TNM, clinical stage and pathology grade, 200 cases 200 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BC00014	Multiple organ diseased tissue array, 63 cases 63 cores, replaced by MC631		160-Eur	US Biomax	tissue
BC00014	Multiple organ diseased tissue array, 63 cases 63 cores, replaced by MC631; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
BC00016	Multiple organ diseased tissues, 54 cases 54 cores, replaced by MC541		160-Eur	US Biomax	tissue
BC00016	Multiple organ diseased tissues, 54 cases 54 cores, replaced by MC541; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
BC00019	Multiple organ squamous cell carcinoma tissue array, 63 cases 63 cores		231-Eur	US Biomax	tissue
BC00019	Multiple organ squamous cell carcinoma tissue array, 63 cases 63 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
BC00111	Multiple organ normal and diseased tissue array (replaced by MCN601), 54 cases 60 cores		231-Eur	US Biomax	tissue
BC00111	Multiple organ normal and diseased tissue array (replaced by MCN601), 54 cases 60 cores; ihc Anti-SMA confirmed		267-Eur	US Biomax	tissue
BC001111	Multiple organ normal and diseased tissue array, 58 cases 60 cores, replaced by MCN601		231-Eur	US Biomax	tissue

BC001111	Multiple organ normal and diseased tissue array, 58 cases 60 cores, replaced by MCN601; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
BC001113	Esophageal adenocarcinoma, cardia adenocarcinoma, normal esophageal and cardia tissue array, 50 cases 50 cores (previously cat# ES501)		189-Eur	US Biomax	tissue
BC001113	Esophageal adenocarcinoma, cardia adenocarcinoma, normal esophageal and cardia tissue array, 50 cases 50 cores (previously cat# ES501); ihc Anti-Cytokeratin (Low MW) confirmed Certified pathologist c		267-Eur	US Biomax	tissue
BC00112	Multiple organ paired normal and cancer (8 types) tissue array, 48 cases 48 cores		160-Eur	US Biomax	tissue
BC00112	Multiple organ paired normal and cancer (8 types) tissue array, 48 cases 48 cores; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
BC001128	Top five cancer tissue array, including TNM and pathology grade, 148 cases 175 cores		485-Eur	US Biomax	tissue
BC001128	Top five cancer tissue array, including TNM and pathology grade, 148 cases 175 cores		397-Eur	US Biomax	tissue
BC001128	Top five cancer tissue array, including TNM and pathology grade, 148 cases 175 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BC00113	Multiple organs tumor and normal tissue, 48 cases 48 cores		189-Eur	US Biomax	tissue
BC00113	Multiple organs tumor and normal tissue, 48 cases 48 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
BC001130	Pancreatic carcinoma and multi-organ adjacent tissue array, including TNM, clinical stage and pathology grade, 81 cases 121 cores		278-Eur	US Biomax	tissue
BC001130	Pancreatic carcinoma and multi-organ adjacent tissue array, including TNM, clinical stage and pathology grade, 81 cases 121 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BC001134	Multiple organs tumor and normal tissue array, including TNM, clinical stage and pathology grade, 150 cases 150 cores		397-Eur	US Biomax	tissue
BC001134	Multiple organs tumor and normal tissue array, including TNM, clinical stage and pathology grade, 150 cases 150 cores; ihc Anti-Actin confirmed		382-Eur	US Biomax	tissue
BC00114	Multiple organ normal and diseased tissue array, 36 cases 60 cores		231-Eur	US Biomax	tissue
BC00114	Multiple organ normal and diseased tissue array, 36 cases 60 cores; ihc Anti-PCNA confirmed		267-Eur	US Biomax	tissue
BC00115	Multiple organ normal and diseased tissue array, 44 cases 64 cores, replaced by MC802		231-Eur	US Biomax	tissue

BC00115	Multiple organ normal and diseased tissue array, 44 cases 64 cores, replaced by MC802; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
BC00116	Carcinoma with adjacent-tissue combined panel tissue array, 44 cases 48 cores		231-Eur	US Biomax	tissue
BC00116	Carcinoma with adjacent-tissue combined panel tissue array, 44 cases 48 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
BC00119	Multiple organ diseased tissue array, 32 cases 32 cores, replaced by MC483		160-Eur	US Biomax	tissue
BC00119	Multiple organ diseased tissue array, 32 cases 32 cores, replaced by MC483; ihc Anti-PCNA confirmed		185-Eur	US Biomax	tissue
BC00432	Multiple organ tumor and adjacent normal tissue array, 39 cases 43 cores		160-Eur	US Biomax	tissue
BC00432	Multiple organ tumor and adjacent normal tissue array, 39 cases 43 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BC01001	Tissue array of gastric diseases biopsied from gastroscop, including TNM, clinical stage and pathology grade, 18 cases 18 cores		231-Eur	US Biomax	tissue
BC01001	Tissue array of gastric diseases biopsied from gastroscop, including TNM, clinical stage and pathology grade, 18 cases 18 cores; ihc Anti-Cytokeratin (Low-MW) confirmed		267-Eur	US Biomax	tissue
BC01011	Stomach carcinoma (multi-tissue combined panel) tissue array, 24 cases 72 cores, replaced by ST721		160-Eur	US Biomax	tissue
BC01011	Stomach carcinoma (multi-tissue combined panel) tissue array, 24 cases 72 cores, replaced by ST721; ihc Anti-Cytokeratin (CK) confirmed		162-Eur	US Biomax	tissue
BC01014	Stomach carcinoma tissue array (multi-tissue combined panel), 71 cases 72 cores, replaced by ST807		231-Eur	US Biomax	tissue
BC01014	Stomach carcinoma tissue array (multi-tissue combined panel), 71 cases 72 cores, replaced by ST807; ihc CgA confirmed		267-Eur	US Biomax	tissue
BC01022	Stomach adenocarcinoma (combination of adjacent and normal) tissue array, 21 cases 63 cores		160-Eur	US Biomax	tissue
BC01022	Stomach adenocarcinoma (combination of adjacent and normal) tissue array, 21 cases 63 cores; ihc Anti-PCNA confirmed		185-Eur	US Biomax	tissue
BC01023	Stomach adenocarcinoma (combination of adjacent and normal) tissue array, 21 cases 63 cores		160-Eur	US Biomax	tissue
BC01023	Stomach adenocarcinoma (combination of adjacent and normal) tissue array, 21 cases 63 cores; ihc Anti-Cytokeratin (Low-MW) confirmed		185-Eur	US Biomax	tissue

BC01024	Stomach adenocarcinoma (combination of adjacent and normal) tissue array, 21 cases 63 cores		160-Eur	US Biomax	tissue
BC01024	Stomach adenocarcinoma (combination of adjacent and normal) tissue array, 21 cases 63 cores, replaced by ST722; ihc Anti-Cytokeratin (CK) confirmed		162-Eur	US Biomax	tissue
BC01071	Carcinoma of stomach, liver and rectum tissue array, 45 cases 48 cores		160-Eur	US Biomax	recombinant
BC01071	Carcinoma of stomach, liver and rectum tissue array, 45 cases 48 cores, replaced by BC01071a; ihc Anti-P53 confirmed		185-Eur	US Biomax	recombinant
BC01071a	Multiple organ cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases 48 cores, replacing BC01071; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BC01081	Adenocarcinoma of stomach, colon and rectum high density tissue array, 556 cases 616 cores		456-Eur	US Biomax	recombinant
BC01081	Adenocarcinoma of stomach, colon and rectum high density tissue array, 556 cases 616 cores; ihc Anti-EMA confirmed		487-Eur	US Biomax	recombinant
BC01114	Stomach adenocarcinoma with matched adjacent tissue and normal tissue array, including TNM, clinical stage and pathology grade, 55 cases 100 cores		231-Eur	US Biomax	tissue
BC01114	Stomach adenocarcinoma with matched adjacent tissue and normal tissue array, including TNM, clinical stage and pathology grade, 55 cases 100 cores, replaced by ST1004; ihc Anti-Cytokeratin (CK) confirmed		258-Eur	US Biomax	tissue
BC02011	Multiple esophageal cancer tissue array, 69 cases 72 cores		160-Eur	US Biomax	tissue
BC02011	Multiple esophageal cancer tissue array, 69 cases 72 cores; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
BC02012	Esophageal carcinoma (multi-tissue combined panel) tissue array, 72 cases 72 cores		160-Eur	US Biomax	tissue
BC02012	Esophageal carcinoma (multi-tissue combined panel) tissue array, 72 cases 72 cores; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
BC02013	Esophageal carcinoma (multi-tissue combined panel) tissue array, 72 cases 72 cores		160-Eur	US Biomax	tissue
BC02013	Esophageal carcinoma (multi-tissue combined panel) tissue array, 72 cases 72 cores; ihc Anti-Cytokeratin (Low-MW) confirmed		185-Eur	US Biomax	tissue

BC02021	Esophagus squamous carcinoma (combination of adjacent and normal) tissue array, 18 cases 54 cores		160-Eur	US Biomax	tissue
BC02021	Esophagus squamous carcinoma (combination of adjacent and normal) tissue array, 18 cases 54 cores; ihc Anti-H-CK confirmed		185-Eur	US Biomax	tissue
BC02022	Esophagus squamous cell carcinoma (combination of adjacent and normal) tissue array, 18 cases 54 cores		160-Eur	US Biomax	tissue
BC02022	Esophagus squamous cell carcinoma (combination of adjacent and normal) tissue array, 18 cases 54 cores; ihc Anti-H-CK confirmed		185-Eur	US Biomax	tissue
BC02023	Esophagus squamous cell carcinoma (combination of adjacent and normal) tissue array, 18 cases 54cores, replaced by ES722		160-Eur	US Biomax	tissue
BC02023	Esophagus squamous cell carcinoma (combination of adjacent and normal) tissue array, 18 cases 54cores, replaced by ES722 ; ihc Anti-H-CK confirmed		185-Eur	US Biomax	tissue
BC02111	Esophagus adenocarcinoma and normal tissue array, 23 cases 80 cores		189-Eur	US Biomax	tissue
BC02111	Esophageal adenocarcinoma tissue array with matched normal adjacent tissue, 21 cases 80 cores; ihc Anti-Cytokeratin (Low-MW) confirmed		185-Eur	US Biomax	tissue
BC03002	Liver disease spectrum tissue array, including TNM, clinical stage and pathology grade, 40 cases 80 cores		266-Eur	US Biomax	tissue
BC03002	Liver disease spectrum tissue array, including TNM, clinical stage and pathology grade, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BC03011	Liver carcinoma (multi-tissue combined panel) tissue array, 63 cases 63 cores, replaced by LV8010		160-Eur	US Biomax	tissue
BC03011	Liver carcinoma (multi-tissue combined panel) tissue array, 63 cases 63 cores, replaced by LV8010; ihc Anti-PCNA confirmed		185-Eur	US Biomax	tissue
BC03013	Liver carcinoma (multi-tissue combined panel) tissue array, 63 cases 63 cores, replaced by LV723		160-Eur	US Biomax	tissue
BC03013	Liver carcinoma (multi-tissue combined panel) tissue array, 63 cases 63 cores, replaced by LV723; ihc Anti-PCNA confirmed		185-Eur	US Biomax	tissue
BC03021	Liver carcinoma (combination of adjacent and normal) tissue array, 42 cases 63 cores, replaced by LV803		231-Eur	US Biomax	tissue
BC03021	Liver carcinoma (combination of adjacent and normal) tissue array, 42 cases 63 cores, replaced by LV803; ihc Anti-PCNA confirmed		267-Eur	US Biomax	tissue

BC03116	Liver carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 70 cases 70 cores		231-Eur	US Biomax	tissue
BC03116	Liver carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 70 cases 70 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
BC03118	Liver carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 100 cases 200 cores		456-Eur	US Biomax	tissue
BC03118	Liver carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 100 cases 200 cores; ihc Anti-Cytokeratin (CK) confirmed		487-Eur	US Biomax	tissue
BC03119	Liver carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 120 cases 120 cores		278-Eur	US Biomax	tissue
BC03119	Liver carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 120 cases 120 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BC04002	Lung disease spectrum tissue array, including TNM, clinical stage and pathology grade, 99 cases 100 cores		266-Eur	US Biomax	tissue
BC04002	Lung disease spectrum tissue array, including TNM, clinical stage and pathology grade, 99 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BC04011	Lung cancer tissue array, including pathology grade, 23 cases 63 cores, replaced by LC721; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
BC04012	Lung carcinoma (multi-tissue combined panel) tissue array, 68 cases 72 cores		160-Eur	US Biomax	tissue
BC04012	Lung carcinoma (multi-tissue combined panel) tissue array, 68 cases 72 cores, replaced by BC04016; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
BC04013	Non-small cell lung carcinoma tissue array, 63 cases 63 core, replaced by LC806		160-Eur	US Biomax	tissue
BC04013	Non-small cell lung carcinoma tissue array, 63 cases 63 core, replaced by LC806; ihc CK confirmed		185-Eur	US Biomax	tissue
BC04014	Non-small cell lung carcinoma (NSCLC) tissue array, 63 cases 63 cores, replaced by LC807		160-Eur	US Biomax	tissue
BC04014	Non-small cell lung carcinoma (NSCLC) tissue array, 63 cases 63 cores, replaced by LC807; ihc Anti-Cytokeratin (Low-MW) confirmed		185-Eur	US Biomax	tissue
BC04015	Lung carcinoma (multi-tissue combined panel) tissue array, 23 cases 63 cores		160-Eur	US Biomax	tissue

BC04015	Lung carcinoma (multi-tissue combined panel) tissue array, 23 cases 63 cores; ihc Anti-Cytokeratin (CK) confirmed		162-Eur	US Biomax	tissue
BC04016	Lung carcinoma tissue array, 72 cases 72 cores, replaced by LC726		160-Eur	US Biomax	tissue
BC04016	Lung carcinoma tissue array, 72 cases 72 cores, replaced by LC726; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
BC04021	Lung carcinoma (multi-tissue combined panel) tissue array, 72 cases 72 cores		160-Eur	US Biomax	tissue
BC04021	Lung carcinoma (multi-tissue combined panel) tissue array, 72 cases 72 cores; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
BC04022	Non-small cell lung carcinoma (NSCLC)(combination of adjacent and normal) tissue array, 18 cases 54 cores		160-Eur	US Biomax	tissue
BC04022	Non-small cell lung carcinoma (NSCLC)(combination of adjacent and normal) tissue array, 18 cases 54 cores; ihc Anti-H-CK confirmed		185-Eur	US Biomax	tissue
BC041114	Lung carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 100 cases 200 cores		456-Eur	US Biomax	tissue
BC041114	Lung carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 100 cases 200 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BC041115	Lung carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 120 cases 120 cores		278-Eur	US Biomax	tissue
BC041115	Lung carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 120 cases 120 cores, replaced by BC041115a; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BC041115a	Lung cancer tissue array with normal lung tissue, including TNM, clinical stage and pathology grade, 120 cases 120 cores, replacing BC041115; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BC04118	Lung squamous cell carcinoma and adjacent normal tissue array, including TNM, clinical stage and pathology grade, 50 cases 100 cores		231-Eur	US Biomax	tissue
BC04118	Lung squamous cell carcinoma and adjacent normal tissue array, including TNM, clinical stage and pathology grade, 50 cases 100 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
BC04119	Lung adenocarcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 30 cases 40 cores, replaced by BC04119b		231-Eur	US Biomax	tissue

BC04119	Lung adenocarcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 30 cases 40 cores, replaced by BC04119b; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BC04119b	Lung adenocarcinoma tissue array with normal lung tissue, including TNM and pathology grade,30 cases 40 cores, replacing BC04119		336-Eur	US Biomax	tissue
BC04119b	Lung adenocarcinoma tissue array with normal lung tissue, including TNM and pathology grade,30 cases 40 cores, replacing BC04119		278-Eur	US Biomax	tissue
BC04119b	Lung adenocarcinoma tissue array with normal lung tissue, including TNM and pathology grade,30 cases 40 cores, replacing BC04119; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BC05002	Colon disease spectrum tissue array, including TNM, clinical stage and pathology grade, 79 cases 80 cores		266-Eur	US Biomax	tissue
BC05002	Colon disease spectrum tissue array, including TNM, clinical stage and pathology grade, 79 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BC05011	Multiple types of colon carcinoma tissue array, 72 cases 72 cores, replaced by CO804		231-Eur	US Biomax	tissue
BC05011	Multiple types of colon carcinoma tissue array, 72 cases 72 cores, replaced by CO804; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
BC050112	Colon metastatic carcinoma tissue array, 23 cases 63 cores, replaced by CO726		231-Eur	US Biomax	tissue
BC050112	Colon metastatic carcinoma tissue array, 23 cases 63 cores, replaced by CO726; ihc Anti-Cytokeratin (Low-MW) confirmed		267-Eur	US Biomax	tissue
BC05012	Colon carcinoma (multi-tissue combined panel) tissue array, 70 cases 72 cores.		231-Eur	US Biomax	tissue
BC05012	Colon carcinoma (multi-tissue combined panel) tissue array, 70 cases 72 cores.; ihc Anti-Cytokeratin (Low-MW) confirmed		267-Eur	US Biomax	tissue
BC05021	Colon adenocarcinoma (combination of adjacent and adjacent normal) tissue array, 18 cases 54 cores, no overlapping with BC05022, replaced by CO722		231-Eur	US Biomax	tissue
BC05021	Colon adenocarcinoma (combination of adjacent and adjacent normal) tissue array, 18 cases 54 cores, no overlapping with BC05022, replaced by CO722; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
BC05022	Colon adenocarcinoma (combination of adjacent and normal) tissue array, 18 cases 54 cores, no overlapping with BC05021		231-Eur	US Biomax	tissue

BC05022	Colon adenocarcinoma (combination of adjacent and normal) tissue array, 18 cases 54 cores, no overlapping with BC05021; ihc Anti-Cytokeratin (Low-MW) confirmed		267-Eur	US Biomax	tissue
BC05023	Colon adenocarcinoma (combination of adjacent and normal) tissue array, with grade and stage (TNM) info, 18 cases 54 cores		231-Eur	US Biomax	tissue
BC05023	Colon adenocarcinoma (combination of adjacent and normal) tissue array, with grade and stage (TNM) info, 18 cases 54 cores; ihc Anti-Epithelial Membrane Antigen (EMA) confirmed		267-Eur	US Biomax	tissue
BC051110	Colon cancer and normal tissue array, including TNM, clinical stage and pathology grade, 120 cases 120 cores		278-Eur	US Biomax	tissue
BC051110	Colon cancer and normal tissue array, including TNM, clinical stage and pathology grade, 120 cases 120 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BC051111	Colon cancer and normal tissue array, including TNM, clinical stage and pathology grade, 100 cases 200 cores		456-Eur	US Biomax	tissue
BC051111	Colon cancer and normal tissue array, including TNM, clinical stage and pathology grade, 100 cases 200 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BC05115	Colon cancer, metastasize to lymph node and liver, and normal tissue array, including TNM, clinical stage and pathology grade, 68 cases 69 cores, replaced by CO702		231-Eur	US Biomax	tissue
BC05115	Colon cancer, metastasize to lymph node and liver, and normal tissue array, including TNM, clinical stage and pathology grade, 68 cases 69 cores, replaced by CO702; ihc Anti-Cytokeratin (Low-MW) conf		258-Eur	US Biomax	tissue
BC05118	Colon cancer and matched adjacent normal tissue array, including TNM, clinical stage and pathology grade, 50 cases 100 cores		266-Eur	US Biomax	tissue
BC05118	Colon cancer and matched adjacent normal tissue array, including TNM, clinical stage and pathology grade, 50 cases 100 cores, replaced by BC05118a; ihc Anti-actin confirmed Certified pathologist code		296-Eur	US Biomax	tissue
BC05118a	Colon cancer tissue array with matched adjacent normal colon tissue, including TNM, clinical stage and pathology grade, 50 cases 100 cores, replacing BC05118; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BC06002	Rectum disease spectrum (rectum cancer progression) tissue array, including TNM and pathology grade, 63 cases 72 cores		321-Eur	US Biomax	recombinant

BC06002	Rectum disease spectrum (rectum cancer progression) tissue array, including TNM and pathology grade, 63 cases 72 cores		266-Eur	US Biomax	recombinant
BC06002	Rectum disease spectrum (rectum cancer progression) tissue array, including TNM and pathology grade, 63 cases 72 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	recombinant
BC06011	Rectum carcinoma (multi-tissue combined panel) tissue array, 71 cases 72 cores		160-Eur	US Biomax	recombinant
BC06011	Rectum carcinoma (multi-tissue combined panel) tissue array, 71 cases 72 cores; ihc Anti-CEA confirmed		185-Eur	US Biomax	recombinant
BC06022	Rectum carcinoma (combination of adjacent and normal) tissue array, 18 cases 54 cores, replaced by RE722		160-Eur	US Biomax	recombinant
BC06022	Rectum carcinoma (combination of adjacent and normal) tissue array, 18 cases 54 cores, replaced by RE722; ihc Anti-Cytokeratin (Low-MW) confirmed		185-Eur	US Biomax	recombinant
BC07001	Kidney disease spectrum (kidney cancer progression) tissue array, including TNM and pathology grade, 40 cases 80 cores		321-Eur	US Biomax	tissue
BC07001	Kidney disease spectrum (kidney cancer progression) tissue array, including TNM and pathology grade, 40 cases 80 cores		266-Eur	US Biomax	tissue
BC07001	Kidney disease spectrum (kidney cancer progression) tissue array, including TNM and pathology grade, 40 cases 80 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
BC07011	Kidney carcinoma (multi-tissue combined panel) tissue array, 23 cases 63 cores, replaced by BC07013		160-Eur	US Biomax	tissue
BC07011	Kidney carcinoma (multi-tissue combined panel) tissue array, 23 cases 63 cores, replaced by BC07013; ihc Anti-EMA confirmed		185-Eur	US Biomax	tissue
BC07012	Kidney carcinoma (multi-tissue combined panel) tissue array, 72 cases 72 cores, replaced by BC07015		160-Eur	US Biomax	tissue
BC07012	Kidney carcinoma (multi-tissue combined panel) tissue array, 72 cases 72 cores, replaced by BC07015; ihc Anti-EMA confirmed		185-Eur	US Biomax	tissue
BC07013	Kidney carcinoma (multi-tissue combined panel) tissue array, 23 cases 63 cores, replacing BC07011		160-Eur	US Biomax	tissue
BC07013	Kidney carcinoma (multi-tissue combined panel) tissue array, 23 cases 63 cores, replacing BC07011; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue

BC07014	Kidney carcinoma (multi-tissue combined panel) tissue array, 72 cases 72 cores		160-Eur	US Biomax	tissue
BC07014	Kidney carcinoma (multi-tissue combined panel) tissue array, 72 cases 72 cores; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
BC07014a	Kidney cancer tissue array, including TNM, clinical stage and pathology grade, 72 cases 72 cores, replacing BC07014; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BC07015	Multiple type kidney cancer tissue array with normal tissues, 71 cases 72 cores, replacing BC07012		231-Eur	US Biomax	tissue
BC07015	Multiple type kidney cancer tissue array with normal tissues, 71 cases 72 cores, replacing BC07012; ihc Anti-Cytokeratin (High MW) confirmed		267-Eur	US Biomax	tissue
BC07114	Kidney clear cell carcinoma tissue array, including TNM and pathology grade, 100 cases 200 cores		558-Eur	US Biomax	tissue
BC07114	Kidney clear cell carcinoma tissue array, including TNM and pathology grade, 100 cases 200 cores		456-Eur	US Biomax	tissue
BC07114	Kidney clear cell carcinoma tissue array, including TNM and pathology grade, 100 cases 200 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BC07115	Kidney clear cell carcinoma tissue array, including TNM and pathology grade, 120 cases 120 cores		321-Eur	US Biomax	tissue
BC07115	Kidney clear cell carcinoma tissue array, including TNM and pathology grade, 120 cases 120 cores		266-Eur	US Biomax	tissue
BC07115	Kidney clear cell carcinoma tissue array, including TNM and pathology grade, 120 cases 120 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BC08013	Breast carcinoma (multi-tissue combined panel) tissue array, 63 cases 63 cores, replaced by BC08014		160-Eur	US Biomax	tissue
BC08013	Breast carcinoma (multi-tissue combined panel) tissue array, 63 cases 63 cores, replaced by BC08014; ihc Anti-ER confirmed		185-Eur	US Biomax	tissue
BC08014	Breast cancer (multiple types of breast cancer) tissue array, 63 cases 63 cores, replaced by BR8018		160-Eur	US Biomax	tissue
BC08014	Breast cancer (multiple types of breast cancer) tissue array, 63 cases 63 cores, replaced by BR8018; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BC08015	Breast carcinoma (multi-tissue combined panel) tissue array, 22 cases 63 cores, replaced by BR728		160-Eur	US Biomax	tissue
BC08015	Breast carcinoma (multi-tissue combined panel) tissue array, 22 cases 63 cores, replaced by BR728; ihc Anti-PCNA confirmed		185-Eur	US Biomax	tissue
BC08016	Breast carcinoma (multi-tissue combined panel) tissue array, 63 cases 63 cores, replaced by BR803		160-Eur	US Biomax	tissue

BC08016	Breast carcinoma (multi-tissue combined panel) tissue array, 63 cases 63 cores, replaced by BR803; ihc Anti-Cytokeratin (Low-MW) confirmed		185-Eur	US Biomax	tissue
BC08022	Breast carcinoma (combination of adjacent and normal) tissue array, 53 cases 63 cores, replacing BN08021		160-Eur	US Biomax	tissue
BC08022	Breast carcinoma (combination of adjacent and normal) tissue array, 53 cases 63 cores, replacing BN08021; ihc Anti-ER confirmed		185-Eur	US Biomax	tissue
BC08023	Breast carcinoma (combination of adjacent and normal) tissue array, 57 cases 63 cores		231-Eur	US Biomax	tissue
BC08023	Breast carcinoma (combination of adjacent and normal) tissue array, 57 cases 63 cores; ihc Anti-Cytokeratin (Low-MW) confirmed		267-Eur	US Biomax	tissue
BC08032	Infiltrating duct carcinoma (combination of adjacent and normal) tissue array, 57 cases 63 cores		231-Eur	US Biomax	tissue
BC08032	Infiltrating duct carcinoma (combination of adjacent and normal) tissue array, 57 cases 63 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
BC081115	Breast cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 110 cases 110 cores, replaced by BC081120		278-Eur	US Biomax	tissue
BC081115	Breast cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 110 cases 110 cores, replaced by BC081120; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BC081116	Breast cancer (IDC) tissue array, with adjacent normal tissue, including TNM and pathology grade, 110 cases 110 cores		278-Eur	US Biomax	tissue
BC081116	Breast cancer (IDC) tissue array, with adjacent normal tissue, including TNM and pathology grade, 110 cases 110 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BC081120	Breast cancer and adjacent normal tissue array, including TNM and pathology grade, 110 cases 110 cores, replacing BC081115		266-Eur	US Biomax	tissue
BC081120	Breast cancer and adjacent normal tissue array, including TNM and pathology grade, 110 cases 110 cores, replacing BC081115; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BC08118	Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 100 cases 100 cores		321-Eur	US Biomax	tissue
BC08118	Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 100 cases 100 cores		266-Eur	US Biomax	tissue

BC08118	Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 100 cases 100 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
BC09012	Endometrial carcinoma (multi-tissue combined panel) tissue array, 63 cases 63 cores		231-Eur	US Biomax	tissue
BC09012	Endometrial carcinoma (multi-tissue combined panel) tissue array, 63 cases 63 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
BC10021	Cervix carcinoma (combination of margin and normal tissues) tissue array, 64 cases 72 cores		231-Eur	US Biomax	tissue
BC10021	Cervix carcinoma (combination of margin and normal tissues) tissue array, 64 cases 72 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
BC10025	Cervical cancer and normal tissue array, 54 cases 54 cores		231-Eur	US Biomax	tissue
BC10025	Cervical cancer and normal tissue array, 54 cases 54 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BC11011	Ovarian carcinoma (multi-tissue combined panel) tissue array (replaced by OV802), 70 cases 72 cores		160-Eur	US Biomax	tissue
BC11011	Ovarian carcinoma (multi-tissue combined panel) tissue array (replaced by OV802), 70 cases 72 cores; ihc Anti-EMA confirmed		185-Eur	US Biomax	tissue
BC110118	Ovarian cancer tissue array, including TNM and pathology grade, 72 cases 72 cores, replacing BC11012		231-Eur	US Biomax	tissue
BC110118	Ovarian cancer tissue array, including TNM and pathology grade, 72 cases 72 cores, replacing BC11012; ihc Anti-Actin confirmed		228-Eur	US Biomax	tissue
BC11012	Ovarian carcinoma (multi-tissue combined panel) tissue array, 70 cases 72 cores		160-Eur	US Biomax	tissue
BC11012	Ovarian carcinoma (multi-tissue combined panel) tissue array, 70 cases 72 cores, replaced by BC11012a; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
BC11012a	Ovary cancer tissue array, including TNM, clinical stage and pathology grade, 72 cases 72 cores, replacing BC11012; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BC111109	Ovary cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 70 cases 70 cores		231-Eur	US Biomax	tissue
BC111109	Ovary cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 70 cases 70 cores; ihc Anti-Actin confirmed		228-Eur	US Biomax	tissue
BC111110	Ovary cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 70 cases 70 cores		231-Eur	US Biomax	tissue

BC111110	Ovary cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 70 cases 70 cores, replaced by OV701; ihc Anti-Actin confirmed		228-Eur	US Biomax	tissue
BC11115	Ovary serous papillary adenocarcinoma, lymph node metastasis with adjacent normal ovary tissue array, including TNM and pathology grade, 100 cases 100 cores		321-Eur	US Biomax	tissue
BC11115	Ovary serous papillary adenocarcinoma, lymph node metastasis with adjacent normal ovary tissue array, including TNM and pathology grade, 100 cases 100 cores		266-Eur	US Biomax	tissue
BC11115	Ovary serous papillary adenocarcinoma, lymph node metastasis with adjacent normal ovary tissue array, including TNM and pathology grade, 100 cases 100 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
BC12011a	Bladder cancer tissue array, including TNM, clinical stage and pathology grade, 63 cases 63 cores, replacing BC12011; ihc Anti-Actin confirmed		162-Eur	US Biomax	tissue
BC12012	Bladder carcinoma (multi-tissue combined panel) tissue array, 63 cases 63 cores, replaced by BL802		231-Eur	US Biomax	tissue
BC12012	Bladder carcinoma (multi-tissue combined panel) tissue array, 63 cases 63 cores, replaced by BL802; ihc Anti-PCNA confirmed		267-Eur	US Biomax	tissue
BC14012	Pancreatic cancer (multi-tissue combined panel), 24 cases 63 cores, replaced by PA721		231-Eur	US Biomax	tissue
BC14012	Pancreatic cancer (multi-tissue combined panel), 24 cases 63 cores, replaced by PA721; ihc Anti-Cytokeration (CK) confirmed		267-Eur	US Biomax	tissue
BC15012	Thyroid carcinoma (multi-tissue combined panel) tissue array, 23 cases 63 cores		231-Eur	US Biomax	tissue
BC15012	Thyroid carcinoma (multi-tissue combined panel) tissue array, 23 cases 63 cores; ihc Anti-Thyroglobulin (TG) antibody confirmed		267-Eur	US Biomax	tissue
BC17012	Medulloblastoma of brain tissue array, 100 cases 100 cores		277-Eur	US Biomax	tissue
BC17012	Medulloblastoma of brain tissue array, 100 cases 100 cores		231-Eur	US Biomax	tissue
BC17012	Medulloblastoma of brain tissue array, 20 cases 60 cores; ihc Anti-Actin confirmed		228-Eur	US Biomax	tissue
BC17013	Brain astrocytoma and meningioma tissue array, 120 cases 120 cores		321-Eur	US Biomax	tissue
BC17013	Brain astrocytoma and meningioma tissue array, 120 cases 120 cores		266-Eur	US Biomax	tissue
BC17013	Brain astrocytoma and meningioma tissue array, 120 cases 120 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue

BC19012	Prostate carcinoma (multi-tissue combined panel) tissue array, 33 cases 63 cores, replaced by PR808		231-Eur	US Biomax	tissue
BC19012	Prostate carcinoma (multi-tissue combined panel) tissue array, 33 cases 63 cores, replaced by PR808; ihc Anti-PCNA confirmed		267-Eur	US Biomax	tissue
BC19013	Prostate carcinoma (multi-tissue combined panel) tissue array, 33 cases 63 cores		231-Eur	US Biomax	tissue
BC19013	Prostate carcinoma (multi-tissue combined panel) tissue array, 33 cases 63 cores; ihc Anti-PCNA confirmed		267-Eur	US Biomax	tissue
BC19014	Prostate carcinoma tissue array, 31 cases 63 cores		231-Eur	US Biomax	tissue
BC19014	Prostate carcinoma tissue array, 31 cases 63 cores; ihc Anti-PTEN confirmed		267-Eur	US Biomax	tissue
BC19015	Prostate carcinoma tissue array, 9 cases 27 cores		160-Eur	US Biomax	tissue
BC19015	Prostate carcinoma tissue array, 9 cases 27 cores; ihc Anti-PCNA confirmed		185-Eur	US Biomax	tissue
BC19017	Prostate carcinoma tissue array, 33 cases 63 cores, replaced by PR809		160-Eur	US Biomax	tissue
BC19017	Prostate carcinoma tissue array, 33 cases 63 cores, replaced by PR809; ihc Anti-PCNA confirmed		267-Eur	US Biomax	tissue
BC19019	Prostate cancer and hyperplasia tissue array, 33 cases 63 cores, replacing BC19011		231-Eur	US Biomax	tissue
BC19019	Prostate cancer and hyperplasia tissue array, 33 cases 63 cores, replacing BC19011; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BC19021	Prostate cancer, adjacent normal tissue and normal tissue array, including TNM, clinical stage and pathology grade, 20 cases 72 cores		266-Eur	US Biomax	tissue
BC19021	Prostate cancer, adjacent normal tissue and normal tissue array, including TNM, clinical stage and pathology grade, 20 cases 72 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BC19111	Normal prostate tissue array, with prostate tumor and hyperplasia, 11 cases 30 cores		160-Eur	US Biomax	tissue
BC19111	Normal prostate tissue array, with prostate tumor and hyperplasia, 11 cases 30 cores; ihc Anti-PCNA confirmed		267-Eur	US Biomax	tissue
BC21011	Skin malignant tumor tissue array, 78 cases 78 cores (squamous carcinoma, adenocarcinoma, basal cell carcinoma, sarcoma, melanoma), replaced by BC21014		231-Eur	US Biomax	tissue
BC21011	Skin malignant tumor tissue array, 78 cases 78 cores (squamous carcinoma, adenocarcinoma, basal cell carcinoma, sarcoma, melanoma), replaced by BC21014; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue

BC21014	Skin malignant tumor tissue array, 78 cases 78 cores, replacing BC21011		231-Eur	US Biomax	tissue
BC21014	Skin malignant tumor tissue array, 78 cases 78 cores, replacing BC21011; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BC23011	Testis tumor combination, 24 cases 72 cores		231-Eur	US Biomax	assays
BC23011	Testis tumor combination, 24 cases 72 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	assays
BC23012	Testis tumor tissue array, 23 cases 63 cores		231-Eur	US Biomax	assays
BC23012	Testis tumor tissue array, 23 cases 63 cores; ihc Anti-LCA confirmed		267-Eur	US Biomax	assays
BC24011	Soft tissue tumor (multi-tissue combined panel) tissue array, 63 cases 63 cores		231-Eur	US Biomax	tissue
BC24011	Soft tissue tumor (multi-tissue combined panel) tissue array, 63 cases 63 cores; ihc Anti-PCNA confirmed		267-Eur	US Biomax	tissue
BC24021	Leiomyosarcoma and Rhabdomyosarcoma tissue array with normal muscles controls, 39 cases 75 cores		231-Eur	US Biomax	tissue
BC24021	Leiomyosarcoma and Rhabdomyosarcoma tissue array with normal muscles controls, 39 cases 75 cores, replaced by SO751; ihc Anti-Des confirmed		267-Eur	US Biomax	tissue
BC27011	Multiple organs, diseased tissue array of oral cavity, 47 cases 48 cores		189-Eur	US Biomax	tissue
BC27011	Multiple organs, diseased tissue array of oral cavity, 47 cases 48 cores; ihc Anti-H-CK confirmed		185-Eur	US Biomax	tissue
BC30011	Heart tissue array, 13 cases 34 cores, replaced by BC30013		231-Eur	US Biomax	tissue
BC30011	Heart tissue array, 13 cases 34 cores, replaced by BC30013; ihc Anti-Vimentin (Vim) confirmed		267-Eur	US Biomax	tissue
BC30013	Heart disease and normal tissue array, replacing BC30011, 18 cases 36 cores		231-Eur	US Biomax	tissue
BC30013	Heart disease and normal tissue array, replacing BC30011, 18 cases 36 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BC34011	Head and neck squamous cell carcinoma tissue array, 24 cases 63 cores		160-Eur	US Biomax	tissue
BC34011	Head and neck squamous cell carcinoma tissue array, 24 cases 63 cores; ihc Anti-H-CK confirmed		185-Eur	US Biomax	tissue
BC34111	Multiple head and neck squamous cell carcinoma tissue array with normal tissue, 36 cases 72 cores, replaced by HN811		160-Eur	US Biomax	tissue
BC34111	Multiple head and neck squamous cell carcinoma tissue array with normal tissue, 36 cases 72 cores, replaced by HN811; ihc Anti-H-CK confirmed		228-Eur	US Biomax	tissue
BC35111	Retinoblastoma and normal adjacent tissue array, 17 cases 34 cores		189-Eur	US Biomax	tissue

BC35111	Retinoblastoma and normal adjacent tissue array, 17 cases 34 cores; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
BCN721	Multiple cancer (12 common types) tissue array with unmatched normal adjacent tissue, 71 cases 72 cores		231-Eur	US Biomax	tissue
BCN721	Multiple cancer (12 common types) tissue array with unmatched normal adjacent tissue, 71 cases 72 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
BCN801	Multiple organ cancer with adjacent tissue combined panel tissue array, 48 cases 80 cores		231-Eur	US Biomax	tissue
BCN801	Multiple organ cancer with adjacent tissue combined panel tissue array, 48 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
BCN961	Multiple organ cancer tissue array with adjacent cancer tissue control tissue array, 57 cases 96 cores, replaced by BCN963		231-Eur	US Biomax	elisa
BCN961	Multiple organ cancer tissue array with adjacent cancer tissue control tissue array, 57 cases 96 cores, replaced by BCN963; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	elisa
BCN962	Combined multiple normal and cancer tissue array, containing germline, embryonic tumors and normal adjacent tissue, 60 cases 96 cores		231-Eur	US Biomax	elisa
BCN962	Combined multiple normal and cancer tissue array, containing germline, embryonic tumors and normal adjacent tissue, 60 cases 96 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	elisa
BCN963	Multiple organ cancer and adjacent normal tissue array, including TNM and pathology grade, 78 cases 96 cores, replacing BCN961		266-Eur	US Biomax	elisa
BCN963	Multiple organ cancer and adjacent normal tissue array, including TNM and pathology grade, 78 cases 96 cores, replaced by BCN963a; ihc Anti-Actin confirmed		258-Eur	US Biomax	elisa
BCN963a	Multiple organ tumor and adjacent normal tissue array, including TNM, clinical stage and pathology grade, 81 cases 96 cores, replacing BCN963; ihc Anti-Actin confirmed		258-Eur	US Biomax	elisa
BE01014	Multiple organ, normal fetus tissue array, 26 cases 78 cores		189-Eur	US Biomax	tissue
BE01014	Multiple organ, normal fetus tissue array, 26 cases 78 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BE01015	Multiple organ, normal fetus tissue array, 50 cases 50 cores		189-Eur	US Biomax	tissue
BE01015	Multiple organ, normal fetus tissue array, 50 cases 50 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue

BL1001	Bladder cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases 100 cores		266-Eur	US Biomax	tissue
BL1001	Bladder cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BL1002	Bladder cancer and normal tissue array, including TNM and pathology grade, 50 cases 100 cores		266-Eur	US Biomax	tissue
BL1002	Bladder cancer and normal tissue array, including TNM and pathology grade, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BL1501	Bladder cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
BL1921	Mid-advanced stage bladder cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores		456-Eur	US Biomax	elisa
BL1921	Mid-advanced stage bladder cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	elisa
BL208	Tissue microarray of bladder cancer and normal tissue, high density (69 cases 208 cores) with grade and stage data		456-Eur	US Biomax	tissue
BL208	Tissue microarray of bladder cancer and normal tissue, high density (69 cases 208 cores) with grade and stage data; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BL2081	Bladder cancer high density tissue array, 203 cases 208 cores		456-Eur	US Biomax	tissue
BL2081	Bladder cancer high density tissue array, 203 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BL2082	Bladder disease spectrum (bladder cancer progression) tissue array, 202 cases 208 cores		456-Eur	US Biomax	tissue
BL2082	Bladder disease spectrum (bladder cancer progression) tissue array, 202 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BL241	Bladder cancer tissue array with self-matching normal adjacent tissues, 10 cases 24 cores		88-Eur	US Biomax	tissue
BL241	Bladder cancer tissue array with self-matching normal adjacent tissues, 10 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	tissue
BL242	Bladder cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases 48 cores		189-Eur	US Biomax	tissue
BL242	Bladder cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases 48 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue

BL243	Bladder cancer tissue array with normal tissues from autopsy, 12 cases 24 cores with stage and grade data		100-Eur	US Biomax	tissue
BL243	Bladder cancer tissue array with normal tissues from autopsy, 12 cases 24 cores with stage and grade data; ihc Anti-Actin confirmed		114-Eur	US Biomax	tissue
BL244	Bladder cancer tissue array with matched adjacent bladder tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
BL481	Bladder cancer tissue array with unmatched normal adjacent tissues, 48 cases 48 cores, with stage and grade data		189-Eur	US Biomax	tissue
BL481	Bladder cancer tissue array with unmatched normal adjacent tissues, 48 cases 48 cores, with stage and grade data; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
BL482	Bladder cancer tissue array, including TNM and pathology grade, 48 cases 48 cores		189-Eur	US Biomax	tissue
BL482	Bladder cancer tissue array, including TNM and pathology grade, 48 cases 48 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BL801	Bladder cancer tissue array, with adjacent normal tissue, pathology grade and TNM stage, 53 cases 80 cores, replaced by BL806		266-Eur	US Biomax	tissue
BL801	Bladder cancer tissue array, with adjacent normal tissue, pathology grade and TNM stage, 53 cases 80 cores, replaced by BL806; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
BL802	Bladder cancer tissue array with normal tissue, 80 cases 80 cores, replacing BC12012		266-Eur	US Biomax	tissue
BL802	Bladder cancer tissue array with normal tissue, 80 cases 80 cores, replacing BC12012; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BL803	Bladder cancer and normal tissue array with TNM and grade data, 40 cases 80 cores		266-Eur	US Biomax	tissue
BL803	Bladder cancer and normal tissue array with TNM and grade data, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BL804	Bladder disease spectrum (urocystic cancer progression) tissue array, 80 cases 80 cores		266-Eur	US Biomax	tissue
BL804	Bladder disease spectrum (urocystic cancer progression) tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BL805	Mid-advanced stage bladder cancer tissue array, with metastasis tissue, including TNM and pathology grade, 80 cases 80 cores		266-Eur	US Biomax	tissue

BL805	Mid-advanced stage bladder cancer tissue array, with metastasis tissue, including TNM and pathology grade, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BL806	Bladder cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 80 cases 80 cores, replacing BL801		266-Eur	US Biomax	tissue
BL806	Bladder cancer tissue array, with matched adjacent normal tissue (NAT), including TNM and pathology grade, 80 cases 80 cores, replacing BL801; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
BLC1501	Bladder cancer mid-density tissue array, 75 cases 150 cores		261-Eur	US Biomax	tissue
BLC1501	Bladder cancer mid-density tissue array, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		281-Eur	US Biomax	tissue
BLC241	Bladder cancer tissue array, 12 cases 24 cores		189-Eur	US Biomax	tissue
BLC241	Bladder cancer tissue array, 12 cases 24 cores; ihc H&E, IHC anti-Cytokeratin		205-Eur	US Biomax	tissue
BLC661	Bladder cancer tissue array, 33 cases 66 cores		225-Eur	US Biomax	tissue
BLC661	Bladder cancer tissue array, 33 cases 66 cores; ihc H&E, IHC anti-Vimentin Cytokeratin		238-Eur	US Biomax	tissue
BM01011	Liver, kidney, lung, muscle, brain, heart, stomach, spleen tissue array, 160 cases 160 cores, replaced by MO1601		278-Eur	US Biomax	tissue
BM01011	Liver, kidney, lung, muscle, brain, heart, stomach, spleen tissue array, 160 cases 160 cores, replaced by MO1601; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BM241	Bone marrow tissue array, 12 cases 24 cores		88-Eur	US Biomax	tissue
BM241	Bone marrow tissue array, 12 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
BM481	Normal bone marrow tissue array, 24 cases 48 cores		160-Eur	US Biomax	tissue
BM481	Normal bone marrow tissue array, 24 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BM482	Multiple myeloma tissue microarray with normal tissue as control, 24 cases 48 cores, replaced by BM483		397-Eur	US Biomax	tissue
BM482	Multiple myeloma tissue microarray with normal tissue as control, 24 cases 48 cores, replaced by BM483; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BM483	Bone marrow tumor and adjacent normal tissue array, including TNM and pathology grade, 24 cases 48 cores, replacing BM482		266-Eur	US Biomax	tissue

BM483	Bone marrow tumor and adjacent normal tissue array, including TNM and pathology grade, 24 cases 48 cores, replacing BM482; ihc Anti-Actin confirmed		382-Eur	US Biomax	tissue
BN00011	Multiple organ normal tissue array, 48 cases 48 cores		160-Eur	US Biomax	tissue
BN00011	Multiple organ normal tissue array, 48 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BN00015	Multiple organ normal tissue array, 47 cases 48 cores		160-Eur	US Biomax	tissue
BN00015	Multiple organ normal tissue array, 47 cases 48 cores; ihc Anti-SMA confirmed		185-Eur	US Biomax	tissue
BN00112	Multiple organ normal tissue array, 40cases 40 cores, replaced by BN00119		160-Eur	US Biomax	tissue
BN00112	Multiple organ normal tissue array, 40cases 40 cores, replaced by BN00119; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BN00119	Multiple organ normal tissue array, 40 cases 40 cores, replacing BN00112		266-Eur	US Biomax	tissue
BN00119	Multiple organ normal tissue array, 40 cases 40 cores, replacing BN00112; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BN01011	Normal stomach tissue (multi-sites) array, 21 cases 63 cores, replaced by BN01011b		160-Eur	US Biomax	tissue
BN01011	Normal stomach tissue (multi-sites) array, 21 cases 63 cores, replaced by BN01011b; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BN01011b	Normal stomach tissue array, 24 cases 72 cores, replacing BN01011		277-Eur	US Biomax	tissue
BN01011b	Normal stomach tissue array, 24 cases 72 cores, replacing BN01011		231-Eur	US Biomax	tissue
BN01011b	Normal stomach tissue array, 24 cases 72 cores, replacing BN01011; ihc Anti-Actin confirmed		228-Eur	US Biomax	tissue
BN01013	Normal stomach tissue (multi-sites) array, 70 cases 72 cores		160-Eur	US Biomax	tissue
BN01013	Normal stomach tissue (multi-sites) array, 70 cases 72 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BN03011	Normal liver tissue array (multi-sites), 20 cases 63 cores, replaced by LVN801		160-Eur	US Biomax	tissue
BN03011	Normal liver tissue array (multi-sites), 20 cases 63 cores, replaced by LVN801; ihc Anti-PCNA confirmed		185-Eur	US Biomax	tissue
BN04011	Normal lung tissue (multi-sites) tissue array, 22 cases 63 cores, replaced by LC725		160-Eur	US Biomax	tissue
BN04011	Normal lung tissue (multi-sites) tissue array, 22 cases 63 cores, replaced by LC725; ihc Anti-PCNA confirmed		185-Eur	US Biomax	tissue

BN05011	Normal colon tissue (multi-site) array, 23 cases 63 cores, replaced by BN05014		160-Eur	US Biomax	tissue
BN05011	Normal colon tissue (multi-site) array, 23 cases 63 cores, replaced by BN05014; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BN05014	Colon normal tissue array, including TNM and pathology grade of 3 cases adenocarcinoma, 24 cases 72 cores, replacing BN05011		160-Eur	US Biomax	tissue
BN05014	Colon normal tissue array, including TNM and pathology grade of 3 cases adenocarcinoma, 24 cases 72 cores, replacing BN05011; ihc Anti-Actin confirmed		228-Eur	US Biomax	tissue
BN06011	Normal rectum tissue (multi-sites) tissue array, 23 cases 63 cores		160-Eur	US Biomax	recom binant
BN06011	Normal rectum tissue (multi-sites) tissue array, 23 cases 63 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	recom binant
BN06012	Normal rectum tissue (multi-sites) tissue array, 70 cases 72 cores		160-Eur	US Biomax	recom binant
BN06012	Normal rectum tissue (multi-sites) tissue array, 70 cases 72 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	recom binant
BN07011	Normal kidney tissue array (multi-sites), 20 cases 54 cores		160-Eur	US Biomax	tissue
BN07011	Normal kidney tissue array (multi-sites), 20 cases 54 cores; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
BN07012	Normal kidney tissue (multi-sites) tissue array, 70 cases 72 cores, replaced by KD803		160-Eur	US Biomax	tissue
BN07012	Normal kidney tissue (multi-sites) tissue array, 70 cases 72 cores, replaced by KD803; ihc Anti-Villin confirmed		185-Eur	US Biomax	tissue
BN08013	Normal breast tissue (multi-sites) array, 71 cases 72 cores, replaced by BRN801		160-Eur	US Biomax	tissue
BN08013	Normal breast tissue (multi-sites) array, 71 cases 72 cores, replaced by BRN801; ihc anti-Cytokeratin confirmed		185-Eur	US Biomax	tissue
BN08111	Breast hyperplasia and normal tissue array, 10 cases 30 cores		231-Eur	US Biomax	tissue
BN08111	Breast hyperplasia and normal tissue array, 10 cases 30 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BN1002	Multiple organ (20) normal tissue array, 100 cases 100 cores, replacing BN1001		266-Eur	US Biomax	tissue
BN1002	Multiple organ (20) normal tissue array, 100 cases 100 cores, replaced by BN1002a; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BN1002a	Multiple organ normal tissue array, 100 cases 100 cores, replacing BN1002; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue

BN113	Multiple organ normal tissue array, replaced by BN126, 45 cases 45 cores		189-Eur	US Biomax	tissue
BN113	Multiple organ normal tissue array, replaced by BN126, 45 cases 45 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BN114	Multiple normal human organ tissue array, 48 cases 48 cores		189-Eur	US Biomax	tissue
BN114	Multiple normal human organ tissue array, 48 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BN115	Multiple organ normal tissue array, 46 cases 46 cores		189-Eur	US Biomax	tissue
BN115	Multiple organ normal tissue array, 46 cases 46 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BN116	Multiple organ normal tissue array, 48 cases 48 cores, replaced by BN129		189-Eur	US Biomax	tissue
BN116	Multiple organ normal tissue array, 48 cases 48 cores, replaced by BN129; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BN117	Multiple organ normal tissue array, 45 cases 45 cores		189-Eur	US Biomax	tissue
BN117	Multiple organ normal tissue array, 45 cases 45 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BN126	Multiple organ normal tissue array, replacing BN113, 45 cases 45 cores		231-Eur	US Biomax	tissue
BN126	Multiple organ normal tissue array, replacing BN113, 45 cases 45 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BN129	Multiple organ adjacent normal tissue array, 48 cases 48 cores, replacing BN116		160-Eur	US Biomax	tissue
BN129	Multiple organ adjacent normal tissue array, 48 cases 48 cores, replacing BN116; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BN242	Multiple normal (12 type) tissue array, 12 cases 24 cores		88-Eur	US Biomax	tissue
BN242	Multiple normal (12 type) tissue array, 12 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
BN243	Multiple normal (12 type) tissue array, 12 cases 24 cores, replacing BN241		88-Eur	US Biomax	tissue
BN243	Multiple normal (12 type) tissue array, 12 cases 24 cores, replaced by BN243a; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	tissue
BN243a	Multiple organ normal tissue array, 12 cases 24 cores, replacing BN243; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
BN29011	Normal bone marrow tissue array, 60 cases 60 cores		231-Eur	US Biomax	tissue
BN29011	Normal bone marrow tissue array, 60 cases 60 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BN481	Multiple human normal organ (12 type) tissue microarray, 24 cases 48 cores		160-Eur	US Biomax	tissue

BN481	Multiple human normal organ (12 type) tissue microarray, 24 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BN482	Normal human tissue microarray from 12 organs from autopsy, 24 cases 48 cores		160-Eur	US Biomax	tissue
BN482	Normal human tissue microarray from 12 organs from autopsy, 24 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BN484	Multiple organ normal tissue array, 24 cases 48 cores		231-Eur	US Biomax	tissue
BN484	Multiple organ normal tissue array, 24 cases 48 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BN501	Normal human top 10 organ tissue array, 50 cases 50 cores, replacing BN00012 and BN00013		160-Eur	US Biomax	tissue
BN501	Normal human top 10 organ tissue array, 50 cases 50 cores, replacing BN00012 and BN00013; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BN961	Normal human tissue panel (24 organs) with two serial tissue array sections in parallel, 24 cases 102 cores, replacing BN861		266-Eur	US Biomax	tissue
BN961	Normal human tissue panel (24 organs) with two serial tissue array sections in parallel, 24 cases 102 cores, replacing BN861; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BO2081	Bone disease spectrum (bone tumor progression) tissue array, 104 cases 208 cores		516-Eur	US Biomax	tissue
BO2081	Bone disease spectrum (bone tumor progression) tissue array, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BO241	Bone and cartilage cancer tissue array with unmatched normal adjacent tissues, 12 cases 24 cores		88-Eur	US Biomax	tissue
BO241	Bone and cartilage cancer tissue array with unmatched normal adjacent tissues, 12 cases 24 cores; ihc Anti-Vimentin (Vim) confirmed		105-Eur	US Biomax	tissue
BO242	Human normal bone tissue array, 12 cases 24 cores, replaced by BO243		100-Eur	US Biomax	tissue
BO242	Human normal bone tissue array, 12 cases 24 cores, replaced by BO243 ; ihc Anti-Actin confirmed		114-Eur	US Biomax	tissue
BO243	Human normal bone and osteosarcoma tissue array, 12 cases 24 cores, replaced by BO244		88-Eur	US Biomax	tissue
BO243	Human normal bone and osteosarcoma tissue array, 12 cases 24 cores, replaced by BO244; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
BO244	Human normal bone and osteosarcoma tissue array, 12 cases 24 cores, replacing BO243		100-Eur	US Biomax	tissue

BO244	Human normal bone and osteosarcoma tissue array, 12 cases 24 cores, replaced by BO244b; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
BO244a	Human normal bone and osteosarcoma tissue array, including TNM and clinical stage, 12 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
BO244b	Human normal bone and osteosarcoma tissue array, including TNM and clinical stage, 12 cases 24 cores, replacing BO244; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
BO481	Bone and cartilage tumor tissue array with unmatched normal tissue, 48 cases 48 cores with TNM data		189-Eur	US Biomax	tissue
BO481	Bone and cartilage tumor tissue array with unmatched normal tissue, 48 cases 48 cores with TNM data; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
BO601	Bone giant cell tumor tissue array, 30 cases 60 cores		231-Eur	US Biomax	tissue
BO601	Bone giant cell tumor tissue array, 30 cases 60 cores; ihc Anti-Vimtin confirmed		267-Eur	US Biomax	tissue
BO801	Bone and cartilage disease spectrum (bone and cartilage cancer progression) tissue array, 80 cases 80 cores		266-Eur	US Biomax	tissue
BO801	Bone and cartilage disease spectrum (bone and cartilage cancer progression) tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR01015	Multiple organ, normal tissue array, 8 normal tissues, 160 cases 160 cores, replacing BR01011		278-Eur	US Biomax	tissue
BR01015	Multiple organ, normal tissue array, 8 normal tissues, 160 cases 160 cores, replacing BR01011; ihc Anti-EMA confirmed		296-Eur	US Biomax	tissue
BR041	Breast cancer tissue array with HER2 IHC control, including TNM and pathology grade, 4 cases 4 cores, replaced by BR042a		88-Eur	US Biomax	tissue
BR041	Breast cancer tissue array with HER2 IHC control, including TNM and pathology grade, 4 cases 4 cores, replaced by BR042a; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
BR042a	Breast cancer tissue array, including TNM and pathology grade, 4 cases 4 cores		88-Eur	US Biomax	tissue
BR042a	Breast cancer tissue array, including TNM and pathology grade, 4 cases 4 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BR082	Breast cancer tissue array with HER2 IHC control, including TNM and pathology grade, 4 cases 8 cores		112-Eur	US Biomax	tissue

BR082	Breast cancer tissue array with HER2 IHC control, including TNM and pathology grade, 4 cases 8 cores; ihc Anti-Actin confirmed		114-Eur	US Biomax	tissue
BR1001	Breast cancer tissue array with matched carcinoma metastasis to lymph nodes, 50 cases 100 cores, replaced by BR1004		314-Eur	US Biomax	tissue
BR1001	Breast cancer tissue array with matched carcinoma metastasis to lymph nodes, 50 cases 100 cores, replaced by BR1004; ihc Anti-Cytokeratin (Low MW) confirmed		296-Eur	US Biomax	tissue
BR10010	Breast cancer and matched metastatic carcinoma tissue array, including TNM and pathology grade, 50 cases 100 cores, replacing BR1004		314-Eur	US Biomax	tissue
BR10010	Breast cancer and matched metastatic carcinoma tissue array, including TNM and pathology grade, with ER, PR and Her-2 (neu) IHC results, 50 cases 100 cores, replaced by BR10010a; ihc Anti-Actin confi		296-Eur	US Biomax	tissue
BR10010a	Breast cancer and matched metastatic carcinoma tissue array, including TNM and pathology grade, with ER, PR and Her-2 (neu) IHC results, 50 cases 100 cores, replacing BR10010; ihc Anti-Actin confirme		296-Eur	US Biomax	tissue
BR1002	Tissue microarray of breast cancer and normal tissue, 97 cases 100 cores, with stage and grade information		266-Eur	US Biomax	tissue
BR1002	Tissue microarray of breast cancer and normal tissue, 97 cases 100 cores, with stage and grade information; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR1003	Breast pre-cancerous disease and cancer tissue array (100 cases 101 cores), with clinical stage and pathology grade data		266-Eur	US Biomax	tissue
BR1003	Breast pre-cancerous disease and cancer tissue array (100 cases 101 cores), with clinical stage and pathology grade data; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR1004	Tissue array of breast carcinoma and matched metastasis in lymph nodes tissue arrays, 50 cases 100 cores, replaced by BR10010		314-Eur	US Biomax	tissue
BR1004	Tissue array of breast carcinoma and matched metastasis in lymph nodes tissue arrays, 50 cases 100 cores, replaced by BR10010; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR1005	Breast cancer and matched metastatic carcinoma of lymph node, 50 cases 100 cores, no overlaps with BR1001 or BR1004		314-Eur	US Biomax	

BR1005	Breast cancer and matched metastatic carcinoma of lymph node, 50 cases 100 cores, no overlaps with BR1001 or BR1004, replaced by BR1005a; ihc Anti-Actin confirmed		296-Eur	US Biomax	
BR1005a	Breast cancer and matched metastatic carcinoma of lymph node tissue array, including TNM, clinical stage and pathology grade, 50 cases 100 cores, replacing BR1005; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR1006	Breast tumor tissue array of varieties and normal adjacent tissue (NAT), 50 cases 100 cores		266-Eur	US Biomax	tissue
BR1006	Breast tumor tissue array of varieties and normal adjacent tissue (NAT), 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR1007	Breast cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases 100 cores		266-Eur	US Biomax	tissue
BR1007	Breast cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR1008	Breast cancer, carcinoma metastasize to lymph nodes and adjacent normal tissue array, including TNM and pathology grade, 100 cases 100 cores, replacing BC08212		266-Eur	US Biomax	tissue
BR1008	Breast cancer, carcinoma metastasize to lymph nodes and adjacent normal tissue array, including TNM and pathology grade, 100 cases 100 cores, replacing BC08212; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR1009	Breast cancer tissue array for antibody screening , including TNM and pathology grade, 50 cases 100 cores		266-Eur	US Biomax	tissue
BR1009	Breast cancer tissue array for antibody screening , including TNM and pathology grade, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR1502	Breast cancer mid-density tissue array, wiht AR ER PR Her-2 P53 EGFR Ki67 IHC results, 75 cases 150 cores, replaced by BR1503		278-Eur	US Biomax	tissue
BR1502	Breast cancer mid-density tissue array, wiht AR ER PR Her-2 P53 EGFR Ki67 IHC results, 75 cases 150 cores, replaced by BR1503; ihc Anti-Vimentin Cytokeratin confirmed		296-Eur	US Biomax	tissue
BR1503	Breast cancer tissue array, including TNM and pathology grade, with IHC results of Her-2, ER, PR, P53 and Ki-67, 75 cases 150 cores, replacing BR1502		278-Eur	US Biomax	tissue
BR1503	Breast cancer tissue array, including TNM and pathology grade, 75 cases 150 cores, replaced by BR1503a; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue

BR1503a	Breast cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases 150 cores, with IHC results of Her-2, ER, PR, AR, P53 and Ki67, 75 cases 150 cores, replacing BR1503; ihc Anti-		296-Eur	US Biomax	tissue
BR1504	Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		321-Eur	US Biomax	tissue
BR1504	Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		266-Eur	US Biomax	tissue
BR1504	Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR1505	Breast cancer tissue array, including TNM, clinical stage, pathology grade and IHC markers (ER, PR, Her-2, AR and Ki67) results, 75 cases 150 cores, no overlaps with BR1503 or BR1504; ihc Anti-Actin		296-Eur	US Biomax	tissue
BR1921	High-density breast invasive ductal and lobular carcinoma tissue array with normal tissues, grading and staging data,192 cases 192 cores		456-Eur	US Biomax	tissue
BR1921	High-density breast invasive ductal and lobular carcinoma tissue array with normal tissues, grading and staging data,192 cases 192 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BR1922	Late stage breast cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores		456-Eur	US Biomax	elisa
BR1922	Late stage breast cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	elisa
BR2001	Breast cancer high-density tissue array, 196 cases 200 cores, replaced by BR2086		456-Eur	US Biomax	elisa
BR2001	Breast cancer high-density tissue array, 196 cases 200 cores, replaced by BR2086; ihc Anti-Proliferating Cell Nuclear Antigen (PCNA) confirmed		487-Eur	US Biomax	elisa
BR208	High-density, multiple breast cancer (1-3 grade) and normal breast tissue array, 70 cases 208 cores		456-Eur	US Biomax	tissue
BR208	High-density, multiple breast cancer (1-3 grade) and normal breast tissue array, 70 cases 208 cores, replaced by BR208b; ihc Anti-Cytokeratin (CK) confirmed		429-Eur	US Biomax	tissue
BR20810	Breast tumor survey tissue array (4 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue

BR20810	Breast tumor survey tissue array (4 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20811	Breast tumor survey tissue array (5 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20811	Breast tumor survey tissue array (5 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20812	Breast tumor survey tissue array (6 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20812	Breast tumor survey tissue array (6 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20813	Breast tumor survey tissue array (7 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20813	Breast tumor survey tissue array (7 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20814	Breast tumor survey tissue array (8 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20814	Breast tumor survey tissue array (8 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20815	Breast tumor survey tissue array (9 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20815	Breast tumor survey tissue array (9 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20816	Breast tumor survey tissue array (10 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20816	Breast tumor survey tissue array (10 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20817	Breast tumor survey tissue array (11 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20817	Breast tumor survey tissue array (11 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue

BR20818	Breast tumor survey tissue array (12 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20818	Breast tumor survey tissue array (12 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20819	Breast tumor survey tissue array (13 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20819	Breast tumor survey tissue array (13 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR2082	Breast disease spectrum (breast cancer progression) tissue array, 206 cases 208 cores		456-Eur	US Biomax	tissue
BR2082	Breast disease spectrum (breast cancer progression) tissue array, 206 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BR20820	Breast tumor survey tissue array (14 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20820	Breast tumor survey tissue array (14 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20821	Breast tumor survey tissue array (15 of 25), including TNM and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20821	Breast tumor survey tissue array (15 of 25), including TNM and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20822	Breast tumor survey tissue array (16 of 25), including TNM and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20822	Breast tumor survey tissue array (16 of 25), including TNM and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20823	Breast tumor survey tissue array (17 of 25), including TNM and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20823	Breast tumor survey tissue array (17 of 25), including TNM and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20824	Breast tumor survey tissue array (18 of 25), including TNM and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20824	Breast tumor survey tissue array (18 of 25), including TNM and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue

BR20825	Breast tumor survey tissue array (19 of 25), including TNM and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20825	Breast tumor survey tissue array (19 of 25), including TNM and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20826	Breast tumor survey tissue array (20 of 25), including TNM and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20826	Breast tumor survey tissue array (20 of 25), including TNM and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20827	Breast tumor survey tissue array (21 of 25), including TNM and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20827	Breast tumor survey tissue array (21 of 25), including TNM and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20828	Breast tumor survey tissue array (22 of 25), including TNM and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20828	Breast tumor survey tissue array (22 of 25), including TNM and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20829	Breast tumor survey tissue array (23 of 25), including TNM and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20829	Breast tumor survey tissue array (23 of 25), including TNM and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR2083	High-density breast cancer tissue array with normal tissue, stage and grade info, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR2083	High-density breast cancer tissue array with normal tissue, stage and grade info, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20830	Breast tumor survey tissue array (24 of 25), including TNM and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR20830	Breast tumor survey tissue array (24 of 25), including TNM and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20831	Breast tumor survey tissue array (25 of 25), including TNM and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue

BR20831	Breast tumor survey tissue array (25 of 25), including TNM and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR20832	Breast tumor survey tissue array (1 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
BR20832	Breast tumor survey tissue array (1 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BR20833	Breast tumor survey tissue array (2 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
BR20833	Breast tumor survey tissue array (2 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BR20834	Breast tumor survey tissue array (3 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
BR20834	Breast tumor survey tissue array (3 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BR20835	Breast tumor survey tissue array (4 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
BR20835	Breast tumor survey tissue array (4 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BR20836	Breast tumor survey tissue array (5 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
BR20836	Breast tumor survey tissue array (5 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BR2085a	High-density (188 cases 208 cores), multiple types of breast cancer of infiltrating ductal, lobular carcinoma and normal breast tissue array, replaced by BR2085c.		456-Eur	US Biomax	tissue
BR2085a	High-density (188 cases 208 cores), multiple types of breast cancer of infiltrating ductal, lobular carcinoma and normal breast tissue array, replaced by BR2085c.; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue

BR2085b	High-density (188 cases 208 cores), multiple types of breast cancer tissue array of infiltrating ductal, lobular carcinoma and normal breast		456-Eur	US Biomax	tissue
BR2085b	High-density (188 cases 208 cores), multiple types of breast cancer tissue array of infiltrating ductal, lobular carcinoma and normal breast; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BR2085c	Breast cancer tissue array, with normal tissue and adjacent normal tissue, including TNM and pathology grade, 188 cases 208 cores, replacing BR2085a		456-Eur	US Biomax	tissue
BR2085c	Breast cancer tissue array, with normal tissue and adjacent normal tissue, including TNM and pathology grade, 188 cases 208 cores, replacing BR2085a; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BR2086	Breast cancer and normal tissue array, including TNM, clinical stage and pathology grade, 208 cases 208 cores, replacing BR2001		456-Eur	US Biomax	tissue
BR2086	Breast cancer and normal tissue array, including TNM, clinical stage and pathology grade, 208 cases 208 cores, replacing BR2001; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BR2087	Breast tumor survey tissue array (1 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR2087	Breast tumor survey tissue array (1 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR2088	Breast tumor survey tissue array (2 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR2088	Breast tumor survey tissue array (2 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR2089	Breast tumor survey tissue array (3 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
BR2089	Breast tumor survey tissue array (3 of 25), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
BR208b	TMA block of high-density (70 cases 208 cores), multiple breast cancer (I-3 grade) and normal breast tissue		40981-Eur	US Biomax	tissue
BR208b	TMA block of high-density (70 cases 208 cores), multiple breast cancer (I-3 grade) and normal breast tissue, replacing BR208; ihc Anti-Cytokeratin (CK) confirmed		429-Eur	US Biomax	tissue

BR2161	Breast cancer tissue array, including TNM and pathology grade, 216 cases 216 cores		456-Eur	US Biomax	tissue
BR2161	Breast cancer tissue array, including TNM and pathology grade, 216 cases 216 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
BR241	Breast cancer test tissue array with self-matched or unmatched normal adjacent tissues, 6 cases 24 cores.		88-Eur	US Biomax	assays
BR241	Breast cancer test tissue array with self-matched or unmatched normal adjacent tissues, 6 cases 24 cores.; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
BR242	Multiple breast cancer test tissue array with unmatched normal adjacent tissues, 12 cases 24 cores, replaced by BR244		88-Eur	US Biomax	assays
BR242	Multiple breast cancer test tissue array with unmatched normal adjacent tissues, 12 cases 24 cores, replaced by BR244; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
BR243	Breast cancer and adjacent normal tissue array, 6 cases 24 cores, replaced by BR243a		88-Eur	US Biomax	tissue
BR243	Breast cancer and adjacent normal tissue array, 6 cases 24 cores, replacing BR241; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
BR243a	Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 6 cases 24 cores, replacing BR243		99-Eur	US Biomax	tissue
BR243a	Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 6 cases 24 cores, replacing BR243		88-Eur	US Biomax	tissue
BR243a	Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 6 cases 24 cores, replaced by BR243f; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
BR243b	Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 6 cases 24 cores, replacing BR243; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
BR243c	Breast cancer tissue array with matched adjacent normal breast tissue, including TNM, clinical stage and pathology grade, 6 cases 24 cores, replaced by BR243d; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
BR243d	Breast cancer tissue array with matched adjacent normal breast tissue, including TNM, clinical stage and pathology grade, 6 cases 24 cores, replacing BR243c; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue

BR243e	Breast cancer tissue array with adjacent normal breast tissue, including TNM, clinical stage and pathology grade, 6 cases 24 cores, replacing BR243a; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
BR243f	Breast cancer tissue array with matched adjacent normal breast tissue, including TNM, clinical stage and pathology grade, 6 cases 24 cores, replacing BR243a; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
BR244	Breast cancer tissue array with adjacent normal tissues, with TNM and grade info, 12 cases 24 cores, replaced by BR245		88-Eur	US Biomax	tissue
BR244	Breast cancer tissue array with adjacent normal tissues, with TNM and grade info, 12 cases 24 cores, replaced by BR245; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
BR245	Breast carcinoma tissue array, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replaced by BR246		88-Eur	US Biomax	tissue
BR245	Breast carcinoma tissue array, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replaced by BR246; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
BR246	Breast cancer tissue array, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replaced by BR246a		88-Eur	US Biomax	tissue
BR246	Breast cancer tissue array, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replaced by BR246a; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
BR246a	Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 12 cases 24 cores, replacing BR246		99-Eur	US Biomax	tissue
BR246a	Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 12 cases 24 cores, replacing BR246		88-Eur	US Biomax	tissue
BR246a	Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 12 cases 24 cores, replacing BR246; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
BR247	Breast cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases 48 cores, 2 sections slide		189-Eur	US Biomax	tissue
BR247	Breast cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases 48 cores, 2 sections slide; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BR451	Breast cancer tissue microarray with matched normal adjacent tissue and metastatic lymph nodes, 45cases 45 cores, with ER, PR and P53 IHC results		160-Eur	US Biomax	tissue

BR451	Breast cancer tissue microarray with matched normal adjacent tissue and metastatic lymph nodes, 45cases 45 cores, with ER, PR and P53 IHC results; ihc Anti-Cytokeratin (CK) confirmed		162-Eur	US Biomax	tissue
BR480	Breast disease spectrum tissue array - progression array, 48 cases 48 cores		314-Eur	US Biomax	tissue
BR480	Breast disease spectrum tissue array - progression array, 48 cases 48 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR481	Breast infiltrating ductal carcinoma not otherwise specified (NOS) and matched adjacent, 12 cases 48 cores		160-Eur	US Biomax	rat
BR481	Breast infiltrating ductal carcinoma not otherwise specified (NOS) and matched adjacent, 12 cases 48 cores; ihc Anti-actin confirmed Certified pathologist code Certified pathologist code		185-Eur	US Biomax	rat
BR482	Multiple breast cancer tissue array with normal tissues from autopsy, 24 cases 48 cores, with stage and grade info		160-Eur	US Biomax	tissue
BR482	Multiple breast cancer tissue array with normal tissues from autopsy, 24 cases 48 cores, with stage and grade info; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
BR483	Multiple breast cancer tissue array with normal tissues from autopsy, with TNM, 48 cases 48 cores		160-Eur	US Biomax	tissue
BR483	Multiple breast cancer tissue array with normal tissues from autopsy, with TNM, 48 cases 48 cores; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
BR484	Breast cancer tissue array, including TNM and pathology grade, 48 cases 48 cores		231-Eur	US Biomax	tissue
BR484	Breast cancer tissue array, including TNM and pathology grade, 48 cases 48 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BR485	Breast cancer and normal tissue array, including TNM and pathology grade, 2 serial sections, 48 cases 96 cores		397-Eur	US Biomax	elisa
BR485	Breast cancer and normal tissue array, including TNM and pathology grade, 2 serial sections, 48 cases 96 cores; ihc Anti-Actin confirmed		382-Eur	US Biomax	elisa
BR486	Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 16 cases 48 cores		225-Eur	US Biomax	tissue
BR486	Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 16 cases 48 cores		189-Eur	US Biomax	tissue
BR486	Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 16 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue

BR601	Breast fibroma and sclerosing adenosis tissue microarray, 30 cases 60 cores		231-Eur	US Biomax	tissue
BR601	Breast fibroma and sclerosing adenosis tissue microarray, 30 cases 60 cores; ihc Anti-Smooth Muscle Actin (SMA) confirmed		267-Eur	US Biomax	tissue
BR602	Breast tumor and normal tissue array, with TNM data, 25 cases 60 cores		----Eur	US Biomax	tissue
BR6161	High-density breast cancer tissue array, with stage, grade and normal breast tissue, 322 cases 616 cores		753-Eur	US Biomax	tissue
BR6161	High-density breast cancer tissue array, with stage, grade and normal breast tissue, 322 cases 616 cores; ihc Anti-Actin confirmed		811-Eur	US Biomax	tissue
BR641	Breast cancer tissue array, 64 cases 66 cores, with TNM data		----Eur	US Biomax	tissue
BR701	Breast cancer tissue array, 70 cases 70 cores, with TNM data plus ER, PR and Her-2 (C-erbB-2, neu< em>) IHC results, replaced by BR962		231-Eur	US Biomax	elisa
BR701	Breast cancer tissue array, 70 cases 70 cores, with TNM data plus ER, PR and Her-2 (C-erbB-2, neu< em>) IHC results, replaced by BR962; ihc Anti-Actin confirmed		296-Eur	US Biomax	elisa
BR721	Breast cancer tissue array with self-matching adjacent tissue and normal tissue, 24 cases 72 cores, no overlaps with other BR TMAs		231-Eur	US Biomax	tissue
BR721	Breast cancer tissue array with self-matching adjacent tissue and normal tissue, 24 cases 72 cores, no overlaps with other BR TMAs; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
BR722	Breast disease spectrum tissue array, 66 cases 72 cores, including normal, precancerous and cancer in different stages		231-Eur	US Biomax	recom binant
BR722	Breast disease spectrum tissue array, 66 cases 72 cores, including normal, precancerous and cancer in different stages; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	recom binant
BR723	Breast various pathology developmental process tissue array, including TNM and pathology grade, 71 cases 72 cores		314-Eur	US Biomax	tissue
BR723	Breast various pathology developmental process tissue array, including TNM and pathology grade, 71 cases 72 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR724	Breast cancer, adjacent and adjacent normal tissue array, 66 cases 72 cores		231-Eur	US Biomax	tissue
BR724	Breast cancer, adjacent and adjacent normal tissue array, 66 cases 72 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue

BR725	Breast cancer, adjacent and adjacent normal tissue array, 68 cases 72 cores		231-Eur	US Biomax	tissue
BR725	Breast cancer, adjacent and adjacent normal tissue array, 68 cases 72 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BR726	Breast cancer tissue array and normal tissue array, with TNM and grade, 24 cases 72 cores		231-Eur	US Biomax	tissue
BR726	Breast cancer tissue array and normal tissue array, with TNM and grade, 24 cases 72 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR727	Breast cancer and normal tissue array, with TNM, stage and grade info, 24 cases 72 cores, replacing BS08011		231-Eur	US Biomax	tissue
BR727	Breast cancer and normal tissue array, with TNM, stage and grade info, 24 cases 72 cores, replacing BS08011; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR728	Breast carcinoma tissue array, with stage and grade info, 24 cases 72 cores, replacing BC08015		231-Eur	US Biomax	tissue
BR728	Breast carcinoma tissue array, with stage and grade info, 24 cases 72 cores, replacing BC08015; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BR801	Breast tumor tissue array, with matched tumor and adjacent normal tissue, 40 cases 80 cores, replaced by BR804		231-Eur	US Biomax	tissue
BR801	Breast tumor tissue array, with matched tumor and adjacent normal tissue, 40 cases 80 cores, replaced by BR804; ihc Anti-Cytokeratin (High MW) confirmed		267-Eur	US Biomax	tissue
BR8010	Breast fibroadenoma tissue array (including normal, lobular, invasive carcinoma and metastasis in lymph nodes), 71 cases 80 cores		231-Eur	US Biomax	tissue
BR8010	Breast fibroadenoma tissue array (including normal, lobular, invasive carcinoma and metastasis in lymph nodes), 71 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR8011	Breast intraductal carcinoma tissue microarray with normal adjacent tissue, 80 cases 80 cores		314-Eur	US Biomax	tissue
BR8011	Breast intraductal carcinoma tissue microarray with normal adjacent tissue, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR8012	Breast cancer and normal tissue array with stage and grade info, 40 cases 80 cores, replaced by BR8014		231-Eur	US Biomax	tissue
BR8012	Breast cancer and normal tissue array with stage and grade info, 40 cases 80 cores, replaced by BR8014; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue

BR8013	Advanced breast cancer and normal tissue array, with stage, TNM and pathology grade info, 80 cases 80 cores		231-Eur	US Biomax	tissue
BR8013	Advanced breast cancer and normal tissue array, with stage, TNM and pathology grade info, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR8014	Breast cancer and normal tissue array, including TNM, clinical stage and pathology grade, 40 cases 80 cores, replacing BR8012		231-Eur	US Biomax	tissue
BR8014	Breast cancer and normal tissue array, including TNM, clinical stage and pathology grade, 40 cases 80 cores, replacing BR8012; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR8015	Breast cancer tissue array, with adjacent normal tissue and normal tissue, including TNM and pathology grade, 80 cases 80 cores, replacing BC08014		231-Eur	US Biomax	tissue
BR8015	Breast cancer tissue array, with adjacent normal tissue and normal tissue, including TNM and pathology grade, 80 cases 80 cores, replacing BC08014; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
BR8016	Middle-advanced stage breast cancer tissue array, with metastasis tissue, including TNM, clinical stage and pathology grade, 80 cases 80 cores		266-Eur	US Biomax	tissue
BR8016	Middle-advanced stage breast cancer tissue array, with metastasis tissue, including TNM, clinical stage and pathology grade, 80 cases 80 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
BR8017	Middle-advanced stage breast cancer tissue array, with metastasis tissue, including TNM, clinical stage and pathology grade, 80 cases 80 cores		266-Eur	US Biomax	tissue
BR8017	Middle-advanced stage breast cancer tissue array, with metastasis tissue, including TNM, clinical stage and pathology grade, 80 cases 80 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
BR8018	Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 80 cases 80 cores, replacing BR808, BC08014		266-Eur	US Biomax	tissue
BR8018	Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 80 cases 80 cores, replacing BR808, BC08014; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
BR802	Breast cancer tissue array, with matched or unmatched adjacent normal tissue array, 40 cases 80 cores, no overlaps with BR801, BR803 and BR1001, replaced by BR802b		231-Eur	US Biomax	tissue

BR802	Breast cancer tissue array, with matched or unmatched adjacent normal tissue array, 40 cases 80 cores, no overlaps with BR801, BR803 and BR1001, replaced by BR802b; ihc Anti-Cytokeratin (High MW) con		267-Eur	US Biomax	tissue
BR802b	Breast invasive ductal carcinoma with matched or unmatched adjacent normal breast tissue array, including TNM and pathology grade, 47cases 80cores, replacing BR802		266-Eur	US Biomax	tissue
BR802b	Breast invasive ductal carcinoma with matched or unmatched adjacent normal breast tissue array, including TNM and pathology grade, 47cases 80cores, replacing BR802; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
BR803	Breast carcinoma (multi-tissue combined panel) tissue array, 79 cases 80 cores, replacing BC08016		189-Eur	US Biomax	tissue
BR803	Breast carcinoma (multi-tissue combined panel) tissue array, 79 cases 80 cores, replaced by BR803a; ihc Anti-Cytokeratin (Low-MW) confirmed		185-Eur	US Biomax	tissue
BR803a	Breast cancer tissue array, including TNM, clinical stage and pathology grade, 80 cases 80 cores, replacing BR803; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
BR804	Breast tumor tissue array, with matched tumor and adjacent normal tissue, replacing BR801, 40 cases 80 cores		231-Eur	US Biomax	tissue
BR804	Breast tumor tissue array, with matched tumor and adjacent normal tissue, 40 cases 80 cores, replaced by BR804a; ihc Anti-Cytokeratin (Low-MW) confirmed		267-Eur	US Biomax	tissue
BR804a	Breast cancer tissue array, including TNM, clinical stage and pathology grade, 40 cases 80 cores, replacing BR804; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BR805	Breast infiltrating lobular carcinoma tissue array, 80 cases 80 cores		266-Eur	US Biomax	tissue
BR805	Breast infiltrating lobular carcinoma tissue array, 80 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
BR806	Breast hyperplasia tissue array, 80 cases 80 cores		231-Eur	US Biomax	tissue
BR806	Breast hyperplasia tissue array, 80 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
BR807	Medullary carcinoma of breast tissue array, 80 cases 80 cores		231-Eur	US Biomax	tissue
BR807	Medullary carcinoma of breast tissue array, 80 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue

BR808	Tissue array of multiple types of breast cancer and normal breast tissue, 80 cases 80 cores, replaced by BR8018		231-Eur	US Biomax	tissue
BR808	Tissue array of multiple types of breast cancer and normal breast tissue, 80 cases 80 cores, replaced by BR8018; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BR809	Breast invasive lobular carcinoma tissue array with adjacent normal tissue, 79 cases 80 cores		266-Eur	US Biomax	tissue
BR809	Breast invasive lobular carcinoma tissue array with adjacent normal tissue, 79 cases 80 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
BR811	Breast cancer tissue array with normal tissues from autopsy, 80 cases 80 cores, with grade and stage data		231-Eur	US Biomax	tissue
BR811	Breast cancer tissue array with normal tissues from autopsy, 80 cases 80 cores, with grade and stage data; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BR812	Breast cancer tissue array with normal tissues from autopsy, 40 cases 80 cores, with TNM data		231-Eur	US Biomax	tissue
BR812	Breast cancer tissue array with normal tissues from autopsy, 40 cases 80 cores, with TNM data; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BR951	Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores, to be replaced by BR95		456-Eur	US Biomax	tissue
BR951	Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores, replaced by BR952; ihc		429-Eur	US Biomax	tissue
BR952	Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores		456-Eur	US Biomax	tissue
BR952	Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores; ihc Anti-Actin confir		429-Eur	US Biomax	tissue
BR953	Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores, replacing BR952		456-Eur	US Biomax	tissue

BR953	Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores, replaced by BR954; ihc		429-Eur	US Biomax	tissue
BR954	Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores, replacing BR953; ihc		429-Eur	US Biomax	tissue
BR961	Breast cancer array with normal and other non-malignant breast tissues, with AR, ER, PR, Her-2 (neu) IHC results, 48 cases 96 cores, replaced by BR962		----Eur	US Biomax	elisa
BR962	Breast cancer array with normal and other non-malignant breast tissues, with AR, ER, PR, Her-2 (neu) IHC results, 48 cases 96 cores, replacing BR961, BR701		231-Eur	US Biomax	elisa
BR962	Breast cancer array with normal and other non-malignant breast tissues, with AR, ER, PR, Her-2 (neu) IHC results, 48 cases 96 cores, replaced by BR963; ihc Anti-Vimentin Cytokeratin confirmed		296-Eur	US Biomax	elisa
BR963	Breast disease spectrum tissue array, including TNM and pathology grade, stage, TNM and IHC markers (AR, PR, ER, Her-2, Ki67, CK14 and p53), 48 cases 96 cores, replacing BR962		314-Eur	US Biomax	elisa
BR963	Breast disease spectrum tissue array, including TNM and pathology grade, stage, TNM and IHC markers (AR, PR, ER, Her-2, Ki67, CK14 and p53), 48 cases 96 cores, replaced by BR963a; ihc Anti-Actin conf		296-Eur	US Biomax	elisa
BR963a	Breast disease spectrum tissue array, including TNM, clinical stage and pathology grade, 48 cases 96 cores, replacing BR963; ihc Anti-Actin confirmed		296-Eur	US Biomax	elisa
BR964	Breast cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		228-Eur	US Biomax	elisa
BRC1021	Breast cancer tissue array, 102 cases 102 cores		225-Eur	US Biomax	tissue
BRC1021	Breast cancer tissue array, 102 cases 102 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
BRC1501	Breast cancer mid-density tissue array, non-overlapping with either BRC1502 or BRC1503, 75 cases 150 cores		225-Eur	US Biomax	tissue

BRC1501	Breast cancer mid-density tissue array, non-overlapping with either BRC1502 or BRC1503, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
BRC1502	Breast cancer mid-density tissue array, non-overlapping with either BRC1501 or BRC1503, 75 cases 150 cores		225-Eur	US Biomax	tissue
BRC1502	Breast cancer mid-density tissue array, non-overlapping with either BRC1501 or BRC1503, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
BRC1503	Breast cancer mid-density tissue array, non-overlapping with BRC1501 or BRC1502, 75 cases 150 cores		225-Eur	US Biomax	tissue
BRC1503	Breast cancer mid-density tissue array, non-overlapping with BRC1501 or BRC1502, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
BRC2281	High density breast cancer tissue array, 228 cases 228 cores		---Eur	US Biomax	tissue
BRC2281	High density breast cancer tissue array, 228 cases 228 cores; ihc H&E, IHC anti-Cytokeratin		434-Eur	US Biomax	tissue
BRC481	Breast cancer and normal tissue array, 16 cases 48 cores		189-Eur	US Biomax	tissue
BRC481	Breast cancer and normal tissue array, 16 cases 48 cores; ihc H&E, IHC anti-Cytokeratin		205-Eur	US Biomax	tissue
BRC491	Human breast invasive ductal carcinoma (IDC) tissue array, non-overlapping with BRC711, 49 cases 49 cores		142-Eur	US Biomax	tissue
BRC491	Human breast invasive ductal carcinoma (IDC) tissue array, non-overlapping with BRC711, 49 cases 49 cores; ihc H&E, IHC anti- Cytokeratin		178-Eur	US Biomax	tissue
BRC51	Breast cancer tissue array BLOCK, Her-2 IHC marker; ihc Anti-Cytokeratin (CK) confirmed		4878-Eur	US Biomax	tissue
BRC711	Human breast invasive ductal cancer tissue array, non-overlapping with BRC491, 71 cases 72 cores		142-Eur	US Biomax	tissue
BRC711	Human breast invasive ductal cancer tissue array, non-overlapping with BRC491, 71 cases 72 cores; ihc H&E, IHC anti-Cytokeratin		178-Eur	US Biomax	tissue
BRC961	Breast cancer array with normal and other non-malignant breast tissues, non-overlapping with BRC962, with AR ER PR Her-2(neu) IHC results, 48 cases 96 cores		225-Eur	US Biomax	elisa
BRC961	Breast cancer array with normal and other non-malignant breast tissues, non-overlapping with BRC962, with AR ER PR Her-2(neu) IHC results, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	elisa
BRC962	Breast cancer and normal tissue array, non-overlapping with BRC961, with TNM data, 48 cases 96 cores		225-Eur	US Biomax	elisa

BRC962	Breast cancer and normal tissue array, non-overlapping with BRC961, with TNM data, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	elisa
BRD181	Breast disease tissue array, 18 cases 18 cores		118-Eur	US Biomax	tissue
BRD181	Breast disease tissue array, 18 cases 18 cores; ihc H&E, IHC anti-Cytokeratin		123-Eur	US Biomax	tissue
BRF401	Breast cancer frozen tissue array, with normal tissue, 40 cases 40 cores, Her-2 and ER PR IHC are supplied when purchase; ihc Anti-Actin confirmed		742-Eur	US Biomax	tissue
BRF401i	Breast cancer frozen tissue array, with normal tissue, 40 cases 40 cores, Her-2 and ER PR IHC are supplied when purchase; ihc Anti-Actin confirmed		742-Eur	US Biomax	tissue
BRF404	Breast invasive ductal carcinoma frozen tissue array, 20 cases 40 cores		167-Eur	US Biomax	tissue
BRF404	Breast invasive ductal carcinoma frozen tissue array, 20 cases 40 cores; ihc Anti-Actin confirmed		742-Eur	US Biomax	tissue
BRM481	Tissue array of breast carcinoma metastasis in lymph nodes, 24 cases 48 cores		189-Eur	US Biomax	tissue
BRM481	Tissue array of breast carcinoma metastasis in lymph nodes, 24 cases 48 cores; ihc H&E, IHC anti-Cytokeratin		205-Eur	US Biomax	tissue
BRM961	Breast cancer tissue array containing primary and matched metastatic tumors (in lymph nodes) and adjacent normal breast tissue, 48 cases 96 cores		314-Eur	US Biomax	elisa
BRM961	Breast cancer tissue array containing primary and matched metastatic tumors (in lymph nodes) and adjacent normal breast tissue, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		281-Eur	US Biomax	elisa
BRN801	Breast normal adjacent tissue and cancer tissue array, 80 cases 80 cores, replacing BN08013		231-Eur	US Biomax	tissue
BRN801	Breast normal adjacent tissue (NAT) and cancer tissue array, 80 cases 80 cores, replaced by BRN801a; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BRN801a	Breast adjacent normal tissue array with breast cancer tissue, including TNM, clinical stage and pathology grade, 80 cases 80 cores, replacing BRN801; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
BS01011	Stomach cancer tissue array, 72 cases 72 cores		231-Eur	US Biomax	tissue
BS01011	Stomach cancer tissue array, 72 cases 72 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
BS01012	Stomach adenocarcinoma tissue array, 72 cases 72 cores		160-Eur	US Biomax	tissue
BS01012	Stomach adenocarcinoma tissue array, 72 cases 72 cores; ihc Anti-Cytokeratin (Low-MW) confirmed		185-Eur	US Biomax	tissue
BS01032	Stomach adenocarcinoma (grade II) tissue array, 63 cases 63 cores, replaced by ST808		160-Eur	US Biomax	tissue

BS01032	Stomach adenocarcinoma (grade II) tissue array, 63 cases 63 cores, replaced by ST808; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BS01041	Stomach adenocarcinoma (grade III) tissue array, 22 cases 63 cores		160-Eur	US Biomax	tissue
BS01041	Stomach adenocarcinoma (grade III) tissue array, 22 cases 63 cores; ihc Anti-Cytokeratin (Low-MW) confirmed		185-Eur	US Biomax	tissue
BS01042	Stomach adenocarcinoma (grade III) tissue array, 22 cases 63 cores, replaced by ST723		160-Eur	US Biomax	tissue
BS01042	Stomach adenocarcinoma (grade III) tissue array, 22 cases 63 cores, replaced by ST723; ihc Anti-Cytokeratin (Low- MW) confirmed		185-Eur	US Biomax	tissue
BS02021	Esophagus squamous cell carcinoma (grade I) tissue array, 21 cases 63 cores		160-Eur	US Biomax	tissue
BS02021	Esophagus squamous cell carcinoma (grade I) tissue array, 21 cases 63 cores; ihc Anti-H-CK confirmed		185-Eur	US Biomax	tissue
BS02031	Esophagus squamous cell carcinoma (grade II) tissue array, 22 cases 63 cores, replaced by ES723		160-Eur	US Biomax	tissue
BS02031	Esophagus squamous cell carcinoma (grade II) tissue array, 22 cases 63 cores, replaced by ES723; ihc Anti-H-CK confirmed		185-Eur	US Biomax	tissue
BS02041	Esophagus squamous cell carcinoma (grade III) tissue array, 23 cases 63 cores		160-Eur	US Biomax	tissue
BS02041	Esophagus squamous cell carcinoma (grade III) tissue array, 23 cases 63 cores; ihc Anti-H-CK confirmed		185-Eur	US Biomax	tissue
BS02051	Esophagus adenocarcinoma tissue array, 33 cases 63 cores		160-Eur	US Biomax	tissue
BS02051	Esophagus adenocarcinoma tissue array, 33 cases 63 cores; ihc Anti-Cytokeratin (Low-MW) confirmed		185-Eur	US Biomax	tissue
BS03011	Hepatocellular carcinoma tissue array, 21 cases 63 cores, replaced by LV804		160-Eur	US Biomax	tissue
BS03011	Hepatocellular carcinoma tissue array, 21 cases 63 cores, replaced by LV804; ihc Anti-PCNA confirmed		185-Eur	US Biomax	tissue
BS03013	Hepatocellular carcinoma tissue array, 22 cases 63 cores		160-Eur	US Biomax	tissue
BS03013	Hepatocellular carcinoma tissue array, 22 cases 63 cores; ihc Anti-AFP confirmed		185-Eur	US Biomax	tissue
BS03014	Hepatocellular carcinoma tissue array, 63 cases 63 cores, replaced by LV809		160-Eur	US Biomax	tissue
BS03014	Hepatocellular carcinoma tissue array, 63 cases 63 cores, replaced by LV809; ihc Anti-AFP confirmed		185-Eur	US Biomax	tissue

BS04011	Lung squamous carcinoma (combination of adjacent and normal) tissue array, 18 cases 54 cores, replaced by LC808		160-Eur	US Biomax	tissue
BS04011	Lung cancer tissue array, including pathology grade, 64 cases 64 core, replaced by LC808; ihc Anti-H-CK confirmed		185-Eur	US Biomax	tissue
BS04031	Lung squamous cell carcinoma tissue array, 63 cases 64 cores, replaced by LC724		160-Eur	US Biomax	tissue
BS04031	Lung squamous cell carcinoma tissue array, 63 cases 64 cores, replaced by LC724; ihc Anti-H-CK confirmed		185-Eur	US Biomax	tissue
BS04041	Lung squamous cell carcinoma (grade II) tissue array, 21 cases 63 cores		160-Eur	US Biomax	tissue
BS04041	Lung squamous cell carcinoma (grade II) tissue array, 21 cases 63 cores; ihc Anti-H-CK confirmed		185-Eur	US Biomax	tissue
BS04071	Lung squamous cell carcinoma (grade III) tissue array, 21 cases 63 cores, replaced by LC723		160-Eur	US Biomax	tissue
BS04071	Lung squamous cell carcinoma (grade III) tissue array, 21 cases 63 cores, replaced by LC723; ihc Anti-Cytokeratin (Low-MW) confirmed		185-Eur	US Biomax	tissue
BS04081	Lung adenocarcinoma (grade II) tissue array, 21 cases 63 cores		160-Eur	US Biomax	tissue
BS04081	Lung adenocarcinoma (grade II) tissue array, 21 cases 63 cores; ihc Anti-Cytokeratin (Low-MW) confirmed		162-Eur	US Biomax	tissue
BS04102	Large cell carcinoma of lung tissue array, 21 cases 63 cores		231-Eur	US Biomax	tissue
BS04102	Large cell carcinoma of lung tissue array, 21 cases 63 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
BS04111	Lung small cell carcinoma tissue array, 33 cases 63 cores		160-Eur	US Biomax	tissue
BS04111	Lung small cell carcinoma tissue array, 33 cases 63 cores; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
BS05011	Colon adenocarcinoma tissue array, 23 cases 63 cores.		160-Eur	US Biomax	tissue
BS05011	Colon adenocarcinoma tissue array, 23 cases 63 cores.; ihc Anti-P53 confirmed		185-Eur	US Biomax	tissue
BS05021	Colon adenocarcinoma (grade I) tissue array, 23 cases 63 cores, replaced by CO723		160-Eur	US Biomax	tissue
BS05021	Colon adenocarcinoma (grade I) tissue array, 23 cases 63 cores, replaced by CO723; ihc Anti-Cytokeratin (Low-MW) confirmed		185-Eur	US Biomax	tissue
BS05031	Colon adenocarcinoma (grade II) tissue array, 21 cases 63 cores, replaced by CO724		160-Eur	US Biomax	tissue

BS05031	Colon adenocarcinoma (grade II) tissue array, 21 cases 63 cores, replaced by CO724; ihc Anti-Cytokeratin (Low-MW) confirmed		185-Eur	US Biomax	tissue
BS05041	Colon adenocarcinoma (grade III) tissue array, 23 cases 63 cores, replaced by CO725		189-Eur	US Biomax	tissue
BS05041	Colon adenocarcinoma (grade III) tissue array, 23 cases 63 cores, replaced by CO725; ihc Anti-Cytokeratin (Low-MW) confirmed		185-Eur	US Biomax	tissue
BS06011	Rectum adenocarcinoma tissue array, 22 cases 63 cores		160-Eur	US Biomax	recombinant
BS06011	Rectum adenocarcinoma tissue array, 22 cases 63 cores; ihc Anti-CEA confirmed		185-Eur	US Biomax	recombinant
BS06021	Rectum adenocarcinoma (grade I) tissue array, 21 cases 63 cores		160-Eur	US Biomax	recombinant
BS06021	Rectum adenocarcinoma (grade I) tissue array, 21 cases 63 cores; ihc Anti-Cytokeratin (Low-MW) confirmed		185-Eur	US Biomax	recombinant
BS06031	Rectum adenocarcinoma (grade II) tissue array, 21 cases 63 cores, replaced by RE723		160-Eur	US Biomax	recombinant
BS06031	Rectum adenocarcinoma (grade II) tissue array, 21 cases 63 cores, replaced by RE723; ihc Anti-Cytokeratin (Low-MW) confirmed		185-Eur	US Biomax	recombinant
BS06041	Rectum adenocarcinoma (grade III) tissue array, 21 cases 63 cores, replaced by RE724		160-Eur	US Biomax	recombinant
BS06041	Rectum adenocarcinoma (grade III) tissue array, 21 cases 63 cores, replaced by RE724; ihc Anti-Cytokeratin (Low-MW) confirmed		185-Eur	US Biomax	recombinant
BS08011	Breast infiltrating ductal carcinoma tissue array, 22 cases 63 cores, replaced by BR727		160-Eur	US Biomax	tissue
BS08011	Breast infiltrating ductal carcinoma tissue array, 22 cases 63 cores, replaced by BR727 ; ihc Anti-ER confirmed		185-Eur	US Biomax	tissue
BS09011	Uteral leiomyoma (hysteromyoma) tissue array, 30 cases 60 cores		231-Eur	US Biomax	tissue
BS09011	Uteral leiomyoma (hysteromyoma) tissue array, 30 cases 60 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BS17011	Brain glioblastoma tissue array, 21 cases 63 cores, replaced by GL811		231-Eur	US Biomax	tissue
BS17011	Brain glioblastoma tissue array, 21 cases 63 cores, replaced by GL811; ihc Anti-GFAP confirmed		267-Eur	US Biomax	tissue
BS17015	Brain glioma tissue array, 63 cases 63 cores, replaced by GL803		231-Eur	US Biomax	tissue
BS17015	Brain glioma tissue array, 63 cases 63 cores, replaced by GL803; ihc Anti-GFAP confirmed		267-Eur	US Biomax	tissue
BS17016	Brain glioma tissue array, 33 cases 63 cores		231-Eur	US Biomax	tissue

BS17016	Brain glioma tissue array, 33 cases 63 cores, replaced by BS17016a; ihc Anti-GFAP confirmed		267-Eur	US Biomax	tissue
BS17016a	Brain glioblastoma tissue array, including pathology grade, 40 cases 80 cores, replacing BS17016; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
BS17017	Brain gliocytoma tissue array, 63 cases 63 cores		231-Eur	US Biomax	tissue
BS17017	Brain gliocytoma tissue array, 63 cases 63 cores; ihc Anti-Glial Fibrillary Acid Protein (GFAP) confirmed		267-Eur	US Biomax	tissue
BS17018	Brain glioblastoma tissue array, 33 cases 63 cores, replaced by GL805		231-Eur	US Biomax	tissue
BS17018	Brain glioblastoma tissue array, 33 cases 63 cores, replaced by GL805; ihc Anti-Glial Fibrillary Acid Protein (GFAP) confirmed		267-Eur	US Biomax	tissue
BS20011	Lymphoma tissue array, 30 cases 30 cores, replaced by NHL481		189-Eur	US Biomax	tissue
BS20011	Lymphoma tissue array, 30 cases 30 cores, replaced by NHL481; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
BS26011	Osteosarcoma tissue array, 32 cases 63 cores, replaced by OS804		231-Eur	US Biomax	tissue
BS26011	Osteosarcoma tissue array, 32 cases 63 cores, replaced by OS804; ihc Anti-PCNA confirmed		267-Eur	US Biomax	tissue
BS36011	Cartilages sarcoma (Chondrosarcoma) tissue array, 25 cases 75 cores, replaced by OS803		266-Eur	US Biomax	tissue
BS36011	Cartilages sarcoma (Chondrosarcoma) tissue array, 25 cases 75 cores, replaced by OS803; ihc Anti-PCNA confirmed		267-Eur	US Biomax	tissue
CIN481	Cervical intraepithelial neoplasia tissue array with cervical disease spectrum, 48 cases 48 cores		225-Eur	US Biomax	tissue
CIN481	Cervical intraepithelial neoplasia tissue array with cervical disease spectrum, 48 cases 48 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
CKIT061	Ckit molecule IHC control array, 3 cases 6 cores		77-Eur	US Biomax	assays
CKIT061	Ckit molecule IHC control array, 3 cases 6 cores; ihc H&E, IHC anti-Vimentin Cytokeratin		85-Eur	US Biomax	assays
CLC601	Colon cancer and lung cancer tissue array, including TNM and pathology grade, 60 cases 60 cores		266-Eur	US Biomax	tissue
CLC601	Colon cancer and lung cancer tissue array, including TNM and pathology grade, 60 cases 60 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CM241	Common 4 types of cancer tissue array, 12 cases 24 cores		88-Eur	US Biomax	tissue
CM241	Common 4 types of cancer tissue array, 12 cases 24 cores; ihc Anti-Vimentin (Vim) confirmed		105-Eur	US Biomax	tissue

CM481	Common 4 types of cancer tissue array, 48 cases 54 cores, with stage and grade data		231-Eur	US Biomax	tissue
CM481	Common 4 types of cancer tissue array, 48 cases 54 cores, with stage and grade data; ihc Anti-Actin confirmed		228-Eur	US Biomax	tissue
CMA241	Human tumor cell array, 12 cell lines 24 cores		278-Eur	US Biomax	human
CMA241	Human tumor cell array, 12 cell lines 24 cores, replaced by CMA241a; ihc Anti-Actin confirmed		267-Eur	US Biomax	human
CMA241a	Human tumor cell array, 12 cell lines 24 cores, replacing CMA241; ihc Anti-Actin confirmed		267-Eur	US Biomax	human
CNS2081	Central nerve disease spectrum (central nerve tumor progression) tissue array, 104 cases 208 cores		516-Eur	US Biomax	tissue
CNS2081	Central nerve disease spectrum (central nerve tumor progression) tissue array, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
CNS801	Brain disease spectrum (brain cancer progression) tissue array, with stage, TNM and grade info, 79 cases 80 cores		314-Eur	US Biomax	tissue
CNS801	Brain disease spectrum (brain cancer progression) tissue array, with stage, TNM and grade info, 79 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CO1002	Colon and rectum carcinoma and normal tissue array, 73 cases 100 cores, replaced by CO1002b		278-Eur	US Biomax	recombinant
CO1002	Colon and rectum carcinoma and normal tissue array, 73 cases 100 cores, replaced by CO1002b; ihc Anti-Actin confirmed		267-Eur	US Biomax	recombinant
CO1002b	Colorectal carcinoma and matched adjacent normal tissue array with lymph node metastasis carcinoma, including TNM and pathology grade, 64 cases 100 cores, replacing CO1002		321-Eur	US Biomax	recombinant
CO1002b	Colorectal carcinoma and matched adjacent normal tissue array with lymph node metastasis carcinoma, including TNM and pathology grade, 64 cases 100 cores, replacing CO1002		266-Eur	US Biomax	recombinant
CO1002b	Colorectal carcinoma and matched adjacent normal tissue array with lymph node metastasis carcinoma, including TNM and pathology grade, 64 cases 100 cores, replacing CO1002; ihc Anti-Actin confirmed		258-Eur	US Biomax	recombinant
CO1003	Colon carcinoma antibody screening array, including TNM, clinical stage and pathology grade, 25 cases 100 cores		231-Eur	US Biomax	
CO1003	Colon carcinoma antibody screening array, including TNM, clinical stage and pathology grade, 25 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	

CO1004	Colon carcinoma tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases 100 cores		231-Eur	US Biomax	tissue
CO1004	Colon carcinoma tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CO1021	Colon cancer tissue array, including TNM, clinical stage and pathology grade, 102 cases 102 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CO1501	Colon adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		321-Eur	US Biomax	tissue
CO1501	Colon adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		266-Eur	US Biomax	tissue
CO1501	Colon adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
CO1502	Colon cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
CO1503	Colon cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
CO1921	High-density colon cancer tissue array with normal tissues, 192 cases 192 cores		456-Eur	US Biomax	tissue
CO1921	High-density colon cancer tissue array with normal tissues, 192 cases 192 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
CO1922	Advanced colon tumor tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores		456-Eur	US Biomax	elisa
CO1922	Advanced colon tumor tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	elisa
CO2001	Colon cancer high-density tissue array, including TNM and pathology grade, 196 cases 200 core		397-Eur	US Biomax	elisa
CO2001	Colon cancer high-density tissue array, including TNM and pathology grade, 196 cases 200 core; ihc Anti-Cytokeratin (Low-MW) confirmed		429-Eur	US Biomax	elisa
CO208	High-density, multiple colon cancer (1-4 grade) and normal colon tissue array, 70 cases 208 cores		456-Eur	US Biomax	tissue
CO208	High-density, multiple colon cancer (1-4 grade) and normal colon tissue array, 70 cases 208 cores; ihc Anti-Cytokeratin (CK) confirmed		487-Eur	US Biomax	tissue
CO2081	Colon disease spectrum (colon cancer progression) tissue array, including TNM and pathology grade, 103 cases 208 cores		456-Eur	US Biomax	tissue

CO2081	Colon disease spectrum (colon cancer progression) tissue array, including TNM and pathology grade, 103 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
CO20810	Colon cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
CO20810	Colon cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
CO20811	Colon tumor survey tissue array (1 of 4), including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
CO20811	Colon tumor survey tissue array (1 of 4), including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
CO20812	Colon tumor survey tissue array (2 of 4), including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
CO20812	Colon tumor survey tissue array (2 of 4), including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
CO20813	Colon tumor survey tissue array (3 of 4), including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
CO20813	Colon tumor survey tissue array (3 of 4), including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
CO20814	Colon tumor survey tissue array (4 of 4), including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
CO20814	Colon tumor survey tissue array (4 of 4), including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
CO2083	High-density colon cancer tissue array with normal tissue, stage and grade info, 104 cases 208 cores		456-Eur	US Biomax	tissue
CO2083	High-density colon cancer tissue array with normal tissue, stage and grade info, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
CO2085a	High-density (208 cases 208 cores), multiple type colon adenocarcinoma (I-4 grade) tissue array with normal colon from autopsy and cancer adjacent tissue		456-Eur	US Biomax	tissue
CO2085a	High-density (208 cases 208 cores), multiple type colon adenocarcinoma (I-4 grade) tissue array with normal colon from autopsy and cancer adjacent tissue; ihc Anti-Cytokeratin (CK) confirmed		487-Eur	US Biomax	tissue
CO2085b	TMA BLOCK of high-density (208 cases 208 cores), multiple type colon adenocarcinoma (I-4 grade) with normal colon from autopsy and cancer adjacent tissue		40981-Eur	US Biomax	tissue

CO2085b	TMA BLOCK of high-density (208 cases 208 cores), multiple type colon adenocarcinoma (I-4 grade) with normal colon from autopsy and cancer adjacent tissue; ihc Anti-Cytokeratin (CK) confirmed		33112-Eur	US Biomax	tissue
CO2086	Colon tumor survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
CO2086	Colon tumor survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Cytokeratin (CK) confirmed		429-Eur	US Biomax	tissue
CO2087	Colon cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
CO2087	Colon cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Cytokeratin (CK) confirmed		429-Eur	US Biomax	tissue
CO2088	Colon cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
CO2088	Colon cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Cytokeratin (CK) confirmed		429-Eur	US Biomax	tissue
CO2089	Colon cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
CO2089	Colon cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
CO208b	TMA Block of high-density (70 cases 208 cores), multiple colon cancer (1-4 grade) and normal colon tissue array block		40981-Eur	US Biomax	tissue
CO208b	TMA Block of high-density (70 cases 208 cores), multiple colon cancer (1-4 grade) and normal colon tissue array block; ihc Anti-Cytokeratin (CK) confirmed		33112-Eur	US Biomax	tissue
CO2161	Colon cancer and normal colon tissue array, including TNM and pathology grade, 216 cases 216 cores		456-Eur	US Biomax	tissue
CO2161	Colon cancer and normal colon tissue array, including TNM and pathology grade, 216 cases 216 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
CO241	Colon cancer test tissue array with self-matching normal adjacent tissue, 6 cases 24 cores		88-Eur	US Biomax	assays

CO241	Colon cancer test tissue array with self-matching normal adjacent tissue, 6 cases 24 cores, replaced by CO241a; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
CO241a	Colon cancer tissue array with adjacent normal colon tissue, including TNM, clinical stage and pathology grade, 6 cases 24 cores, replacing CO241; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
CO242	Multiple colon cancer test tissue array with self-matching normal adjacent tissue, 10 cases 24 cores.		88-Eur	US Biomax	assays
CO242	Multiple colon cancer test tissue array with self-matching normal adjacent tissue, 10 cases 24 cores, replaced by CO242a; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
CO242a	Colon carcinoma tissue array with adjacent normal colon tissue as control, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing CO242; ihc Anti-Actin confirmed		81-Eur	US Biomax	tissue
CO243	Colon cancer tissue array with normal tissue controls, 9 cases 24 cores		88-Eur	US Biomax	tissue
CO243	Colon cancer tissue array with normal tissue controls, 9 cases 24 cores, replaced by CO243a; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	tissue
CO243a	Colon carcinoma tissue array with matched adjacent normal colon tissue as control, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing CO243; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
CO244	Colon cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases 48 cores		189-Eur	US Biomax	tissue
CO244	Colon cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases 48 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
CO481	Colonic adenocarcinoma and matched adjacent tissue array, with TNM data, 12 cases 48 cores		160-Eur	US Biomax	tissue
CO481	Colonic adenocarcinoma and matched adjacent tissue array, with TNM data, 12 cases 48 cores; ihc Anti-actin confirmed Certified pathologist code Certified pathologist code		210-Eur	US Biomax	tissue
CO482	Tissue array of colonic carcinoma with TNM data and normal colon tissue, 24 cases 48 cores		160-Eur	US Biomax	tissue
CO482	Tissue array of colonic carcinoma with TNM data and normal colon tissue, 24 cases 48 cores; ihc Anti-Cytokeratin (CK) confirmed		210-Eur	US Biomax	tissue

CO483	Multiple colon cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores, with stage and grade information		160-Eur	US Biomax	tissue
CO483	Multiple colon cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores, with stage and grade information; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
CO484	Colon cancer tissue array with normal tissues with TNM and grade, 48 cases 48 cores		189-Eur	US Biomax	tissue
CO484	Colon cancer tissue array with normal tissues with TNM and grade, 48 cases 48 cores, replaced by CO484a; ihc Anti-Cytokeratin (CK) confirmed		210-Eur	US Biomax	tissue
CO484a	Colon cancer tissue array with adjacent normal tissues, including TNM, clinical stage and pathology grade, 48 cases 48 cores, replacing CO484; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
CO485	Colon cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases 48 cores		231-Eur	US Biomax	tissue
CO485	Colon cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases 48 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
CO486	Colon cancer tissue array, including TNM, clinical stage and pathology grade, 2 serial sections, 48 cases 96 cores		397-Eur	US Biomax	elisa
CO486	Colon cancer tissue array, including TNM, clinical stage and pathology grade, 2 serial sections, 48 cases 96 cores; ihc Anti-Cytokeratin (CK) confirmed		382-Eur	US Biomax	elisa
CO487	Colon adenocarcinoma with matched adjacent colon tissue array, including TNM and pathology grade, 16 cases 48 cores		225-Eur	US Biomax	tissue
CO487	Colon adenocarcinoma with matched adjacent colon tissue array, including TNM and pathology grade, 16 cases 48 cores		189-Eur	US Biomax	tissue
CO487	Colon adenocarcinoma with matched adjacent colon tissue array, including TNM and pathology grade, 16 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
CO488	Colon adenocarcinoma with matched adjacent colon tissue array, including TNM, clinical stage and pathology grade, 16 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
CO601	Colon cancer tissue array, with matched normal tissues, 29 cases 60 cores, with TNM data		----Eur	US Biomax	tissue
CO6161	High-density colon cancer array, with stage, grade and normal colon tissue, 322 cases 616 cores		753-Eur	US Biomax	tissue

CO6161	High-density colon cancer array, with stage, grade and normal colon tissue, 322 cases 616 cores; ihc Anti-Actin confirmed		811-Eur	US Biomax	tissue
CO641	Colon cancer tissue array, 64 cases 66 cores, with TNM data		----Eur	US Biomax	tissue
CO701	Colon cancer tissue array, with grade 1-4 and normal colon tissue, 70 cases 70 cores, with stage and grade information		231-Eur	US Biomax	tissue
CO701	Colon cancer tissue array, with grade 1-4 and normal colon tissue, 70 cases 70 cores, with stage and grade information; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CO702	Colon cancer tissue array, with metastasis tissue and adjacent normal tissue, including TNM and pathology grade, 69 cases 69 cores, replacing BC05115		266-Eur	US Biomax	tissue
CO702	Colon cancer tissue array, with metastasis tissue and adjacent normal tissue, including TNM and pathology grade, 69 cases 69 cores, replacing BC05115; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
CO721	Colon cancer tissue array with stage and grade info, 24 cases 72 cores		231-Eur	US Biomax	tissue
CO721	Colon cancer tissue array with stage and grade info, 24 cases 72 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
CO722	Colon adenocarcinoma tissue array with matched tumor adjacent and adjacent normal tissue control, with stage and grade info, 24 cases 72 cores, replacing BC05021		231-Eur	US Biomax	tissue
CO722	Colon adenocarcinoma tissue array with matched tumor adjacent and adjacent normal tissue control, with stage and grade info, 24 cases 72 cores, replacing BC05021; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
CO723	Colon well differentiated adenocarcinoma and adjacent normal tissue array, with stage and grade info, 24 cases 72 cores, replacing BS05021		231-Eur	US Biomax	tissue
CO723	Colon well differentiated adenocarcinoma and adjacent normal tissue array, with stage and grade info, 24 cases 72 cores, replacing BS05021; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
CO724	Colon moderately differentiated adenocarcinoma and adjacent normal tissue array, with stage and grade info, 24 cases 72 cores, replacing BS05031		278-Eur	US Biomax	tissue
CO724	Colon moderately differentiated adenocarcinoma and adjacent normal tissue array, with stage and grade info, 24 cases 72 cores, replacing BS05031; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue

CO725	Colon poorly differentiated adenocarcinoma and adjacent normal tissue array, with stage and grade info, 24 cases 72 cores, replacing BS05041		231-Eur	US Biomax	tissue
CO725	Colon poorly differentiated adenocarcinoma and adjacent normal tissue array, with stage and grade info, 24 cases 72 cores, replacing BS05041; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
CO726	Metastatic colon carcinoma tissue array, 24 cases 72 cores, replacing BC050112		266-Eur	US Biomax	tissue
CO726	Metastatic colon carcinoma tissue array, 24 cases 72 cores, replacing BC050112; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
CO801	Colon cancer tissue array, with matched or unmatched adjacent normal tissue, 40 cases 80 cores, no overlaps with CO802		231-Eur	US Biomax	tissue
CO801	Colon cancer tissue array, with matched or unmatched adjacent normal tissue, 40 cases 80 cores, no overlaps with CO802; ihc Anti-Cytokeratin (High MW) confirmed		267-Eur	US Biomax	tissue
CO802	Colon carcinoma (multi-tissue combined panel) tissue array, 80 cases 80 cores, no overlaps with CO801		189-Eur	US Biomax	tissue
CO802	Colon carcinoma (multi-tissue combined panel) tissue array, 80 cases 80 cores, no overlaps with CO801, replaced by CO802b; ihc Anti-Cytokeratin (CK) confirmed		258-Eur	US Biomax	tissue
CO802a	Colon cancer tissue array with adjacent normal colon tissue, including TNM and clinical stage, 80 cases 80 cores, replacing CO802; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
CO802b	Colon cancer tissue array with adjacent normal colon tissue, including pathology grade and clinical stage, 80 cases 80 cores, replacing CO802; ihc Anti-Actin confirmed		228-Eur	US Biomax	tissue
CO803	Colon cancer tissue array, with matched tumor and adjacent normal tissue, 40 cases 80 cores		231-Eur	US Biomax	tissue
CO803	Colon cancer tissue array, with matched tumor and adjacent normal tissue, 40 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
CO804	Multiple types of colon carcinoma tissue array (replacing BC05011), 80 cases 80 cores		231-Eur	US Biomax	tissue
CO804	Multiple types of colon carcinoma tissue array (replacing BC05011), 80 cases 80 cores, replaced by CO804a; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
CO804a	Colon cancer tissue array, including TNM, clinical stage and pathology grade, 80 cases 80 cores, replcing CO804; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue

CO805	Colon adenocarcinoma and normal tissue array with stage and grade information, 40 cases 80 cores		231-Eur	US Biomax	tissue
CO805	Colon adenocarcinoma and normal tissue array with stage and grade information, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CO806	Colon normal adjacent tissue array, replacing BN05012, 80 cases 80 cores		231-Eur	US Biomax	tissue
CO806	Colon normal adjacent tissue array, replacing BN05012, 80 cases 80 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
CO807	Advanced colon cancer tissue array, with stage and grade info, 80 cases 80 cores		266-Eur	US Biomax	tissue
CO807	Advanced colon cancer tissue array, with stage and grade info, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CO808	Colon disease spectrum (colon cancer progression) tissue array, 76 cases 80 cores		266-Eur	US Biomax	tissue
CO808	Colon disease spectrum (colon cancer progression) tissue array, 76 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CO809	Colon polyp and colitis tissue array, including colon adenoma and normal tissue, 80 cases 80 cores		263-Eur	US Biomax	recombinant
CO809	Colon polyp and colitis tissue array, including colon adenoma and normal tissue, 80 cases 80 cores; ihc Anti-Actin confirmed		263-Eur	US Biomax	recombinant
CO811	Colon cancer tissue array with normal tissues from autopsy, with TNM data, 80 cases 80 cores		231-Eur	US Biomax	tissue
CO811	Colon cancer tissue array with normal tissues from autopsy, with TNM data, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CO812	Colon carcinoma and normal tissue array, 80 cases 80 cores		231-Eur	US Biomax	tissue
CO812	Colon carcinoma and normal tissue array, 80 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
CO951	Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases 95 cores		456-Eur	US Biomax	tissue
CO951	Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases 95 cores, to be replaced by CO952; ihc Anti-Cytokeratin (C		429-Eur	US Biomax	tissue

CO952	Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases 95 cores, replacing CO951; ihc Anti-Cytokeratin (CK) confi		429-Eur	US Biomax	tissue
CO961	Colon cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	elisa
CO962	Colon cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	elisa
CO991	Colorectal (colon and rectum) cancer with matched lymph node metastasis tissue array, 44 cases 99 cores.		266-Eur	US Biomax	recom binant
CO991	Colorectal (colon and rectum) cancer with matched lymph node metastasis tissue array, 44 cases 99 cores, replaced by CO992.; ihc Anti-Cytokeratin (High MW) confirmed		258-Eur	US Biomax	recom binant
CO992	Colorectal (colon and rectum) cancer with matched lymph node metastasis and normal adjacent tissue array, 43 cases 99 cores		266-Eur	US Biomax	recom binant
CO992	Colorectal (colon and rectum) cancer with matched lymph node metastasis and normal adjacent tissue array, 43 cases 99 cores, replacing CO991; ihc Anti-Cytokeratin (CK) confirmed		258-Eur	US Biomax	recom binant
COC1021	Colon cancer tissue array, 102 cases 102 cores		225-Eur	US Biomax	tissue
COC1021	Colon cancer tissue array, 102 cases 102 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	tissue
COC1501	Colon cancer mid-density tissue array, non-overlapping with either COC1502 or COC1503, 75 cases 150 cores		----Eur	US Biomax	tissue
COC1501	Colon cancer mid-density tissue array, non-overlapping with either COC1502 or COC1503, 75 cases 150 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	tissue
COC1502	Colon cancer mid-density tissue array, non-overlapping with either COC1501 or COC1503 75 cases 150 cores		----Eur	US Biomax	tissue
COC1502	Colon cancer mid-density tissue array, non-overlapping with either COC1501 or COC1503 75 cases 150 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	tissue
COC1503	Colon cancer mid-density tissue array, non-overlapping with either COC1501 or COC1502, 75 cases 150 cores		225-Eur	US Biomax	tissue
COC1503	Colon cancer mid-density tissue array, non-overlapping with either COC1501 or COC1502, 75 cases 150 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	tissue

COC2281	High density colon cancer tissue array, 228 cases 228 cores		---Eur	US Biomax	tissue
COC2281	High density colon cancer tissue array, 228 cases 228 cores; ihc H&E, IHC anti- Cytokeratin		434-Eur	US Biomax	tissue
COC481	Colon cancer and normal tissue array, non-overlapping with COC482???16 cases 48 cores		166-Eur	US Biomax	tissue
COC481	Colon cancer and normal tissue array, non-overlapping with COC482???16 cases 48 cores; ihc H&E, IHC anti- Cytokeratin		205-Eur	US Biomax	tissue
COC482	Colon cancer and normal tissue array, non-overlapping with COC481???16 cases 48 cores		166-Eur	US Biomax	tissue
COC482	Colon cancer and normal tissue array, non-overlapping with COC481???16 cases 48 cores; ihc H&E, IHC anti- Cytokeratin		205-Eur	US Biomax	tissue
COC961	Colon cancer and normal tissue array, non-overlapping with COC962???48 cases 96 cores		189-Eur	US Biomax	elisa
COC961	Colon cancer and normal tissue array, non-overlapping with COC962???48 cases 96 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	elisa
COC962	Colon cancer and normal tissue array, non-overlapping with COC961, 48 cases 96 cores		189-Eur	US Biomax	elisa
COC962	Colon cancer and normal tissue array, non-overlapping with COC961, 48 cases 96 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	elisa
CR1001	Multiple uterine carcinoma tissue array with normal tissue, 49 cases 100 cores		231-Eur	US Biomax	tissue
CR1001	Multiple uterine carcinoma tissue array with normal tissue, 49 cases 100 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
CR1002	Cervix carcinoma for antibody screening array, including TNM, clinical stage and pathology grade, 25 cases 100 cores		231-Eur	US Biomax	
CR1002	Cervix carcinoma for antibody screening array, including TNM, clinical stage and pathology grade, 25 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	
CR1003	Cervix cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases 100 cores		231-Eur	US Biomax	tissue
CR1003	Cervix cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CR1501	Cervical cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
CR1921	Middle-advanced stage uterine cervix cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores		456-Eur	US Biomax	elisa

CR1921	Middle-advanced stage uterine cervix cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	elisa
CR208	Cervical cancer high density tissue array, with normal cervix tissue as control, 69 cases 208 cores, with grade and stage		456-Eur	US Biomax	tissue
CR208	Cervical cancer high density tissue array, with normal cervix tissue as control, 69 cases 208 cores, with grade and stage; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
CR2081	High-density cervix cancer tissue array with normal tissues, with stage and grade info, 104 cases 208 cores		456-Eur	US Biomax	tissue
CR2081	High-density cervix cancer tissue array with normal tissues, with stage and grade info, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
CR2082	High-density cervical cancer tissue array with normal tissues, with stage and grade info, 69 cases 208 cores		456-Eur	US Biomax	tissue
CR2082	High-density cervical cancer tissue array with normal tissues, with stage and grade info, 69 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
CR2083	Uterine cervical cancer and cancer adjacent normal tissue survey tissue array (1 of 5), including TNM and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
CR2083	Uterine cervical cancer and cancer adjacent normal tissue survey tissue array (1 of 5), including TNM and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
CR2084	Cervical cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
CR2084	Cervical cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
CR2085	Cervix cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
CR2085	Cervix cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
CR2086	Cervix tumor tissue array (4 of 5), including TNM and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
CR2086	Cervix tumor tissue array (4 of 5), including TNM and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue

CR2087	Uterine cervical cancer tissue survey tissue array (5 of 5), including TNM and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
CR2087	Uterine cervical cancer tissue survey tissue array (5 of 5), including TNM and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
CR2088	Cervix cancer survey tissue array (1 of 2), with normal tissue, including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
CR2088	Cervix cancer survey tissue array (1 of 2), with normal tissue, including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
CR2089	Cervix cancer survey tissue array (2 of 2), including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
CR2089	Cervix cancer survey tissue array (2 of 2), including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
CR241	Cervix cancer test tissue array with self-matching or unmatched normal adjacent tissue, 11 cases 24 cores		88-Eur	US Biomax	assays
CR241	Cervix cancer test tissue array with self-matching or unmatched normal adjacent tissue, 11 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
CR242	Multiple cervix cancer test tissue array with self-matching or unmatched normal adjacent tissues, 22 cases 24 cores		88-Eur	US Biomax	assays
CR242	Multiple cervix cancer test tissue array with self-matching or unmatched normal adjacent tissues, 22 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
CR243	Uterine cervix cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases 48 cores, 2 sections slide		160-Eur	US Biomax	tissue
CR243	Uterine cervix cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases 48 cores, 2 sections slide; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
CR244	Uterine cervix cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 12 cases 24 cores, replacing CR241		189-Eur	US Biomax	tissue
CR244	Uterine cervix cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 12 cases 24 cores, replacing CR241; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue

CR245	Cervical cancer tissue array with matched adjacent cervical tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
CR481	Cervical cancer tissue array with normal adjacent tissues, 24 cases 48 cores, with grade and stage data		160-Eur	US Biomax	tissue
CR481	Cervical cancer tissue array with normal adjacent tissues, 24 cases 48 cores, with grade and stage data; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
CR482	Multiple cervix cancer tissue array with 4 normal tissues control from autopsy, 24 cases 48 cores, with grade and stage data		160-Eur	US Biomax	tissue
CR482	Multiple cervix cancer tissue array with 4 normal tissues control from autopsy, 24 cases 48 cores, with grade and stage data; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
CR483	Multiple cervix cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores, with TNM data		160-Eur	US Biomax	tissue
CR483	Multiple cervix cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores, with TNM data; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
CR484	Cervix squamous cell carcinoma tissue array with matched adjacent cervix tissue, including TNM and pathology grade, 16 cases 48 cores		225-Eur	US Biomax	tissue
CR484	Cervix squamous cell carcinoma tissue array with matched adjacent cervix tissue, including TNM and pathology grade, 16 cases 48 cores		189-Eur	US Biomax	tissue
CR484	Cervix squamous cell carcinoma tissue array with matched adjacent cervix tissue, including TNM and pathology grade, 16 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
CR485	Cervix cancer and adjacent normal tissue array, including TNM and pathology grade, 48 cases 48 cores		231-Eur	US Biomax	tissue
CR485	Cervix cancer and adjacent normal tissue array, including TNM and pathology grade, 48 cases 48 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CR501	Cervical cancer and normal tissue array with TNM and grade, 50 cases 50 cores		160-Eur	US Biomax	tissue
CR501	Cervical cancer and normal tissue array with TNM and grade, 50 cases 50 cores; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue

CR601	Cervical carcinoma tissue array with cervical disease spectrum (normal, inflammation, CIN, malignant I-III), 59 cases 60 cores, replaced by CR602		231-Eur	US Biomax	tissue
CR601	Cervical carcinoma tissue array with cervical disease spectrum (normal, inflammation, CIN, malignant I-III), 59 cases 60 cores, replaced by CR602; ihc Anti-Cytokeratin (CK)		267-Eur	US Biomax	tissue
CR602	Tissue array of uterine cervical disease spectrum (cervical cancer, CIN, inflammation and adjacent normal tissue), 60 cases 60 cores, replacing CR601		231-Eur	US Biomax	tissue
CR602	Tissue array of uterine cervical disease spectrum (cervical cancer, CIN, inflammation and adjacent normal tissue), 60 cases 60 cores, replacing CR601; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
CR6161	High-density uterine cervix cancer array, with stage, grade and normal cervical tissue, 322 cases 616 cores		872-Eur	US Biomax	tissue
CR6161	High-density uterine cervix cancer array, with stage, grade and normal cervical tissue, 322 cases 616 cores; ihc Anti-Actin confirmed		811-Eur	US Biomax	tissue
CR701	Cervical carcinoma, adjacent tissue and adjacent normal tissue array, including TNM and pathology grade, 70 cases 70 cores		266-Eur	US Biomax	tissue
CR701	Cervical carcinoma, adjacent tissue and adjacent normal tissue array, including TNM and pathology grade, 70 cases 70 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CR721	Uterine cervix cancer and normal tissue array, with grade and stage data, 24 cases 72 cores		231-Eur	US Biomax	tissue
CR721	Uterine cervix cancer and normal tissue array, with grade and stage data, 24 cases 72 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CR802	Cervical cancer tissue array, matched or unmatched tumor and adjacent normal tissue, 74 cases 80 cores		231-Eur	US Biomax	tissue
CR802	Cervical cancer tissue array, matched or unmatched tumor and adjacent normal tissue, 74 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
CR803	Multiple (uterine cervix) cervical squamous cancer tissue array, 80 cases 80 cores, replacing BS10011		231-Eur	US Biomax	tissue
CR803	Multiple (uterine cervix) cervical squamous cancer tissue array, 80 cases 80 cores, replacing BS10011; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
CR804	Cervical cancer and normal tissue array with TNM and grade, 40 cases 80 cores		231-Eur	US Biomax	tissue

CR804	Cervical cancer and normal tissue array with TNM and grade, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CR805	Cervix cancer and normal tissue array, with stage and grade info, 80 cases 80 cores		231-Eur	US Biomax	tissue
CR805	Cervix cancer and normal tissue array, with stage and grade info, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CR806	Mid-advanced stage uterine cervix cancer tissue array, with metastasis tissue, including TNM and pathology grade, 80 cases 80 cores		266-Eur	US Biomax	tissue
CR806	Mid-advanced stage uterine cervix cancer tissue array, with metastasis tissue, including TNM and pathology grade, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CR811	Cervical cancer tissue array with normal tissues from autopsy, 40 cases 80 cores, with grade and TNM data		231-Eur	US Biomax	tissue
CR811	Cervical cancer tissue array with normal tissues from autopsy, 40 cases 80 cores, with grade and TNM data; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CVD231	Cardiovascular disease tissue array, non-overlapping with CVD481, 23 cases 23 cores		166-Eur	US Biomax	tissue
CVD231	Cardiovascular disease tissue array, non-overlapping with CVD481, 23 cases 23 cores; ihc H&E, IHC anti-CD34		178-Eur	US Biomax	tissue
CVD481	Cardiovascular disease tissue array, no overlapping with CVD231, 24 cases 48 cores		189-Eur	US Biomax	tissue
CVD481	Cardiovascular disease tissue array, no overlapping with CVD231, 24 cases 48 cores; ihc H&E, IHC anti-CD34		205-Eur	US Biomax	tissue
CXC1021	Cervix cancer tissue array, 102 cases 102 cores		225-Eur	US Biomax	tissue
CXC1021	Cervix cancer tissue array, 102 cases 102 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
CXC1501	Cervical cancer mid-density tissue array, 75 cases 150 cores		225-Eur	US Biomax	tissue
CXC1501	Cervical cancer mid-density tissue array, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
CXC241	Cervical cancer tissue array, 12 cases 24 cores		189-Eur	US Biomax	tissue
CXC241	Cervical cancer tissue array, 12 cases 24 cores; ihc H&E, IHC anti-Cytokeratin		205-Eur	US Biomax	tissue
CXC481	Cervix cancer and normal tissue array, 16 cases 48 cores		225-Eur	US Biomax	tissue
CXC481	Cervix cancer and normal tissue array, 16 cases 48 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue

CXC961	Cervical cancer and normal tissue array, non-overlapping with CXC962, 48 cases 96 cores		225-Eur	US Biomax	elisa
CXC961	Cervical cancer and normal tissue array, non-overlapping with CXC962, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	elisa
CXC962	Cervical cancer and normal tissue array, non-overlapping with CXC961, 48 cases 96 cores		225-Eur	US Biomax	elisa
CXC962	Cervical cancer and normal tissue array, non-overlapping with CXC961, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	elisa
CyFDA	FDA normal organ tissue array of cynomolgus monkey, 99 cases 99 cores		314-Eur	US Biomax	tissue
CyFDA	FDA normal organ tissue array of cynomolgus monkey, 99 cases 99 cores, replaced by CyFDA1; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
CyFDA1	FDA multiple organ normal tissue array of cynomolgus monkey, 34 organs 99 cores, replacing CyFDA; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
DGS2081	Digestive system tissue array, including TNM, stage and grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
DGS2081	Digestive system tissue array, including TNM, stage and grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
DID381	Digestive system disease tissue array, 38 cases 38 cores		166-Eur	US Biomax	tissue
DID381	Digestive system disease tissue array, 38 cases 38 cores; ihc H&E, IHC anti- Cytokeratin		178-Eur	US Biomax	tissue
DOG1061	GIST DOG1 molecule IHC control array, 3 cases 6 cores		77-Eur	US Biomax	dog
DOG1061	GIST DOG1 molecule IHC control array, 3 cases 6 cores; ihc H&E, IHC anti-Vimentin Cytokeratin		85-Eur	US Biomax	dog
EM1021	Endometrium cancer and normal tissue array, including TNM and pathology grade, 102 cases 102 cores		314-Eur	US Biomax	tissue
EM1021	Endometrium cancer and normal tissue array, including TNM and pathology grade, 102 cases 102 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
EMC1021	Endometrial cancer tissue array, 102 caese 102 cores		225-Eur	US Biomax	tissue
EMC1021	Endometrial cancer tissue array, 102 caese 102 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
EMC1501	Endometrial cancer mid-density tissue array, non-overlapping with EMC1502, 75 cases 150 cores		225-Eur	US Biomax	tissue
EMC1501	Endometrial cancer mid-density tissue array, non-overlapping with EMC1502, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue

EMC1502	Endometrial cancer mid-density tissue array, non-overlapping with EMC1501, 75 caese 150 cores		225-Eur	US Biomax	tissue
EMC1502	Endometrial cancer mid-density tissue array, non-overlapping with EMC1501, 75 caese 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
EMC241	Endometrium cancer tissue array, 12 cases 24 cores		189-Eur	US Biomax	tissue
EMC241	Endometrium cancer tissue array, 12 cases 24 cores; ihc H&E, IHC anti-Cytokeratin		205-Eur	US Biomax	tissue
EMC961	Endometrial cancer and normal tissue array, non-overlapping with EMC962, 48 cases 96 cores		225-Eur	US Biomax	elisa
EMC961	Endometrial cancer and normal tissue array, non-overlapping with EMC962, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	elisa
EMC962	Endometrial cancer and normal tissue array, non-overlapping with EMC961???48 cases 96 cores		225-Eur	US Biomax	elisa
EMC962	Endometrial cancer and normal tissue array, non-overlapping with EMC961???48 cases 96 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	elisa
EN801	Endocrine tumor tissue array, 40 cases 80 cores.		266-Eur	US Biomax	tissue
EN801	Endocrine tumor tissue array, 40 cases 80 cores, replaced by EN801a; ihc IHC confirmed		296-Eur	US Biomax	tissue
EN801a	Endocrine cancer tissue array, including TNM and clinical stage, 40 cases 80 cores, replacing EN801; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ENS2081	Endocrine system benign, alignant tumor and normal tissue array, including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
ENS2081	Endocrine system benign, alignant tumor and normal tissue array, including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
ERC031	Estrogen receptor IHC control array, 3 cases 3 cores		77-Eur	US Biomax	recom binant
ERC031	Estrogen receptor (ER) IHC control array, 3 cases 3 cores; ihc H&E, IHC anti-ER		85-Eur	US Biomax	recom binant
ES1001	Esophagus cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases 100 cores		266-Eur	US Biomax	tissue
ES1001	Esophagus cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases 100 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
ES1002	Esophageal cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases 100 cores		266-Eur	US Biomax	tissue

ES1002	Esophageal cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ES1201	Tissue array of esophageal squamous carcinoma and matched adjacent tissue, 60 cases 120 cores, replaced by ES1202		278-Eur	US Biomax	tissue
ES1201	Tissue array of esophageal squamous carcinoma and matched adjacent tissue, 60 cases 120 cores, replaced by ES1202; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ES1202	Esophageal tumor tissue array, with stage, grade and matched adjacent tissue, 60 cases 120 cores, replacing ES1201		278-Eur	US Biomax	tissue
ES1202	Esophageal tumor tissue array, with stage, grade and matched adjacent tissue, 60 cases 120 cores, replacing ES1201; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
ES1501	Esophagus squamous cell carcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		321-Eur	US Biomax	tissue
ES1501	Esophagus squamous cell carcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		266-Eur	US Biomax	tissue
ES1501	Esophagus squamous cell carcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
ES1502	Esophageal cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
ES1921	Middle-advanced stage esophagus cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores		456-Eur	US Biomax	elisa
ES1921	Middle-advanced stage esophagus cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	elisa
ES2001	Esophagus squamous cell carcinoma and metastatic carcinoma tissue array, with adjacent tissue and adjacent normal tissue, including TNM and pathology grade, 120 cases 200 cores		516-Eur	US Biomax	tissue
ES2001	Esophagus squamous cell carcinoma and metastatic carcinoma tissue array, with adjacent tissue and adjacent normal tissue, including TNM and pathology grade, 120 cases 200 cores; ihc Anti-Cytokeratin		429-Eur	US Biomax	tissue
ES208	High density esophageal cancer tissue array, with normal tissue, grade and TNM, 69 cases 208 cores		456-Eur	US Biomax	tissue

ES208	High density esophageal cancer tissue array, with normal tissue, grade and TNM, 69 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
ES2081	Esophageal disease (progression) spectrum tissue array, 103 cases 208 cores		456-Eur	US Biomax	tissue
ES2081	Esophageal disease (progression) spectrum tissue array, 103 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
ES2082	High-density esophageal cancer and normal tissue array, with TNM and grade info, 208 cases 208 cores		456-Eur	US Biomax	tissue
ES2082	High-density esophageal cancer and normal tissue array, with TNM and grade info, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
ES241	Esophagus cancer test tissue array with self-matching normal adjacent tissue, 6 cases 24 cores		88-Eur	US Biomax	assays
ES241	Esophagus cancer test tissue array with self-matching normal adjacent tissue, 6 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
ES242	Multiple esophagus cancer test tissue array with matched or unmatched normal adjacent tissue, 11 cases 24 cores		88-Eur	US Biomax	assays
ES242	Multiple esophagus cancer test tissue array with matched or unmatched normal adjacent tissue, 11 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
ES243	Esophagus cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases 48 cores		189-Eur	US Biomax	tissue
ES243	Esophagus cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases 48 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
ES244	Esophageal squamous cell carcinoma tissue array with matched adjacent esophageal tissue, including TNM and pathology grade, 12 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
ES481	Esophageal cancer tissue array with matched or unmatched normal adjacent tissues (18 cases 48 cores) with stage and grade info		160-Eur	US Biomax	tissue
ES481	Esophageal cancer tissue array with matched or unmatched normal adjacent tissues (18 cases 48 cores) with stage and grade info; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
ES482	Multiple esophagus cancer tissue array with unmatched normal adjacent tissues, 48 cases 48 cores, with grade and stage data		160-Eur	US Biomax	tissue

ES482	Multiple esophagus cancer tissue array with unmatched normal tissues, 48 cases 48 cores, with grade and stage data; ihc Anti-Actin confirmed		162-Eur	US Biomax	tissue
ES483	Esophagus cancer and matched adjacent tissue array, including TNM and pathology grade, 16 cases 48 cores		189-Eur	US Biomax	tissue
ES483	Esophagus cancer and matched adjacent tissue array, including TNM and pathology grade, 16 cases 48 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ES721	Esophagus cancer and normal tissue array with TNM and grade info, 24 cases 72 cores		231-Eur	US Biomax	tissue
ES721	Esophagus cancer and normal tissue array with TNM and grade info, 24 cases 72 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ES722	Esophageal cancer and adjacent tissue array, with stage and grade info, 30 cases 72 cores, replacing BC02023		231-Eur	US Biomax	tissue
ES722	Esophageal cancer and adjacent tissue array, with stage and grade info, 30 cases 72 cores, replacing BC02023; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
ES723	Esophageal squamous cell carcinoma tissue array, with stage, grade and normal tissue, 23 cases 72 cores, replacing BS02031		231-Eur	US Biomax	tissue
ES723	Esophageal squamous cell carcinoma tissue array, with stage, grade and normal tissue, 23 cases 72 cores, replacing BS02031; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
ES781	Esophagus cancer tissue array, including TNM and pathology grade, 26 cases 78 cores, replacing BC02111		266-Eur	US Biomax	tissue
ES781	Esophagus cancer tissue array, including TNM and pathology grade, 26 cases 78 cores, replacing BC02111; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ES801	Esophagus cancer, with matched normal adjacent tissue array, 40 cases 80 cores, replaced by ES8010		231-Eur	US Biomax	tissue
ES801	Esophagus cancer, with matched normal adjacent tissue array, 40 cases 80 cores, replaced by ES8010; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
ES8010	Esophageal cancer and adjacent normal tissue array, with TNM and grade info, 40 cases 80 cores, replacing ES801		231-Eur	US Biomax	tissue
ES8010	Esophageal cancer and adjacent normal tissue array, with TNM and grade info, 40 cases 80 cores, replacing ES801; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
ES8011	Esophageal cancer tissue array, with normal tissue, TNM and grade info, 40 cases 80 cores		231-Eur	US Biomax	tissue

ES8011	Esophageal cancer tissue array, with normal tissue, TNM and grade info, 40 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
ES8012	Middle-advanced stage esophageal cancer tissue array, with metastasis tissue, including TNM, clinical stage and pathology grade, 80 cases 80 cores		278-Eur	US Biomax	tissue
ES8012	Middle-advanced stage esophageal cancer tissue array, with metastasis tissue, including TNM, clinical stage and pathology grade, 80 cases 80 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
ES802	Esophageal squamous cell carcinoma tissue array, grade I-III, 40 cases 80 cores, no overlaps with ES801		231-Eur	US Biomax	tissue
ES802	Esophageal squamous cell carcinoma tissue array, grade I-III, 40 cases 80 cores, no overlaps with ES801; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
ES803	Esophageal inflammation, hyperplasia and atypical hyperplasia tissue array, 80 cases 80 cores		231-Eur	US Biomax	tissue
ES803	Esophageal inflammation, hyperplasia and atypical hyperplasia tissue array, 80 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
ES804	Esophageal cancer progression tissue array, 76 cases 80 cores		231-Eur	US Biomax	tissue
ES804	Esophageal cancer progression tissue array, 76 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
ES805	Esophagus cancer and normal tissue array, with grade and stage data, 40 cases 80 cores		231-Eur	US Biomax	tissue
ES805	Esophagus cancer and normal tissue array, with grade and stage data, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ES806	Metastatic esophageal cancer tissue array, 40 cases 80 cores		231-Eur	US Biomax	tissue
ES806	Metastatic esophageal cancer tissue array, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ES807	Esophageal cancer and normal tissue array, with stage and grade info, 80 cases 80 cores		231-Eur	US Biomax	tissue
ES807	Esophageal cancer and normal tissue array, with stage and grade info, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ES808	Esophagus cancer and normal tissue array, with TNM and grade info, 78 cases 80 cores		231-Eur	US Biomax	tissue
ES808	Esophagus cancer and normal tissue array, with TNM and grade info, 78 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue

ES809	Esophageal disease spectrum (esophageal cancer progression) tissue array, 78 cases 80 cores		231-Eur	US Biomax	tissue
ES809	Esophageal disease spectrum (esophageal cancer progression) tissue array, 78 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ES810	Esophagus cancer with matched lymph node metastasis tissue array, 40 cases 80 cores		231-Eur	US Biomax	tissue
ES810	Esophagus cancer with matched lymph node metastasis tissue array, 40 cases 80 cores; ihc Anti-Cytokeratin (Low-MW) confirmed		296-Eur	US Biomax	tissue
ES811	Esophageal cancer tissue array with normal tissues from autopsy, 40 cases 80 cores, plus grade and stage information		231-Eur	US Biomax	tissue
ES811	Esophageal cancer tissue array with normal tissues from autopsy, 40 cases 80 cores, plus grade and stage information; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ES961	Esophagus squamous cell carcinoma tissue array, including TNM and pathology grade, 48 cases 96 cores		336-Eur	US Biomax	elisa
ES961	Esophagus squamous cell carcinoma tissue array, including TNM and pathology grade, 48 cases 96 cores		278-Eur	US Biomax	elisa
ES961	Esophagus squamous cell carcinoma tissue array, including TNM and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	elisa
ES962	Esophageal squamous cell carcinoma tissue array, including TNM, clinical stage and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	elisa
ESC1021	Esophagus cancer tissue array, 102 cases 102 cores		225-Eur	US Biomax	tissue
ESC1021	Esophagus cancer tissue array, 102 cases 102 cores; ihc H&E, IHC anti-Vimentin Cytokeratin		238-Eur	US Biomax	tissue
ESC1501	Esophageal cancer mid-density tissue array, non-overlapping with ESC1502???75 cases 150 cores		225-Eur	US Biomax	tissue
ESC1501	Esophageal cancer mid-density tissue array, non-overlapping with ESC1502???75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
ESC1502	Esophagus cancer mid-density tissue array, non-overlapping with ESC1501, 75 cases 150 cores		---Eur	US Biomax	tissue
ESC241	Esophagus cancer tissue array, 12 cases 24 cores		166-Eur	US Biomax	tissue
ESC241	Esophagus cancer tissue array, 12 cases 24 cores; ihc H&E, IHC anti-Cytokeratin		205-Eur	US Biomax	tissue
ESC242	Esophagus cancer tissue array, 12 cases 24 cores; ihc H&E, IHC anti-Cytokeratin		205-Eur	US Biomax	tissue
ESC481	Esophagus cancer and normal tissue array, 16 cases 48 cores		189-Eur	US Biomax	tissue

ESC481	Esophagus cancer and normal tissue array, 16 cases 48 cores; ihc H&E, IHC anti-Cytokeratin		205-Eur	US Biomax	tissue
ESC961	Esophageal cancer tissue array, non-overlapping with ESC962, 48 cases 96 cores		189-Eur	US Biomax	elisa
ESC961	Esophageal cancer tissue array, non-overlapping with ESC962, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	elisa
ESC962	Esophagus cancer tissue array, non-overlapping with ESC961, 48 cases 96 cores		189-Eur	US Biomax	elisa
ESC962	Esophagus cancer tissue array, non-overlapping with ESC961, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	elisa
FBN401	Normal human multiple organ frozen tissue array (20 organs in duplicate), 20 cases 40 cores; ihc Anti-Actin confirmed		278-Eur	US Biomax	tissue
FBN404	Multiple organ normal frozen tissue array, 20 cases 40 cores		167-Eur	US Biomax	tissue
FBN404	Multiple organ normal frozen tissue array, 20 cases 40 cores; ihc Anti-Actin confirmed		394-Eur	US Biomax	tissue
FBN406	Multiple organ normal frozen tissue array, 20 cases 40 cores, replacing FBN404		167-Eur	US Biomax	tissue
FBN406	Multiple organ normal frozen tissue array, 20 cases 40 cores, replacing FBN404; ihc Anti-Actin confirmed		394-Eur	US Biomax	tissue
FBN406a	Multiple organ normal frozen tissue array, 20 organs 40 cores; ihc Anti-Actin confirmed		394-Eur	US Biomax	tissue
FBN407	Multiple organ normal frozen tissue array, 20 cases 40 cores, replacing FBN404		281-Eur	US Biomax	tissue
FBN407	Multiple organ normal frozen tissue array, 20 cases 40 cores, replaced by FBN407a; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue
FBN407a	Multiple organ normal frozen tissue array, 20 cases 40 cores, replaing FBN407; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue
FCO401	Colorectal organ carcinoma frozen tissue array, including TNM, clinical stage, 40 cases 40 cores, replaced by FCO401a		293-Eur	US Biomax	recombinant
FCO401	Colorectal organ carcinoma frozen tissue array, including TNM, clinical stage, 40 cases 40 cores, replaced by FCO401a; ihc Anti-Actin confirmed		626-Eur	US Biomax	recombinant
FCO401a	Frozen colorectal adenocarcinoma tissue array, including TNM and clinical stage, 40 cases 40 cores, replacing FCO401		781-Eur	US Biomax	recombinant
FCO401a	Frozen colorectal adenocarcinoma tissue array, including TNM and clinical stage, 40 cases 40 cores, replacing FCO401		331-Eur	US Biomax	recombinant

FCO401a	Frozen colorectal adenocarcinoma tissue array, including TNM and clinical stage, 40 cases 40 cores, replacing FCO401; ihc Anti-Actin confirmed		626-Eur	US Biomax	recom binant
FDA800	Multiple organ tumor tissue array, 72 cases of variety of cancers 72 cores, replacing FDA802-2 or FDA803-2		266-Eur	US Biomax	tissue
FDA800	Multiple organ tumor tissue array, 72 cases of variety of cancers 72 cores, replacing FDA802-2 or FDA803-2; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
FDA801	FDA normal and tumor organ tissue array of human (2 slide set), replaced by FDA802, 144 cases 144 cores, for FDA guidelines to test tissue specificity of antibodies.		278-Eur	US Biomax	assays
FDA801	FDA normal and tumor organ tissue array of human (2 slide set), replaced by FDA802, 144 cases 144 cores, for FDA guidelines to test tissue specificity of antibodies.; ihc Anti-Actin confirmed		296-Eur	US Biomax	assays
FDA802	FDA normal and tumor organ tissue array of human (2 slide set), replaced by FDA803, 144 cases 144 cores, for FDA guidelines to test tissue specificity of antibodies.		278-Eur	US Biomax	assays
FDA802	FDA normal and tumor organ tissue array of human (2 slide set), replaced by FDA803, 144 cases 144 cores, for FDA guidelines to test tissue specificity of antibodies.; ihc Anti-Actin confirmed		296-Eur	US Biomax	assays
FDA803	FDA normal and tumor organ tissue array of human (2 slide set), replaced by FDA804, 144 cases 144 cores, for FDA guidelines to test tissue specificity of antibodies.		278-Eur	US Biomax	assays
FDA803	FDA normal and tumor organ tissue array of human (2 slide set), replaced by FDA804, 144 cases 144 cores, for FDA guidelines to test tissue specificity of antibodies.; ihc Anti-Actin confirmed		296-Eur	US Biomax	assays
FDA804	FDA normal and tumor organ tissue array of human (2 slide set), replaced by FDA805, 144 cases 144 cores, for FDA guidelines to test tissue specificity of antibodies		278-Eur	US Biomax	assays
FDA804	FDA normal and tumor organ tissue array of human (2 slide set), replaced by FDA805, 144 cases 144 cores, for FDA guidelines to test tissue specificity of antibodies; ihc Anti-Actin confirmed		296-Eur	US Biomax	assays
FDA804-2	Multiple tumor and 6 types of normal organ tissue array (slide 2 of 2 slide set), replacing FDA803-2, recommended by FDA to test tissue specificity, 72 cases 72 cores, replaced by FDA807-2		278-Eur	US Biomax	recom binant

FDA804-2	Multiple tumor and 6 types of normal organ tissue array (slide 2 of 2 slide set), replacing FDA803-2, recommended by FDA to test tissue specificity, 72 cases 72 cores, replaced by FDA807-2; ihc Anti-		267-Eur	US Biomax	recombinant
FDA805	FDA normal and tumor organ tissue array of human (2 slide set), replacing FDA804, 144 cases 144 cores, for FDA guidelines to test tissue specificity of antibodies		314-Eur	US Biomax	assays
FDA805	FDA normal and tumor organ tissue array of human (2 slide set), replacing FDA804, 144 cases 144 cores, for FDA guidelines to test tissue specificity of antibodies; ihc Anti-Actin confirmed		296-Eur	US Biomax	assays
FDA805-2	Multiple organ cancer and 6 types of normal organ tissue array, including TNM and pathology grade, 72 cases 72 cores, replaced by FDA808-2		278-Eur	US Biomax	tissue
FDA805-2	Multiple organ cancer and 6 types of normal organ tissue array, including TNM and pathology grade, 72 cases 72 cores, replaced by FDA808-2; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
FDA806	FDA normal and tumor organ tissue array of human (2 slide set), replacing FDA805, 144 cases 144 cores, for FDA guidelines to test tissue specificity of antibodies		380-Eur	US Biomax	assays
FDA806	FDA normal and tumor organ tissue array of human (2 slide set), replacing FDA805, 144 cases 144 cores, for FDA guidelines to test tissue specificity of antibodies		314-Eur	US Biomax	assays
FDA806	FDA normal and tumor organ tissue array of human (2 slide set), replacing FDA805, 144 cases 144 cores, for FDA guidelines to test tissue specificity of antibodies; ihc Anti-Actin confirmed		296-Eur	US Biomax	assays
FDA807	FDA normal and tumor organ tissue array of human (2 slide set), replacing FDA806, 144 cases 144 cores, for FDA guidelines to test tissue specificity of antibodies; ihc Anti-Actin confirmed		296-Eur	US Biomax	assays
FDA807-1	Multiple organ normal tissue array, tissue 72 cores, replaced by FDA808-1; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
FDA807-2	Multiple organ tumor tissue array with adjacent normal human organs, including TNM and pathology grade, 72 cases 72 cores, replacing FDA806-2		336-Eur	US Biomax	tissue
FDA807-2	Multiple organ tumor tissue array with adjacent normal human organs, including TNM and pathology grade, 72 cases 72 cores, replacing FDA806-2		278-Eur	US Biomax	tissue

FDA807-2	Multiple organ tumor tissue array with adjacent normal human organs, including TNM and pathology grade, 72 cases 72 cores, replacing FDA806-2; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
FDA808	FDA normal and tumor organ tissue array of human (2 slide set), replacing FDA807, 144 cases 144 cores, for FDA guidelines to test tissue specificity of antibodies; ihc Anti-Actin confirmed		296-Eur	US Biomax	assays
FDA808-1	Multiple organ normal tissue array, tissue 72 cores, replaced by FDA808a-1; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
FDA808-2	Multiple organ tumor tissue array with adjacent normal human organs, including TNM and pathology grade, 72 cases 72 cores, replacing FDA805-2		277-Eur	US Biomax	tissue
FDA808-2	Multiple organ tumor tissue array with adjacent normal human organs, including TNM and pathology grade, 72 cases 72 cores, replacing FDA805-2		231-Eur	US Biomax	tissue
FDA808-2	Multiple normal organ and tumor tissue array with adjacent normal human organs, including TNM and pathology grade, 72 cases 72 cores, replaced by FDA808a-2; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
FDA808a	FDA normal and tumor organ tissue array of human (2 slide set), replacing FDA808, 144 cases 144 cores, for FDA guidelines to test tissue specificity of antibodies; ihc Anti-Actin confirmed		296-Eur	US Biomax	assays
FDA808a-1	Multiple organ normal tissue array, 72 cases 72 cores, replacing FDA808-1; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
FDA808a-2	Multiple organ tumor tissue array with adjacent normal human organs, including TNM, clinical stage and pathology grade, 72 cases 72 cores, replacing FDA808-2; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
FDA901	FDA Standard Frozen Tissue Array, for therapeutic and diagnostic antibody validation for FDA approval, total 30 organs, 3 individual donors per organ, spanning two frozen tissue microarray slides.; ih		1438-Eur	US Biomax	tissue
FDA901-1	FDA Standard Frozen Tissue Array, for therapeutic and diagnostic antibody validation for FDA approval, total 30 organs, 3 individual donors per organ. (slide one); ihc Anti-Actin confirmed		858-Eur	US Biomax	tissue
FDA901-2	FDA Standard Frozen Tissue Array, for therapeutic and diagnostic antibody validation for FDA approval, total 30 organs, 3 individual donors per organ. (slide two); ihc Anti-Actin confirmed		858-Eur	US Biomax	tissue

FDA902	FDA Standard Frozen Tissue Array (2 slide set), for therapeutic and diagnostic monoclonal antibody validation recommended by FDA, 90 tissue cores of 30 organs, 3 individual donors per organ		199-Eur	US Biomax	recombinant
FDA902	FDA Standard Frozen Tissue Array (2 slide set), for therapeutic and diagnostic monoclonal antibody validation recommended by FDA, 90 tissue cores of 30 organs, 3 individual donors per organ, replaced		1206-Eur	US Biomax	recombinant
FDA902-2	FDA Standard Frozen Tissue Array, for therapeutic and diagnostic antibody validation for FDA approval, 15 cases 45 cores, replaced by FDA902b-2; ihc Anti-Actin confirmed		858-Eur	US Biomax	tissue
FDA902a	FDA Standard Frozen Tissue Array, for therapeutic and diagnostic antibody validation for FDA approval, total 30 organs, 3 individual donors per organ, spanning two frozen tissue microarray slides, rep		1206-Eur	US Biomax	tissue
FDA902b	FDA Standard Frozen Tissue Array (2 slide set), for therapeutic and diagnostic monoclonal antibody validation recommended by FDA, 90 tissue cores of 30 organs, 3 individual donors per organ, replacing		1206-Eur	US Biomax	recombinant
FDA902b-2	FDA Standard Frozen Tissue Array, for therapeutic and diagnostic antibody validation for FDA approval, 45 cases 45 cores, slide 2 of 2 tissue arrays, replacing FDA902-2; ihc Anti-Actin confirmed		1206-Eur	US Biomax	tissue
FDA992	FDA normal organ tissue array of human tissue, 67cases 100 cores		278-Eur	US Biomax	tissue
FDA992	FDA normal organ tissue array of human tissue, 67cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
FDA993	FDA normal human organ tissue array, 67cases 100 cores, replaced by FDA995		278-Eur	US Biomax	tissue
FDA993	FDA normal human organ tissue array, 67cases 100 cores, replaced by FDA995; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
FDA994	FDA normal human organ tissue array, 99 cores 33 sites 75 cases, replacing FDA993, replaced by FDA995		314-Eur	US Biomax	tissue
FDA994	FDA normal human organ tissue array, 99 cores 33 sites 75 cases, replacing FDA993, replaced by FDA995; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
FDA995	FDA normal human organ tissue array, 99 cores 33 sites 75 cases, replaced by FDA997		278-Eur	US Biomax	tissue
FDA995	FDA normal human organ tissue array, 99 cores 33 sites 75 cases, replaced by FDA997; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue

FDA997	FDA normal organ tissue array of human, 47 cases 99 cores, for FDA guidelines to test tissue specificity of antibodies, replaced by FDA998		314-Eur	US Biomax	assays
FDA997	FDA normal organ tissue array of human, 47 cases 99 cores, for FDA guidelines to test tissue specificity of antibodies, replaced by FDA998; ihc Anti-Actin confirmed		296-Eur	US Biomax	assays
FDA998	FDA normal organ tissue array of human, 47 cases 99 cores, replaced by FDA999		314-Eur	US Biomax	tissue
FDA998	FDA normal organ tissue array of human, 47 cases 99 cores, replaced by FDA999; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
FDA999	Multiple organ normal tissue array, 47 cases 99 cores, replacing FDA998		314-Eur	US Biomax	tissue
FDA999	Multiple organ normal tissue array, 47 cases 99 cores, replaced by FDA999a; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
FDA999a	Multiple organ normal tissue array, 47 cases 99 cores, replacing FDA999; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
FDG281f	Normal dog multiple organ frozen tissue array, 28 cases 28 cores		199-Eur	US Biomax	tissue
FDG281f	Normal dog multiple organ frozen tissue array, 28 cases 28 cores; ihc Anti-Actin confirmed		278-Eur	US Biomax	tissue
FDG281m	Normal male dog multiple organ frozen tissue array, 28 cases 28 cores		199-Eur	US Biomax	tissue
FDG281m	Normal male dog multiple organ frozen tissue array, 24 organs 24 cores; ihc Anti-Actin confirmed		394-Eur	US Biomax	tissue
FFE301	Human normal fetal frozen tissue array, total of 15 major organs from one case, 15 organs 30 cores, replaced by FFE302		199-Eur	US Biomax	tissue
FFE301	Human normal fetal frozen tissue array, total of 15 major organs from one case, 15 organs 30 cores, replaced by FFE302; ihc Anti-Actin confirmed		394-Eur	US Biomax	tissue
FFE302	Multiple organ normal frozen tissue array, 15 cases 30 cores, replacing FFE301		199-Eur	US Biomax	tissue
FFE302	Multiple organ normal frozen tissue array, 15 cases 30 cores, replacing FFE301; ihc Anti-Actin confirmed		394-Eur	US Biomax	tissue
FFE302a	Multiple organ normal frozen tissue array, 15 organs 30 cores; ihc Anti-Actin confirmed		394-Eur	US Biomax	tissue
FMC281	Multiple tumor and corresponding normal frozen tissue (14 types) array, 14 cases 28 cores, previously named FMC401		91-Eur	US Biomax	tissue
FMC281	Multiple tumor and corresponding normal frozen tissue (14 types) array, 14 cases 28 cores, previously named FMC401; ihc Anti-Actin confirmed		394-Eur	US Biomax	tissue

FMC282	Multiple organ cancer frozen tissue array, including TNM and clinical stage, 28 cases 28 cores, replaced by FMC282a; ihc Anti-Actin confirmed		394-Eur	US Biomax	tissue
FMC282a	Multiple organ cancer frozen tissue array, including pathology grade, 28 cases 28 cores, replacing FMC282; ihc Anti-Actin confirmed		394-Eur	US Biomax	tissue
FMC401	Multiple organ cancer frozen tissue array, 20 cases 40 cores; ihc Anti-Actin confirmed		510-Eur	US Biomax	tissue
FMC402	Multiple organ cancer frozen tissue array, with normal tissue 40 cases 40 cores		91-Eur	US Biomax	tissue
FMC402	Multiple organ cancer frozen tissue array, with normal tissue 40 cases 40 cores, replaced by FMC402a; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue
FMC402a	Multiple organ cancer frozen tissue array, with normal tissue, including pathology grade, 40 cases 40 cores, replaced by FMC402b; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue
FMC402b	Multiple organ cancer frozen tissue array, with normal tissue, including pathology grade, 40 cases 40 cores, replacing FMC402a; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue
FMC405	Multiple organ carcinoma frozen tissue array, including TNM and clinical stage, 40 cases 40 cores		167-Eur	US Biomax	tissue
FMC405	Multiple organ carcinoma frozen tissue array, including TNM and clinical stage, 40 cases 40 cores, replaced by FMC405a; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue
FMC405a	Multiple organ cancer frozen tissue array, including pathology grade, 40 cases 40 cores, replacing FMC405; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue
FMC406	Digestive system carcinoma frozen tissue array, including TNM and clinical stage information, 40 cases 40 cores		167-Eur	US Biomax	tissue
FMC406	Digestive system carcinoma frozen tissue array, including TNM and clinical stage information, 40 cases 40 cores; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue
FMC406c	Frozen multiple human organ cancer tissue array, including TNM and clinical stage, 40 cases 40 cores; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue
FMC407	Multiple organ cancer frozen tissue array, including TNM and clinical stage, 40 cases 40 cores		331-Eur	US Biomax	tissue
FMC407	Multiple organ cancer frozen tissue array, including TNM and clinical stage, 40 cases 40 cores; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue
FMC407b	Multiple organ cancer frozen tissue array, including TNM information, 40 cases 40 cores, replacing FMC407; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue

FMC408	Multiple organ cancer frozen tissue array, including TNM and clinical stage, 40 cases 40 cores		167-Eur	US Biomax	tissue
FMC408	Multiple organ cancer frozen tissue array, including TNM and clinical stage, 40 cases 40 cores; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue
FMC409	Multiple organ cancer frozen tissue array, 20 cases 40 cores???replacing FMC401		281-Eur	US Biomax	tissue
FMC409	Multiple organ cancer frozen tissue array, 20 cases 40 cores???replacing FMC401; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue
FMC409a	Frozen multiple organ cancer tissue array, 20 cases 40 cores, replacing FMC409; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue
FMO721	FDA standard normal mouse multiple organ frozen tissue array, two slides, 24 cases 72 cores		293-Eur	US Biomax	tissue
FMO721	FDA standard normal mouse multiple organ frozen tissue array, two slides, 24 cases 72 cores; ihc Anti-Actin confirmed		742-Eur	US Biomax	tissue
FMO901	FDA standard normal mouse multiple organ frozen tissue array, slide one, 15 organs 45 cores		293-Eur	US Biomax	tissue
FMO901	FDA standard normal mouse multiple organ frozen tissue array, slide one, 15 organs 45 cores; ihc Anti-Actin confirmed		858-Eur	US Biomax	tissue
FMO901-1	Normal mouse multiple organ frozen tissue array, for therapeutic and diagnostic antibody validation, 15 organs 45 cores, slide 1 of 2 tissue arrays; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue
FMO901-2	Normal mouse multiple organ frozen tissue array, for therapeutic and diagnostic antibody, 15 organs 45 cores, slide 2 of 2 tissue arrays; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue
FMS151	Brains of multiple species frozen tissue array, 14 cases 15 cores		293-Eur	US Biomax	tissue
FMS151	Brains of multiple species frozen tissue array, 14 cases 15 cores; ihc Anti-Actin confirmed		220-Eur	US Biomax	tissue
FMS152	Liver of multiple species frozen tissue array, 14 cases 15 cores		293-Eur	US Biomax	tissue
FMS152	Liver of multiple species frozen tissue array, 14 cases 15 cores; ihc Anti-Actin confirmed		220-Eur	US Biomax	tissue
FRA781	FDA standard normal rat multiple organ frozen tissue array, two slides, 26 cases 78 cores		331-Eur	US Biomax	tissue
FRA781	Standard normal rat multiple organ frozen tissue array, two slides, 26 cases 78 cores; ihc Anti-Actin confirmed		742-Eur	US Biomax	tissue
FRA781-1	FDA standard normal rat multiple organ frozen tissue array, slide one, 26 cases 78 cores; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue

FRA781-2	FDA standard normal rat multiple organ frozen tissue array, slide two, 26 cases 78 cores; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue
FRA901	Normal rat multiple organ (recommended by FDA) frozen tissue array, slide one, 15 cases 45 cores		331-Eur	US Biomax	recombinant
FRA901	Normal rat multiple organ (recommended by FDA) frozen tissue array, slide one, 15 cases 45 cores; ihc Anti-Actin confirmed		858-Eur	US Biomax	recombinant
FRA901-1	FDA standard normal rat multiple organ frozen tissue array, slide one, 15 cases 45 cores, replaced by FRA901a-1; ihc Anti-Actin confirmed		626-Eur	US Biomax	tissue
FRA901-2	Normal rat multiple organ (recommended by FDA) frozen tissue array, slide two, 15 cases 45 cores, replaced by FRA901a-2; ihc Anti-Actin confirmed		626-Eur	US Biomax	recombinant
FRA901a	Normal rat multiple organ frozen tissue array, for therapeutic and diagnostic antibody validation, 45 cases 45 cores, 2 slides set, replacing FRA901; ihc Anti-Actin confirmed		858-Eur	US Biomax	tissue
FRA901a-1	Normal rat multiple organ frozen tissue array, for therapeutic and diagnostic antibody validation for FDA approval, 45 cases 45 cores, slide 2 of 2 tissue arrays, replacing FRA901-1; ihc Anti-Actin c		626-Eur	US Biomax	tissue
FRA901a-2	Normal rat multiple organ frozen tissue array, for therapeutic and diagnostic antibody validation for FDA approval, 45 cases 45 cores, slide 2 of 2 tissue arrays, replacing FRA901-2; ihc Anti-Actin c		626-Eur	US Biomax	tissue
FRB281f	Normal female rabbit multiple organ frozen tissue array, 28 cases 28 cores		293-Eur	US Biomax	polyclonal
FRB281f	Normal female rabbit multiple organ frozen tissue array, 28 organs 28 cores; ihc Anti-Actin confirmed		278-Eur	US Biomax	polyclonal
FRB281m	Normal male rabbit multiple organ frozen tissue array, 28 cases 28 cores		293-Eur	US Biomax	polyclonal
FRB281m	Normal male rabbit multiple organ frozen tissue array, 25 organs 25 cores; ihc Anti-Actin confirmed		394-Eur	US Biomax	polyclonal
FRB901	FDA standard normal rabbit multiple organ frozen tissue array, slide one, 15 organs 45 cores		331-Eur	US Biomax	polyclonal
FRB901	FDA standard normal rabbit multiple organ frozen tissue array, slide one, 15 organs 45 cores; ihc Anti-Actin confirmed		626-Eur	US Biomax	polyclonal
FRS801	Female reproductive system tissue array, with stage and grade info, 80 cases 80 cores		314-Eur	US Biomax	tissue
FRS801	Female reproductive system tissue array, with stage and grade info, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
GA2081	Gallbladder disease spectrum (cholecystic cancer progression) tissue array, 103 cases 208 cores		236-Eur	US Biomax	tissue

GA2081	Gallbladder disease spectrum (cholecystic cancer progression) tissue array, 103 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
GA801	Gallbladder disease spectrum (gallbladder cancer progression) tissue array, 80 cases 80 cores		123-Eur	US Biomax	tissue
GA801	Gallbladder disease spectrum (gallbladder cancer progression) tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		382-Eur	US Biomax	tissue
GI101	Multiple organ gastrointestinal (GI) tract cancer metastasis tissue array, 50 cases 100 cores		266-Eur	US Biomax	assays
GI101	Multiple organ gastrointestinal (GI) tract cancer metastasis tissue array, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	assays
GI481	GI cancer (gastric, colon and rectal carcinoma) tissue array, 24 cases 48 cores		160-Eur	US Biomax	recombinant
GI481	GI cancer (gastric, colon and rectal carcinoma) tissue array, 24 cases 48 cores; ihc Anti-Cytokeratin (CK) confirmed		162-Eur	US Biomax	recombinant
GI961	GI cancer (esophageal, gastric, liver, gall bladder, large intestine and small intestine carcinoma) tissue array, 48 cases 96 cores		231-Eur	US Biomax	elisa
GI961	GI cancer (esophageal, gastric, liver, gall bladder, large intestine and small intestine carcinoma) tissue array, 48 cases 96 cores; ihc Anti-Cytokeratin (CK) confirmed		228-Eur	US Biomax	elisa
GIP541	Visceral peritoneum tissue array, 27 cases 54 cores		173-Eur	US Biomax	tissue
GIP541	Visceral peritoneum tissue array, 27 cases 54 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
GIST481	Gastrointestinal stromal tumor tissue array, 24 cases 48 cores		225-Eur	US Biomax	assays
GIST481	Gastrointestinal stromal tumor tissue array, 24 cases 48 cores; ihc H&E, IHC anti- CD117, CD34, S100		238-Eur	US Biomax	assays
GIST801	Gastrointestinal stromal tumor (GIST) tissue array, 80 cases 80 cores		231-Eur	US Biomax	assays
GIST801	Gastrointestinal stromal tumor (GIST) tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	assays
GIST802	Multiple organ stromal tumor tissue array (containing stomach, colon, rectum, small intestine, cardia, pancreas, retroperitoneum stroma and pelvic cavity), 80 cases 80 cores, no overlapping with GIST8		296-Eur	US Biomax	recombinant
GL1001	Multiple brain cancer and normal adjacent tissue array, 100 cases 100 cores		266-Eur	US Biomax	tissue

GL1001	Multiple brain cancer and normal adjacent tissue array, 100 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
GL1002	Brain tumor and normal tissue array, 50 cases 100 cores		266-Eur	US Biomax	tissue
GL1002	Brain tumor and normal tissue array, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
GL1003	Brain tumor tissue array for antibody screening, 25 cases 100 cores		266-Eur	US Biomax	tissue
GL1003	Brain tumor tissue array for antibody screening, 25 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
GL1921	Mid-advanced stage brain tumor tissue array, including pathology grade, 96 cases 192 cores		456-Eur	US Biomax	elisa
GL1921	Mid-advanced stage brain tumor tissue array, including pathology grade, 96 cases 192 cores; ihc Anti-Cytokeratin (CK) confirmed		487-Eur	US Biomax	elisa
GL208	Brain primary tumor high density (69 cases 208 cores) tissue microarray of astrocytoma, glioblastoma, glioblastoma multiforme (GBM) and normal tissue		456-Eur	US Biomax	tissue
GL208	Brain primary tumor high density (69 cases 208 cores) tissue microarray of astrocytoma, glioblastoma, glioblastoma multiforme (GBM) and normal tissue; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
GL2082	Brain tumor (meningioma, astrocytoma and glioblastoma) tissue array, 104 cases 208 cores		456-Eur	US Biomax	tissue
GL2082	Brain tumor (meningioma, astrocytoma and glioblastoma) tissue array, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
GL2083	Brain tumor and normal tissue array with pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
GL2083	Brain tumor and normal tissue array with pathology grade, 208 cases 208 cores, replaced by GL2083a; ihc Anti-Cytokeratin (CK) confirmed		487-Eur	US Biomax	tissue
GL2083a	Brain tumor tissue array, including TNM, clinical stage and pathology grade, 208 cases 208 cores, replacing GL2083; ihc Anti-Cytokeratin (CK) confirmed		487-Eur	US Biomax	tissue
GL241	Multiple brain cancer tissue array with self-matching normal adjacent tissues, 10 cases 24 cores		88-Eur	US Biomax	tissue
GL241	Multiple brain cancer tissue array with self-matching normal adjacent tissues, 10 cases 24 cores, replaced by GL241a; ihc Anti-Glial Fibrillary Acid Protein (GFAP) confirmed		90-Eur	US Biomax	tissue

GL241a	Brain tumor tissue array with adjacent normal brain tissue, including pathology grade, 10 cases 24 cores, replacing GL241; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
GL242	Brain tumor tissue array, with normal tissue, 2 serial sections, 24 cases 48 cores		189-Eur	US Biomax	tissue
GL242	Brain tumor tissue array, with normal tissue, 2 serial sections, 24 cases 48 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
GL481	Multiple brain cancer tissue array with unmatched normal adjacent tissues, 48 cases 48 cores		160-Eur	US Biomax	tissue
GL481	Astrocytoma and glioblastoma tissue array with unmatched normal adjacent tissues, 48 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
GL482	Brain tumor tissue array, with normal tissue, 48 cases 48 cores		231-Eur	US Biomax	tissue
GL482	Brain tumor tissue array, with normal tissue, 48 cases 48 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
GL721	Brain tumor and normal tissue array with TNM and grade info, 24 cases 72 cores		266-Eur	US Biomax	tissue
GL721	Brain tumor and normal tissue array with TNM and grade info, 24 cases 72 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
GL722	Brain glioma (astrocytoma) tissue array, 24 cases 72 cores		266-Eur	US Biomax	tissue
GL722	Brain glioma (astrocytoma) tissue array, 24 cases 72 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
GL801	Brain glioma tissue array, with matched or unmatched adjacent normal tissue, 76 cases 80 cores		231-Eur	US Biomax	tissue
GL801	Brain glioma tissue array, with matched or unmatched adjacent normal tissue, 76 cases 80 cores; ihc Anti-Glial Fibrillary acid protein antibody confirmed		267-Eur	US Biomax	tissue
GL802	Glioblastoma (grade IV) tissue array, 40 cases 80 cores, replaced by GL805		231-Eur	US Biomax	tissue
GL802	Glioblastoma (grade IV) tissue array, 40 cases 80 cores, replaced by GL805; ihc Anti-Glial Fibrillary Acid Protein (GFAP) confirmed		267-Eur	US Biomax	tissue
GL803	Brain tumor tissue array of glioblastoma, astrocytoma, ependymoma, oligo astrocytoma, medulloblastoma and oligodendroglioma, 78 cases 80 cores, replacing BS17015		266-Eur	US Biomax	tissue

GL803	Brain tumor tissue array of glioblastoma, astrocytoma, ependymoma, oligo astrocytoma, medulloblastoma and oligodendroglioma, 78 cases 80 cores, replaced by GL803a; ihc Anti-Glial Fibrillary Acid Prot		296-Eur	US Biomax	tissue
GL803a	Brain tumor and adjacent normal tissue array, including pathology grade, 80 cases 80 cores, replacing GL803; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
GL804	Brain tumor and normal tissue array with grade and TNM data, 40 cases 80 cores		266-Eur	US Biomax	tissue
GL804	Brain tumor and normal tissue array with grade and TNM data, 40 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
GL805	Glioblastoma multiforme (GBM) tissue array, 40 cases 80 cores, replaced by GL806		266-Eur	US Biomax	tissue
GL805	Glioblastoma multiforme (GBM) tissue array, 40 cases 80 cores, replaced by GL806; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
GL806	Brain glioblastoma and normal tissue array, 40 cases 80 cores, replacing GL805		266-Eur	US Biomax	tissue
GL806	Brain glioblastoma multiforme(GBM) tissue array, 40 cases 80 cores, replaced by GL806a; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
GL806a	Brain glioblastoma multiforme(GBM) tissue array, 40 cases 80 cores, replacing GL806; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
GL807	Brain glioma and normal tissue array, including pathology grade, 40 cases 80 cores		266-Eur	US Biomax	tissue
GL807	Brain glioma and normal tissue array, including pathology grade, 40 cases 80 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
GL808	Brain tumor tissue array, with matched adjacent normal tissue, 80 cases 80 cores		266-Eur	US Biomax	tissue
GL808	Brain tumor tissue array, with matched adjacent normal tissue, 80 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
GL811	Brain tumor and normal tissue array, with pathology grade, 27 cases 81 cores, replacing BS17011		266-Eur	US Biomax	tissue
GL811	Brain tumor and normal tissue array, with pathology grade, 27 cases 81 cores, replacing BS17011; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
HE1001	Heart disease spectrum (heart tumor progression) tissue array, 50 cases 100 cores		266-Eur	US Biomax	tissue
HE1001	Heart disease spectrum (heart tumor progression) tissue array, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue

HER2	Her-2 IHC Bio-marker control TMA, for CAP proficiency test survey, with breast invasive ductal carcinoma, 10 cases 10 cores; ihc Anti-Actin confirmed		114-Eur	US Biomax	assays
HL481	Hodgkin's lymphoma tumor tissue array, 48 cases 48 cores		231-Eur	US Biomax	tissue
HL481	Hodgkin's lymphoma tumor tissue array, 48 cases 48 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
HL801	Hodgkin's lymphoma tissue array, 45 cases 80 cores		266-Eur	US Biomax	tissue
HL801	Hodgkin's lymphoma tissue array, 45 cases 80 cores; ihc Anti-Leukocyte Common Antigen antibody confirmed		267-Eur	US Biomax	tissue
HN241	Head & Neck cancer test tissue array with unmatched normal adjacent tissue, 12 cases 24 cores		88-Eur	US Biomax	assays
HN241	Head & Neck cancer test tissue array with unmatched normal adjacent tissue, 12 cases 24 cores, replaced by HN241a; ihc Anti-Cytokeratin (CK) confirmed		90-Eur	US Biomax	assays
HN241a	Head and neck cancer tissue array with adjacent normal head and neck tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing HN241; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
HN242	Multiple Head & Neck cancer test tissue array with unmatched normal adjacent tissue, 12 cases 24 cores		88-Eur	US Biomax	assays
HN242	Multiple Head & Neck cancer test tissue array with unmatched normal adjacent tissue, 12 cases 24 cores, replaced by HN242a; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
HN242a	Head and neck cancer tissue array, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing HN242; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
HN481	Head & Neck cancer tissue array with unmatched normal adjacent tissues, 24 cases 48 cores with stage and grade data		160-Eur	US Biomax	tissue
HN481	Head & Neck cancer tissue array with unmatched normal adjacent tissues, 24 cases 48 cores with stage and grade data; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
HN482	Multiple Head & Neck cancer tissue array with normal tissue from autopsy, 48 cases 48 cores with stage and grade data, replaced by HN483		160-Eur	US Biomax	tissue
HN482	Multiple Head & Neck cancer tissue array with normal tissue from autopsy, 48 cases 48 cores with stage and grade data, replaced by HN483; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue

HN483	Multiple head and neck cancer with normal tissue array, including TNM and pathology grade, 48 cases 48 cores, replacing HN482		160-Eur	US Biomax	tissue
HN483	Multiple head and neck cancer with normal tissue array, including TNM and pathology grade, 48 cases 48 cores, replacing HN482; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
HN801	Multiple head and neck tumor tissue array with normal tissue, 40 cases 80 cores		266-Eur	US Biomax	tissue
HN801	Multiple head and neck tumor tissue array with normal tissue, 40 cases 80 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
HN802	Multiple head and neck tumor with normal tissue array, with stage and grade info, 80 cases 80 cores		266-Eur	US Biomax	tissue
HN802	Multiple head and neck tumor with normal tissue array, with stage and grade info, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
HN803	Head and neck squamous cancer tissue array, including TNM and pathology grade, 80 cases 80 cores		266-Eur	US Biomax	tissue
HN803	Head and neck squamous cancer tissue array, including TNM and pathology grade, 80 cases 80 cores, replaced by HN803a; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
HN803a	Multiple head and neck cancer tissue array with normal tissue, including TNM, clinical stage and pathology grade, 80 cases 80 cores, replacing HN803; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
HN811	Head and Neck tumor and normal tissue array, including TNM, clinical stage and pathology grade, 27 cases 81 cores, replacing BC34111		266-Eur	US Biomax	tissue
HN811	Head and Neck tumor and normal tissue array, including TNM, clinical stage and pathology grade, 27 cases 81 cores, replacing BC34111; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
HND181	Head and neck disease tissue array, 18 cases 18 cores		166-Eur	US Biomax	tissue
HND181	Head and neck disease tissue array, 18 cases 18 cores; ihc H&E, IHC anti-Cytokeratin		178-Eur	US Biomax	tissue
HNT961	Head and neck disease tissue array, 48 cases 96 cores		225-Eur	US Biomax	elisa
HNT961	Head and neck disease tissue array, 48 cases 96 cores; ihc H&E, IHC anti-Vimentin cytokeratin		238-Eur	US Biomax	elisa
HRC041	HER2 IHC control array, 4 cases 4 cores		77-Eur	US Biomax	
HRC041	HER2 IHC control array, 4 cases 4 cores; ihc H&E, IHC anti-HER2		85-Eur	US Biomax	

IC00011	Tissue array of gastritis with intestinal metaplasia and gastric carcinoma, 80 cases 80 cores, replaced by IC00011b		231-Eur	US Biomax	assays
IC00011	Tissue array of gastritis with intestinal metaplasia and gastric carcinoma, 80 cases 80 cores, replaced by IC00011b; ihc Anti-Cytokeratin (Low MW) confirmed		267-Eur	US Biomax	assays
IC00011b	Gastric carcinoma, gastritis with intestinal metaplasia tissue array, including TNM and pathology grade, 80 cases 80 cores, replacing IC00011		321-Eur	US Biomax	assays
IC00011b	Gastric carcinoma, gastritis with intestinal metaplasia tissue array, including TNM and pathology grade, 80 cases 80 cores, replacing IC00011		266-Eur	US Biomax	assays
IC00011b	Gastric carcinoma, gastritis with intestinal metaplasia tissue array, including TNM and pathology grade, 80 cases 80 cores, replacing IC00011; ihc Anti-Actin confirmed		258-Eur	US Biomax	assays
IC03001	Liver tissue, type B hepatitis and hepatic cirrhosis tissue array, 80 cases 80 cores, replaced by LV805		231-Eur	US Biomax	tissue
IC03001	Liver tissue, type B hepatitis and hepatic cirrhosis tissue array, 80 cases 80 cores, replaced by LV805; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
KD1001	Kidney cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases 100 cores		231-Eur	US Biomax	tissue
KD1001	Kidney cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
KD1002	Kidney cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases 100 cores		231-Eur	US Biomax	tissue
KD1002	Kidney cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
KD1501	Kidney cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
KD1502	Kidney cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
KD1921	Mid-advanced stage kidney cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores		456-Eur	US Biomax	elisa

KD1921	Mid-advanced stage kidney cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	elisa
KD208	High density tissue array (70 cases 208 cores) of kidney cancer and normal tissue		456-Eur	US Biomax	tissue
KD208	High density tissue array (70 cases 208 cores) of kidney cancer and normal tissue; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
KD20810	Kidney cancer survey tissue array (1 of 3), with normal tissue, including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
KD20810	Kidney cancer survey tissue array (1 of 3), with normal tissue, including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
KD20811	Kidney cancer survey tissue array (2 of 3), including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
KD20811	Kidney cancer survey tissue array (2 of 3), including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
KD20812	Kidney cancer survey tissue array (3 of 3), including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
KD20812	Kidney cancer survey tissue array (3 of 3), including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
KD2082	High density kidney cancer tissue array with normal tissues, with TNM and grade info, 104 cases 208 cores		456-Eur	US Biomax	tissue
KD2082	High density kidney cancer tissue array with normal tissues, with TNM and grade info, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
KD2083	Kidney cancer tissue array with normal tissues, with stage and grade info, 69 cases 208 cores		456-Eur	US Biomax	tissue
KD2083	Kidney cancer tissue array with normal tissues, with stage and grade info, 69 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
KD2084	Renal disease spectrum tissue array, with stage and TNM info, 104 cases 208 cores		456-Eur	US Biomax	tissue
KD2084	Renal disease spectrum tissue array, with stage and TNM info, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
KD2085	Kidney cancer survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
KD2085	Kidney cancer survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue

KD2086	Kidney cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
KD2086	Kidney cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
KD2087	Kidney cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
KD2087	Kidney cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
KD2088	Kidney cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
KD2088	Kidney cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
KD2089	Kidney cancer survey tissue array (5 of 5), including TNM and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
KD2089	Kidney cancer survey tissue array (5 of 5), including TNM and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
KD241	Kidney cancer test tissue array with matched cancer adjacent normal tissue, 6 cases 24 cores		88-Eur	US Biomax	assays
KD241	Kidney cancer test tissue array with matched cancer adjacent normal tissue, 6 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
KD242	Multiple Kidney cancer test tissue array with unmatched normal adjacent tissue, 10 cases 24 cores		88-Eur	US Biomax	assays
KD242	Multiple Kidney cancer test tissue array with unmatched normal adjacent tissue, 10 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
KD243	Kidney cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases 48 cores		189-Eur	US Biomax	tissue
KD243	Kidney cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases 48 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
KD244	Kidney clear cell carcinoma tissue array with matched kidney adjacent tissue, including TNM and pathology grade, 12 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
KD481	Tissue array of kidney clear cell carcinoma and matched adjacent tissue, with stage and grade data, 12 cases 48 cores		160-Eur	US Biomax	tissue

KD481	Tissue array of kidney clear cell carcinoma and matched adjacent tissue, with stage and grade data, 12 cases 48 cores; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
KD482	Tissue array of kidney carcinoma and matched adjacent tissue, with stage and grade data, 24 cases 48 cores		160-Eur	US Biomax	tissue
KD482	Tissue array of kidney carcinoma and matched adjacent tissue, with stage and grade data, 24 cases 48 cores; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
KD483	Multiple Kidney cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores, with stage and grade data		160-Eur	US Biomax	tissue
KD483	Multiple Kidney cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores, with stage and grade data; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
KD484	Kidney cancer tissue array, including TNM and pathology grade, 48 cases 48 cores		189-Eur	US Biomax	tissue
KD484	Kidney cancer tissue array, including TNM and pathology grade, 48 cases 48 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
KD485	Kidney cancer tissue array, with normal tissue, including TNM and pathology grade, 48 cases 48 cores		189-Eur	US Biomax	tissue
KD485	Kidney cancer tissue array, with normal tissue, including TNM and pathology grade, 48 cases 48 cores; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
KD486	Kidney clear cell carcinoma with matched adjacent kidney tissue array, including TNM and pathology grade, 16 cases 48 cores		225-Eur	US Biomax	tissue
KD486	Kidney clear cell carcinoma with matched adjacent kidney tissue array, including TNM and pathology grade, 16 cases 48 cores		189-Eur	US Biomax	tissue
KD486	Kidney clear cell carcinoma with matched adjacent kidney tissue array, including TNM and pathology grade, 16 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
KD6161	High-density renal cancer array, with stage, grade and normal renal tissue, 322 cases 616 cores		753-Eur	US Biomax	tissue
KD6161	High-density renal cancer array, with stage, grade and normal renal tissue, 322 cases 616 cores; ihc Anti-Actin confirmed		811-Eur	US Biomax	tissue
KD801	Kidney cancer tissue array, with matched adjacent normal tissue, 40 cases 80 cores		231-Eur	US Biomax	tissue
KD801	Kidney cancer tissue array, with matched adjacent normal tissue, 40 cases 80 cores; ihc Anti-Cytokeratin (High MW) confirmed		228-Eur	US Biomax	tissue

KD802	Kidney multiple cancer tissue array (clear, granular and transitional cell carcinoma, etc), 80 cases 80 cores		231-Eur	US Biomax	tissue
KD802	Kidney multiple cancer tissue array (clear, granular and transitional cell carcinoma, etc), 80 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
KD803	Normal kidney tissue array, replacing BN07012, 80 cases 80 cores		231-Eur	US Biomax	tissue
KD803	Normal kidney tissue array, replacing BN07012, 80 cases 80 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
KD804	Multiple types of kidney cancer and normal, adjacent normal tissue array, 80 cases 80 cores, with stage and grade information		231-Eur	US Biomax	tissue
KD804	Multiple types of kidney cancer and normal, adjacent normal tissue array, 80 cases 80 cores, with stage and grade information; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
KD806	Advanced kidney cancer tissue array, with stage and grade info, 80 cases 80 cores		231-Eur	US Biomax	tissue
KD806	Advanced kidney cancer tissue array, with stage and grade info, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
KD807	Kidney disease spectrum (renal cancer progression) tissue array, 80 cases 80 cores		231-Eur	US Biomax	tissue
KD807	Kidney disease spectrum (renal cancer progression) tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
KD808	Mid-advanced stage kidney cancer and metastatic carcinoma tissue array, including TNM and pathology grade, 80 cases 80 cores		231-Eur	US Biomax	tissue
KD808	Mid-advanced stage kidney cancer and metastatic carcinoma tissue array, including TNM and pathology grade, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
KD811	Renal carcinoma and normal tissue array, with TNM, 40 cases 80 cores		231-Eur	US Biomax	tissue
KD811	Kidney carcinoma and normal tissue array, with TNM, 40 cases 80 cores; ihc Anti-Actin confirmed		228-Eur	US Biomax	tissue
KD951	Kidney cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage, pathology grade and survival data, 32 cases 95 cores		456-Eur	US Biomax	tissue
KD951	Kidney cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage, pathology grade and survival data, 32 cases 95 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue

KD961	Kidney tumor tissue array with normal tissue as control, including TNM, clinical stage and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	elisa
KD962	Kidney cancer tissue array with normal tissue as control, including TNM, clinical stage and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	elisa
KD991	Kidney cancer tissue array with matched cancer adjacent and cancer adjacent normal tissue, 33 cases 99 cores		231-Eur	US Biomax	tissue
KD991	Kidney cancer tissue array with matched cancer adjacent and cancer adjacent normal tissue, 33 cases 99 cores; ihc Anti-Cytokeratin (High MW) confirmed		267-Eur	US Biomax	tissue
KIC1501	Kidney cancer mid-density tissue array, non-overlapping with KIC1502, 75 cases 150 cores		225-Eur	US Biomax	tissue
KIC1501	Kidney cancer mid-density tissue array, non-overlapping with KIC1502, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
KIC1502	Kidney cancer mid-density tissue array, non-overlapping with KIC1501, 75 cases 150 cores		225-Eur	US Biomax	tissue
KIC1502	Kidney cancer mid-density tissue array, non-overlapping with KIC1501, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
KIC241	Kidney cancer tissue array, 12 cases 24 cores		166-Eur	US Biomax	tissue
KIC241	Kidney cancer tissue array, 12 cases 24 cores; ihc H&E, IHC anti-Cytokeratin		205-Eur	US Biomax	tissue
KIC481	Kidney cancer and normal tissue array, 16 cases 48 cores		189-Eur	US Biomax	tissue
KIC481	Kidney cancer and normal tissue array, 16 cases 48 cores; ihc H&E, IHC anti-Cytokeratin		205-Eur	US Biomax	tissue
KIC961	Kidney cancer and normal tissue array, non-overlapping with KIC962, 48 cases 96 cores		225-Eur	US Biomax	elisa
KIC961	Kidney cancer and normal tissue array, non-overlapping with KIC962, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	elisa
KIC962	Kidney cancer and normal tissue array, non-overlapping with KIC961, 48 cases 96 cores		225-Eur	US Biomax	elisa
KIC962	Kidney cancer and normal tissue array, non-overlapping with KIC961, 48 cases 96 cores; ihc H&E, IHC anti-Vimentin Cytokeratin		238-Eur	US Biomax	elisa
LC10010	Small cell lung carcinoma tissue array, for antibody screening, including TNM and clinical stage, 50 cases 100 cores		231-Eur	US Biomax	tissue

LC10010	Small cell lung carcinoma tissue array, for antibody screening, including TNM and clinical stage, 50 cases 100 cores, replaced by LC10010a; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
LC10010a	Lung carcinoma tissue array with normal lung tissue as control, including TNM and clinical stage, 50 cases 100 cores, replacing LC10010; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LC10011	Non-small cell lung carcinoma (NSCLC) tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases 100 cores		231-Eur	US Biomax	tissue
LC10011	Non-small cell lung carcinoma (NSCLC) tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases 100 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
LC10012	Lung non-small cell cancer tissue array, with adjacent tissue and normal tissue, including TNM and pathology grade, 50 cases 100 cores, replacing LC1006		266-Eur	US Biomax	tissue
LC10012	Lung non-small cell cancer tissue array, with adjacent tissue and normal tissue, including TNM and pathology grade, 50 cases 100 cores, replacing LC1006; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LC10013	Lung adenocarcinoma tissue array with adjacent normal lung tissue, including TNM and pathology grade, 50 cases 100 cores, replacing LC1002		266-Eur	US Biomax	tissue
LC10013	Lung adenocarcinoma tissue array with adjacent normal lung tissue, including TNM and pathology grade, 50 cases 100 cores, replacing LC1002; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
LC1002	Lung adenocarcinoma (grade II-III) tissue array with self-matched adjacent normal tissue, and 4 non-cancer normal lung tissue, 52 cases 100 cores, replaced by LC10013		231-Eur	US Biomax	tissue
LC1002	Lung adenocarcinoma (grade II-III) tissue array with self-matched adjacent normal tissue, and 4 non-cancer normal lung tissue, with TNM info, 52 cases 100 cores, replaced by LC10013; ihc Anti-Cytokeratin		296-Eur	US Biomax	tissue
LC1004	Lung carcinoma (multi-tissue combined panel) tissue array, 50 cases 100 cores		231-Eur	US Biomax	tissue
LC1004	Lung carcinoma (multi-tissue combined panel) tissue array, 50 cases 100 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
LC1005	Lung carcinoma progression tissue array, 77 cases 100 cores		266-Eur	US Biomax	tissue

LC1005	Lung carcinoma progression tissue array, 77 cases 100 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
LC1006	Non-small cell lung carcinoma (NSCLC) tissue array with matched adjacent normal tissue as control, 56 cases 100 cores, with stage and grade data, replacing LC1001		231-Eur	US Biomax	tissue
LC1006	Non-small cell lung carcinoma (NSCLC) tissue array with matched adjacent normal tissue as control, 56 cases 100 cores, with stage and grade data, replacing LC1001; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
LC1007	Lung tuberculosis tissue array with normal tissue, 48 cases 100 cores		231-Eur	US Biomax	tissue
LC1007	Lung tuberculosis tissue array with normal tissue, 48 cases 100 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
LC1008	Non-small cell lung carcinoma array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases 100 cores		231-Eur	US Biomax	
LC1008	Non-small cell lung carcinoma array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	
LC1009	Lung small cell carcinoma tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases 100 cores		231-Eur	US Biomax	tissue
LC1009	Lung small cell carcinoma tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LC1201	Lung disease spectrum tissue array, 116 cases 120 cores, with grade and stage information		278-Eur	US Biomax	tissue
LC1201	Lung disease spectrum tissue array, 116 cases 120 cores, with grade and stage information; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LC1501	Lung adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		321-Eur	US Biomax	tissue
LC1501	Lung adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		266-Eur	US Biomax	tissue
LC1501	Lung adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
LC1502	Lung cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue

LC1503	Lung cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
LC1921	High density non-small cell lung carcinoma (NSCLC) tissue array, with stage and grade info, 192 cases 192 cores		456-Eur	US Biomax	tissue
LC1921	High density non-small cell lung carcinoma (NSCLC) tissue array, with stage and grade info, 192 cases 192 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LC1922	Middle-advanced stage lung non-small cell carcinoma tissue array, including TNM and pathology grade, 96 cases 192 cores		456-Eur	US Biomax	elisa
LC1922	Middle-advanced stage lung non-small cell carcinoma tissue array, including TNM and pathology grade, 96 cases 192 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	elisa
LC2001	Lung cancer high-density (192 cases 200 cores) tissue array		397-Eur	US Biomax	tissue
LC2001	Lung cancer high-density (192 cases 200 cores) tissue array; ihc Anti-Cytokeratin (Low-MW) confirmed		382-Eur	US Biomax	tissue
LC2081	Multiple lung carcinoma (Non-small cell lung carcinoma, NSCLC) and normal tissue form necroscopy tissue array, 70 cases 208 cores, with stage and grade information		456-Eur	US Biomax	tissue
LC2081	Multiple lung carcinoma (Non-small cell lung carcinoma, NSCLC) and normal tissue form necroscopy tissue array, 70 cases 208 cores, with stage and grade information; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LC20810	Lung cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
LC20810	Lung cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Cytokeratin (CK) confirmed		429-Eur	US Biomax	tissue
LC20811	Lung cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
LC20811	Lung cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
LC20812	Lung cancer tissue array (1 of 5), with normal tissue, including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue

LC20812	Lung cancer tissue array (1 of 5), with normal tissue, including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LC20813	Lung cancer tissue array (2 of 5), including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
LC20813	Lung cancer tissue array (2 of 5), including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LC20814	Lung cancer tissue array (3 of 5), including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
LC20814	Lung cancer tissue array (3 of 5), including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LC20815	Lung cancer tissue array (4 of 5), including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
LC20815	Lung cancer tissue array (4 of 5), including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LC20816	Lung cancer tissue array (5 of 5), including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
LC20816	Lung cancer tissue array (5 of 5), including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LC2082	Multiple lung carcinoma and normal tissue array, 70 cases 208 cores		456-Eur	US Biomax	tissue
LC2082	Multiple lung carcinoma and normal tissue array, 70 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LC2083	Lung disease spectrum (pulmonary cancer progression) tissue array, 193 cases 208 cores		456-Eur	US Biomax	tissue
LC2083	Lung disease spectrum (pulmonary cancer progression) tissue array, 193 cases 208 cores; ihc Anti-Cytokeratin (CK) confirmed		487-Eur	US Biomax	tissue
LC2084	High-density Lung cancer tissue array with normal tissues, with stage and grade info, 104 cases 208 cores		456-Eur	US Biomax	tissue
LC2084	High-density Lung cancer tissue array with normal tissues, with stage and grade info, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
LC2085a	High-density (188 cases 208 cores), multiple types of lung cancer (I-3 grade) tissue array with normal lung from autopsy and cancer adjacent tissue		456-Eur	US Biomax	tissue
LC2085a	High-density (188 cases 208 cores), multiple types of lung cancer (I-3 grade) tissue array with normal lung from autopsy and cancer adjacent tissue; ihc Anti-Cytokeratin (CK) confirmed		487-Eur	US Biomax	tissue

LC2085b	High-density (208 cores), multiple types of lung cancer (grade 1-3) tissue array with normal lung and cancer adjacent tissue, and staging info, 188 cases 208 cores (duplicate of LC2085a)		456-Eur	US Biomax	tissue
LC2085b	High-density (208 cores), multiple types of lung cancer (grade 1-3) tissue array with normal lung and cancer adjacent tissue, and staging info, 188 cases 208 cores (duplicate of LC2085a); ihc Anti-Cy		487-Eur	US Biomax	tissue
LC2086	Normal lung tissue array, 104 cases 208 cores		456-Eur	US Biomax	tissue
LC2086	Normal lung tissue array, 104 cases 208 cores; ihc Anti-Cytokeratin (CK) confirmed		429-Eur	US Biomax	tissue
LC2087	Lung tumor survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
LC2087	Lung tumor survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Cytokeratin (CK) confirmed		429-Eur	US Biomax	tissue
LC2088	Lung cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
LC2088	Lung cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
LC2089	Lung cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
LC2089	Lung cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Cytokeratin (CK) confirmed		429-Eur	US Biomax	tissue
LC2161	Lung cancer tissue array, including TNM and pathology grade, 216 cases 216 cores		456-Eur	US Biomax	tissue
LC2161	Lung cancer tissue array, including TNM and pathology grade, 216 cases 216 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LC241	Non-small cell lung carcinoma (NSCLC) test tissue array, with self-matching normal adjacent tissue, 6 cases 24 cores		88-Eur	US Biomax	assays
LC241	Non-small cell lung carcinoma (NSCLC) test tissue array, with self-matching normal adjacent tissue, 6 cases 24 cores; ihc Anti-Cytokeratin (High MW) confirmed		90-Eur	US Biomax	assays
LC242	Non-small cell lung carcinoma (NSCLC) test tissue array, with unmatched normal adjacent tissue, 12 cases 24 cores		88-Eur	US Biomax	assays

LC242	Non-small cell lung carcinoma (NSCLC) test tissue array, with unmatched normal adjacent tissue, 12 cases 24 cores; ihc Anti-Cytokeratin (High MW) confirmed		90-Eur	US Biomax	assays
LC243	Lung cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases 48 cores		189-Eur	US Biomax	tissue
LC243	Lung cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases 48 cores; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
LC481	Tissue array of lung carcinoma and matched adjacent tissue, 12 cases 48 cores		160-Eur	US Biomax	tissue
LC481	Tissue array of lung carcinoma and matched adjacent tissue, 12 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
LC482	Non-small cell lung carcinoma (NSCLC) tissue array, with 4 normal tissue control from autopsy, 24 cases 48 cores, with grade and stage status		160-Eur	US Biomax	tissue
LC482	Non-small cell lung carcinoma (NSCLC) tissue array, with 4 normal tissue control from autopsy, 24 cases 48 cores, with grade and stage status; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
LC483	Multiple lung cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores		160-Eur	US Biomax	tissue
LC483	Multiple lung cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
LC484	Lung cancer tissue array, including TNM and pathology grade, 48 cases 48 cores		231-Eur	US Biomax	tissue
LC484	Lung cancer tissue array, including TNM and pathology grade, 48 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
LC485	Lung cancer tissue array, with normal tissue, including TNM and pathology grade, 48 cases 48 cores		189-Eur	US Biomax	tissue
LC485	Lung cancer tissue array, with normal tissue, including TNM and pathology grade, 48 cases 48 cores; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
LC486	Lung cancer and matched adjacent lung tissue array, including TNM and pathology grade, 16 cases 48 cores		188-Eur	US Biomax	tissue
LC486	Lung cancer and matched adjacent lung tissue array, including TNM and pathology grade, 16 cases 48 cores		160-Eur	US Biomax	tissue

LC486	Lung cancer and matched adjacent lung tissue array, including TNM and pathology grade, 16 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
LC487	Lung disease spectrum tissue array, including TNM and pathology grade, 24 cases 48 cores		225-Eur	US Biomax	tissue
LC487	Lung disease spectrum tissue array, including TNM and pathology grade, 24 cases 48 cores		189-Eur	US Biomax	tissue
LC487	Lung disease spectrum tissue array, including TNM and pathology grade, 24 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
LC488	Lung cancer tissue array with matched adjacent lung tissue, including TNM, clinical stage and pathology grade, 16 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
LC501	Tissue array of multi-type lung cancer and normal tissue with TNM and grade, 50 cases 50 cores		160-Eur	US Biomax	tissue
LC501	Tissue array of multi-type lung cancer and normal tissue with TNM and grade, 50 cases 50 cores; ihc Anti-Cytokeratin (CK) confirmed		210-Eur	US Biomax	tissue
LC601	Non-small cell lung carcinoma (NSCLC) and normal tissue array, 25 cases plus normal tissues, with TNM data		----Eur	US Biomax	tissue
LC6161	High-density lung cancer array, with stage, grade and normal lung tissue, 322 cases 616 cores		753-Eur	US Biomax	tissue
LC6161	High-density lung cancer array, with stage, grade and normal lung tissue, 322 cases 616 cores; ihc Anti-Actin confirmed		811-Eur	US Biomax	tissue
LC641	Non-small cell lung carcinoma (NSCLC) tissue array, 64 cases 66 cores, with TNM data		----Eur	US Biomax	tissue
LC721	Non-small cell lung carcinoma (NSCLC) tissue array, 24 cases 72 cores, replacing BC04011		231-Eur	US Biomax	tissue
LC721	Non-small cell lung carcinoma (NSCLC) tissue array, 24 cases 72 cores, replacing BC04011; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
LC722	Lung cancer and normal tissue array, with TNM and grade data, 24 cases 72 cores		231-Eur	US Biomax	tissue
LC722	Lung cancer and normal tissue array, with TNM and grade data, 24 cases 72 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LC723	Lung cancer and adjacent normal tissue array, with TNM and grade info, 24 cases 72 cores, replacing BS04071		231-Eur	US Biomax	tissue
LC723	Lung cancer and adjacent normal tissue array, with TNM and grade info, 24 cases 72 cores, replacing BS04071; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue

LC724	Lung cancer and adjacent normal tissue array, with TNM and grade info, 24 cases 72 cores, replacing BS04031		231-Eur	US Biomax	tissue
LC724	Lung cancer and adjacent normal tissue array, with TNM and grade info, 24 cases 72 cores, replacing BS04031; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
LC725	Normal lung tissue array, 24 cases 72 cores, replacing BN04011		278-Eur	US Biomax	tissue
LC725	Normal lung tissue array, 24 cases 72 cores, replacing BN04011; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
LC726	Lung carcinoma tissue array, including TNM, clinical stage and pathology grade, 72 cases 72 cores, replacing BC04016		231-Eur	US Biomax	tissue
LC726	Lung carcinoma tissue array, including TNM, clinical stage and pathology grade, 72 cases 72 cores, replaced by LC726a; ihc Anti-Actin confirmed		228-Eur	US Biomax	tissue
LC726a	Lung cancer tissue array, including TNM, clinical stage and pathology grade, 72 cases 72 cores, replacing LC726; ihc Anti-Actin confirmed		228-Eur	US Biomax	tissue
LC727	Lung large cell carcinoma tissue array, including TNM and clinical stage, 24 cases 72 cores		231-Eur	US Biomax	tissue
LC727	Lung large cell carcinoma tissue array, including TNM and clinical stage, 24 cases 72 cores; ihc Anti-Epithelial Membrane Antigen (EMA) confirmed		267-Eur	US Biomax	tissue
LC801	Lung carcinoma (multi-tissue combined panel) tissue array, 79 cases 80 cores		189-Eur	US Biomax	tissue
LC801	Lung carcinoma (multi-tissue combined panel) tissue array, 79 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
LC802	Lung small cell carcinoma tissue array (40 cases 80 cores)		266-Eur	US Biomax	tissue
LC802	Lung small cell carcinoma tissue array, with normal lung tissue, 40 cases 80 cores; ihc Anti-Chromogranin A (CgA) confirmed		228-Eur	US Biomax	tissue
LC803	Lung carcinoma (multi-tissue combined panel, 80 cases 80 cores) tissue array		231-Eur	US Biomax	tissue
LC803	Lung carcinoma (multi-tissue combined panel, 80 cases 80 cores) tissue array; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
LC805	Lung large cell carcinoma and bronchioloalveolar carcinoma tissue array, 40 cases 80 cores		231-Eur	US Biomax	tissue
LC805	Lung large cell carcinoma and bronchioloalveolar carcinoma tissue array, 40 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		228-Eur	US Biomax	tissue
LC806	Multiple types of lung carcinoma tissue array, 80 cases 80 cores, replacing BC04013		231-Eur	US Biomax	tissue

LC806	Multiple types of lung carcinoma tissue array, 80 cases 80 cores, replacing BC04013; ihc Anti-Cytokeratin (CK) confirmed		228-Eur	US Biomax	tissue
LC807	Lung cancer and normal tissue array, with TNM and grade info, 77 cases 80 cores, replacing BC04014		231-Eur	US Biomax	tissue
LC807	Lung cancer and normal tissue array, with TNM and grade info, 77 cases 80 cores, replacing BC04014; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LC808	Lung squamous cell carcinoma tissue array, with TNM, stage and grade, 80 cases 80 cores, replacing BS04011		231-Eur	US Biomax	tissue
LC808	Lung squamous cell carcinoma tissue array, with TNM, stage and grade, 80 cases 80 cores, replacing BS04011; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LC809	Lung disease spectrum (pulmonary cancer progression) tissue array, 78 cases 80 cores		231-Eur	US Biomax	tissue
LC809	Lung disease spectrum (pulmonary cancer progression) tissue array, 78 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LC810	Lung cancer with matched lymph node metastasis tissue array, 40 cases 80 cores		231-Eur	US Biomax	tissue
LC810	Lung cancer with matched lymph node metastasis tissue array, 40 cases 80 cores, replaced by LC814; ihc Anti-Cytokeratin (High MW) confirmed		296-Eur	US Biomax	tissue
LC811	Lung cancer tissue array with normal tissues, 80 cases 80 cores		278-Eur	US Biomax	tissue
LC811	Lung cancer tissue array with normal tissues, 80 cases 80 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
LC812	Lung cancer tissue array with normal tissues from autopsy, with TNM data, 40 cases 80 cores		231-Eur	US Biomax	tissue
LC812	Lung cancer tissue array with normal tissues from autopsy, with TNM data, 40 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
LC813	Multiple non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma tissue array with normal lung tissue, 77 cases 80 cores, replacing BC04014		231-Eur	US Biomax	tissue
LC813	Multiple non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma tissue array with normal lung tissue, 77 cases 80 cores, replacing BC04014; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
LC814	Lung cancer with matched lymph node metastasis tissue array, 40 cases 80 cores		231-Eur	US Biomax	tissue
LC814	Lung cancer with matched lymph node metastasis tissue array, 40 cases 80 cores, replacing LC810; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue

LC815	Lung cancer and normal tissue array with stage and grade info, 40 cases 80 cores		231-Eur	US Biomax	tissue
LC815	Lung cancer and normal tissue array with stage and grade info, 40 cases 80 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
LC816	Advanced lung cancer and normal tissue array, with stage TNM and grade info, 80 cases 80 cores		231-Eur	US Biomax	tissue
LC816	Advanced lung cancer and normal tissue array, with stage TNM and grade info, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LC817	Lung cancer tissue array with matched lymph node metastatic tissue, including TNM, clinical stage and pathology grade, 40 cases 80 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
LC951	Lung cancer tissue array with normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 40 cases 95 cores		456-Eur	US Biomax	tissue
LC951	Lung cancer tissue array with normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 40 cases 95 cores; ihc Anti-Cytokeratin (CK) confirmed		487-Eur	US Biomax	tissue
LC961	Lung cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	elisa
LC962	Lung cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	elisa
LC991	Lung squamous cell carcinoma (grade I-III) tissue array with matched tumor adjacent and normal control, 33 cases 99 cores		231-Eur	US Biomax	tissue
LC991	Lung squamous cell carcinoma (grade I-III) tissue array with matched tumor adjacent and normal control, 33 cases 99 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
LC992	Lung adenocarcinoma (grade I-III, 33 cases) tissue array with matched tumor adjacent and normal control, 33 cases 99 cores		231-Eur	US Biomax	tissue
LC992	Lung adenocarcinoma (grade I-III, 33 cases) tissue array with matched tumor adjacent and normal control, 33 cases 99 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
LM208	High density tissue microarray of Hodgkin's Disease, Non-Hodgkin's lymphoma and normal lymph node tissues, 69 cases 208 cores		456-Eur	US Biomax	tissue

LM208	High density tissue microarray of Hodgkin's Disease, Non-Hodgkin's lymphoma and normal lymph node tissues, 69 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LM241	Multiple lymphoma tissue array with normal tissues, 12 cases 24 cores		88-Eur	US Biomax	tissue
LM241	Multiple lymphoma tissue array with normal tissues, 12 cases 24 cores; ihc Anti-CD20 confirmed		105-Eur	US Biomax	tissue
LM481	Multiple lymphoma tissue array with normal tissues, 48 cases 48 cores		160-Eur	US Biomax	tissue
LM481	Multiple lymphoma tissue array with normal tissues, 48 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
LM482	Myeloma, lymphoma and normal tissue array, 48 cases 48 cores		266-Eur	US Biomax	tissue
LM482	Myeloma, lymphoma and normal tissue array, 48 cases 48 cores, replaced by LM482a; ihc Anti-Actin confirmed		320-Eur	US Biomax	tissue
LM482a	Lymphoma tissue array with normal lymph node tissue as control, 48 cases 48 cores, replacing LM482; ihc Anti-Actin confirmed		320-Eur	US Biomax	tissue
LM721	Lymphoma and normal lymph node tissue array, 24 cases 72 cores		266-Eur	US Biomax	tissue
LM721	Lymphoma and normal lymph node tissue array, 24 cases 72 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LM801	Lymphoma (Hodgkin's and non-Hodgkin's disease) tissue array, 80 cases 80 cores		266-Eur	US Biomax	tissue
LM801	Lymphoma (Hodgkin's and non-Hodgkin's disease) tissue array, 80 cases 80 cores, replaced by LM801a; ihc Anti-Proliferating Cell Nuclear Antigen (PCNA) confirmed		267-Eur	US Biomax	tissue
LM801a	Lymphoma tissue array with adjacent normal lymph node and spleen tissue as control, 80 cases 80 cores, replacing LM801; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
LM802	Lymphoma (Hodgkin's and non-Hodgkin's disease) tissue array, 80 cases 80 cores, replaced by NHL803		266-Eur	US Biomax	tissue
LM802	Lymphoma (Hodgkin's and non-Hodgkin's disease) tissue array, 80 cases 80 cores, replaced by NHL803; ihc Anti-Leukocyte Common Antigen (LCA) confirmed		267-Eur	US Biomax	tissue
LM803	Lymphoma and normal lymph node tissue array, 40 cases 80 cores		231-Eur	US Biomax	tissue
LM803	Lymphoma and normal lymph node tissue array, 40 cases 80 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
LN801	Normal lymphatic (lymph node, thymus, spleen, tonsil and appendix) tissue array, 80 cases 80 cores, replaced by LN802		231-Eur	US Biomax	tissue

LN801	Normal lymphatic (lymph node, thymus, spleen, tonsil and appendix) tissue array, 80 cases 80 cores, replaced by LN802; ihc Anti-Actin confirmed		228-Eur	US Biomax	tissue
LN802	Multiple organ lymph tissue array, 80 cases 80 cores, replacing LN801		231-Eur	US Biomax	tissue
LN802	Multiple organ lymph tissue array, 80 cases 80 cores, replacing LN801; ihc Anti-Actin confirmed		228-Eur	US Biomax	tissue
LP208	High density larynx and pharynx cancer tissue array with normal tissue (69 cases 208 core) including stage and grade data		456-Eur	US Biomax	tissue
LP208	High density larynx and pharynx cancer tissue array with normal tissue (69 cases 208 core) including stage and grade data; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LP241	Larynx and pharynx cancer tissue array with self-matching normal adjacent tissues, 10 cases 24 cores		88-Eur	US Biomax	tissue
LP241	Larynx and pharynx cancer tissue array with self-matching normal adjacent tissues, 10 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	tissue
LP481	Larynx and pharynx cancer tissue array with unmatched normal tissues, 48 cases 48, cores with stage and grade data		160-Eur	US Biomax	tissue
LP481	Larynx and pharynx cancer tissue array with unmatched normal tissues, 48 cases 48, cores with stage and grade data; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
LP721	Laryngeal cancer and normal tissue array, with grade and TNM information, 24 cases 72 cores		266-Eur	US Biomax	tissue
LP721	Laryngeal cancer and normal tissue array, with grade and TNM information, 24 cases 72 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LP801	Larynx and pharynx cancer tissue array, with matched adjacent normal tissue, 70 cases 80 cores		231-Eur	US Biomax	tissue
LP801	Larynx and pharynx cancer tissue array, with matched adjacent normal tissue, 70 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
LP802	Laryngeal disease spectrum (progression) tissue array, 78 cases 80 cores		278-Eur	US Biomax	tissue
LP802	Laryngeal disease spectrum (progression) tissue array, 78 cases 80 cores; ihc Anti-Actin confirmed		382-Eur	US Biomax	tissue
LP803	Laryngeal squamous cell carcinoma tissue array, 80 cases 80 cores		266-Eur	US Biomax	tissue
LP803	Laryngeal squamous cell carcinoma tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LP804	Laryngeal cancerous, cancer adjacent and normal tissue array, with grade and stage info, 40 cases 80 cores		266-Eur	US Biomax	tissue

LP804	Laryngeal cancerous, cancer adjacent and normal tissue array, with grade and stage info, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LUC1021	Lung cancer tissue array, 102 cases 102 cores		225-Eur	US Biomax	tissue
LUC1021	Lung cancer tissue array, 102 cases 102 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
LUC1501	Lung cancer mid-density tissue array, non-overlapping with LUC1502 or LUC1503, 75 cases 150 cores		225-Eur	US Biomax	tissue
LUC1501	Lung cancer mid-density tissue array, non-overlapping with LUC1502 or LUC1503, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
LUC1502	Lung cancer mid-density tissue array, non-overlapping with LUC1501 or LUC1503, 75 cases 150 cores		225-Eur	US Biomax	tissue
LUC1502	Lung cancer mid-density tissue array, non-overlapping with LUC1501 or LUC1503, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
LUC1503	Lung cancer mid-density tissue array, non-overlapping with LUC1501 or LUC1502, 75 cases 150 cores		225-Eur	US Biomax	tissue
LUC1503	Lung cancer mid-density tissue array, non-overlapping with LUC1501 or LUC1502, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
LUC2281	High density lung cancer tissue array, 228 cases 228 cores		403-Eur	US Biomax	tissue
LUC2281	High density lung cancer tissue array, 228 cases 228 cores; ihc H&E, IHC anti-Cytokeratin		434-Eur	US Biomax	tissue
LUC481	Lung cancer and normal tissue array, non-overlapping with LUC482, 16 cases 48 cores		166-Eur	US Biomax	tissue
LUC481	Lung cancer and normal tissue array, non-overlapping with LUC482, 16 cases 48 cores; ihc H&E, IHC anti-Cytokeratin		205-Eur	US Biomax	tissue
LUC482	Lung cancer and normal tissue array, non-overlapping with LUC481, 16 cases 48 cores		166-Eur	US Biomax	tissue
LUC482	Lung cancer and normal tissue array, non-overlapping with LUC481, 16 cases 48 cores; ihc H&E, IHC anti-Cytokeratin		205-Eur	US Biomax	tissue
LUC961	Lung cancer and normal tissue array, without overlapping with LUC962, 48 cases 96 cores		189-Eur	US Biomax	elisa
LUC961	Lung cancer and normal tissue array, without overlapping with LUC962, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	elisa
LUC962	Lung cancer and normal tissue array, without overlapping with LUC961, 48 cases 96 cores		189-Eur	US Biomax	elisa

LUC962	Lung cancer and normal tissue array, without overlapping with LUC961, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	elisa
LUD151	Lung disease tissue array, 15 cases 15 cores		166-Eur	US Biomax	tissue
LUD151	Lung disease tissue array, 15 cases 15 cores; ihc H&E, IHC anti-Cytokeratin		178-Eur	US Biomax	tissue
LUD481	Lung disease and normal tissue array, 16 cases 48 cores		225-Eur	US Biomax	tissue
LUD481	Lung disease and normal tissue array, 16 cases 48 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	tissue
LUP541	Visceral pleura tissue array, 27 cases 54 cores		225-Eur	US Biomax	tissue
LUP541	Visceral pleura tissue array, 27 cases 54 cores; ihc H&E, IHC anti-Vimentin Cytokeratin		238-Eur	US Biomax	tissue
LV1001	Liver cancer antibody screening array, including TNM, clinical stage and pathology grade, 25 cases 100 cores		231-Eur	US Biomax	
LV1001	Liver cancer antibody screening array, including TNM, clinical stage and pathology grade, 25 cases 100 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	rat
LV1002	Liver cancer tissue array, including TNM, clinical stage and pathology grade, 50 cases 100 cores		231-Eur	US Biomax	tissue
LV1002	Liver cancer tissue array, including TNM, clinical stage and pathology grade, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LV1003	Liver cancer tissue array, with HBV infection information, including TNM and pathology grade, 50 cases 100 cores		314-Eur	US Biomax	tissue
LV1003	Liver cancer tissue array, with HBV infection information, including TNM and pathology grade, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LV1201	Multiple diseases of liver tissue array, including TNM, clinical stage and pathology grade, 120 cases 120 cores		397-Eur	US Biomax	tissue
LV1201	Multiple diseases of liver tissue array, including TNM, clinical stage and pathology grade, 120 cases 120 cores; ihc Anti-Cytokeratin (CK) confirmed		320-Eur	US Biomax	tissue
LV1501	Liver hepatocellular carcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		321-Eur	US Biomax	tissue
LV1501	Liver hepatocellular carcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		266-Eur	US Biomax	tissue

LV1501	Liver hepatocellular carcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
LV1502	Liver cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
LV1503	Liver cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
LV1921	Liver late stage tumor tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores		456-Eur	US Biomax	elisa
LV1921	Liver late stage tumor tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores; ihc Anti-Cytokeratin (CK) confirmed		487-Eur	US Biomax	elisa
LV2001	High-density liver cancer tissue array, paraffin section, 200 cases 200 cores		397-Eur	US Biomax	tissue
LV2001	High-density liver cancer tissue array, paraffin section, 200 cases 200 cores; ihc Anti-Cytokeratin (High MW) confirmed		382-Eur	US Biomax	tissue
LV208	Liver cancer (hepatocellular carcinoma) and normal tissue high density (69 cases 208 cores) tissue microarray, with stage and grade info		456-Eur	US Biomax	tissue
LV208	Liver cancer (hepatocellular carcinoma) and normal tissue high density (69 cases 208 cores) tissue microarray, with stage and grade info; ihc Anti-Cytokeratin (CK) confirmed		487-Eur	US Biomax	tissue
LV2081	Hepatic disease spectrum (liver cancer progression) tissue array, 103 cases 208 cores		516-Eur	US Biomax	tissue
LV2081	Hepatic disease spectrum (liver cancer progression) tissue array, 103 cases 208 cores; ihc Anti-Cytokeratin (CK) confirmed		592-Eur	US Biomax	tissue
LV20810	Liver cancer survey tissue array (2 of 3), with normal tissue, including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
LV20810	Liver cancer survey tissue array (2 of 3), with normal tissue, including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LV20811	Liver cancer survey tissue array (3 of 3), with normal tissue, including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
LV20811	Liver cancer survey tissue array (3 of 3), with normal tissue, including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LV20812	Liver tissue cancer tissue array, containing HBV infection, TNM and pathology grade information, 104 cases 208 cores		456-Eur	US Biomax	tissue

LV20812	Liver disease tissue array, including HBV infection, TNM and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
LV2082	Liver cancer tissue array with normal tissues, with TNM and grade info, 104 cases 208 cores		456-Eur	US Biomax	tissue
LV2082	Liver cancer tissue array with normal tissues, with TNM and grade info, 104 cases 208 cores; ihc Anti-Cytokeratin (CK) confirmed		429-Eur	US Biomax	tissue
LV2083	High-density liver cancer tissue array with normal tissues, with stage and grade info, 69 cases 208 cores		456-Eur	US Biomax	tissue
LV2083	High-density liver cancer tissue array with normal tissues, with stage and grade info, 69 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LV2084	Liver cancer survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		516-Eur	US Biomax	tissue
LV2084	Liver cancer survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Cytokeratin (CK) confirmed		429-Eur	US Biomax	tissue
LV2085	Liver cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
LV2085	Liver cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
LV2086	Liver cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
LV2086	Liver cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Cytokeratin (CK) confirmed		429-Eur	US Biomax	tissue
LV2087	Liver cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
LV2087	Liver cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
LV2088	Liver cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
LV2088	Liver cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue

LV2089	Liver cancer survey tissue array (1 of 3), with normal tissue, including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
LV2089	Liver cancer survey tissue array (1 of 3), with normal tissue, including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LV2091	Liver cancer tissue array with normal liver tissue as control, including TNM, clinical stage and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
LV2161	Liver cancer tissue array, with normal tissue, including TNM and pathology grade, 216 cases 216 cores		456-Eur	US Biomax	tissue
LV2161	Liver cancer tissue array, with normal tissue, including TNM and pathology grade, 216 cases 216 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LV241	Liver cancer test tissue array with self-matching normal adjacent tissue, 6 cases 24 cores		88-Eur	US Biomax	assays
LV241	Liver cancer test tissue array with self-matching normal adjacent tissue, 6 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
LV242	Multiple Liver cancer test tissue array with unmatched normal adjacent tissue, 12 cases 24 cores		88-Eur	US Biomax	assays
LV242	Multiple Liver cancer test tissue array with unmatched normal adjacent tissue, 12 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
LV243	Liver cancer tissue array with normal tissues from autopsy, 12 cases 24 cores, with grade and stage		88-Eur	US Biomax	tissue
LV243	Liver cancer tissue array with normal tissues from autopsy, 12 cases 24 cores, with grade and stage; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
LV244	Liver cancer tissue array, with stage and grade info, 8 cases 24 cores		88-Eur	US Biomax	tissue
LV244	Liver cancer tissue array, with stage and grade info, 8 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
LV245	Liver cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases 48 cores		189-Eur	US Biomax	tissue
LV245	Liver cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases 48 cores; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
LV481	Liver cancer tissue array with normal adjacent tissues, 23 cases 48 cores, with grade and stage data		160-Eur	US Biomax	tissue

LV481	Liver cancer tissue array with normal adjacent tissues, 23 cases 48 cores, with grade and stage data; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
LV482	Multiple liver cancer tissue array with 4 normal tissues control from autopsy, with TNM, 24 cases 48 cores		160-Eur	US Biomax	tissue
LV482	Multiple liver cancer tissue array with 4 normal tissues control from autopsy, with TNM, 24 cases 48 cores; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
LV483	Multiple liver cancer tissue array with normal tissue control from autopsy, with TNM data, 48 cases 48 cores		160-Eur	US Biomax	tissue
LV483	Multiple liver cancer tissue array with normal tissue control from autopsy, with TNM data, 48 cases 48 cores; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
LV484	Liver cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases 48 cores		231-Eur	US Biomax	tissue
LV484	Liver cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases 48 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
LV485	Liver cancer tissue array, including TNM, clinical stage and pathology grade, 2 serial sections, 48 cases 96 cores		397-Eur	US Biomax	elisa
LV485	Liver cancer tissue array, including TNM, clinical stage and pathology grade, 2 serial sections, 48 cases 96 cores; ihc Anti-Cytokeratin (CK) confirmed		382-Eur	US Biomax	elisa
LV486	Liver cancer tissue array with matched adjacent tumor tissue, including TNM and pathology grade, 16 cases 48 cores		231-Eur	US Biomax	tissue
LV486	Liver cancer tissue array with matched adjacent tumor tissue, including TNM and pathology grade, 16 cases 48 cores; ihc Anti-Actin confirmed		228-Eur	US Biomax	tissue
LV487	Hepatocellular carcinoma tissue array with matched liver adjacent tissue, including TNM and pathology grade, 16 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
LV6161	High-density liver cancer array, with clinical stage, pathology grade and normal hepatic tissue, 322 cases 616 cores		753-Eur	US Biomax	tissue
LV6161	High-density liver cancer array, with clinical stage, pathology grade and normal hepatic tissue, 322 cases 616 cores; ihc Anti-Cytokeratin (CK) confirmed		811-Eur	US Biomax	tissue

LV631	Hepatocellular carcinoma tissue array with matched normal cancer adjacent tissue, 55 cases 63 cores		231-Eur	US Biomax	tissue
LV631	Hepatocellular carcinoma tissue array with matched normal cancer adjacent tissue, 55 cases 63 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
LV721	Hepatocellular carcinoma and normal tissue array with stage and grade information, 24 cases 72 cores		231-Eur	US Biomax	tissue
LV721	Hepatocellular carcinoma and normal tissue array with stage and grade information, 24 cases 72 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
LV723	Liver cancer and adjacent normal tissue array, including TNM and pathology grade, 72 cases 72 cores, replacing BC03013		231-Eur	US Biomax	tissue
LV723	Liver cancer and adjacent normal tissue array, including TNM and pathology grade, 72 cases 72 cores, replacing BC03013; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LV801	Liver cancer tissue array, with matched or unmatched adjacent normal tissue, 75 cases 80 cores		231-Eur	US Biomax	tissue
LV801	Liver cancer tissue array, with matched or unmatched adjacent normal tissue, 75 cases 80 cores; ihc Anti-Cytokeratin (High MW) confirmed		267-Eur	US Biomax	tissue
LV8010	Liver cancer and normal tissue array, with stage and grade info, 80 cases 80 cores, replacing BC03011		231-Eur	US Biomax	tissue
LV8010	Liver cancer and normal tissue array, with stage and grade info, 80 cases 80 cores, replacing BC03011; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LV8011	Liver disease spectrum (hepatic cancer progression) tissue array, 76 cases 80 cores		231-Eur	US Biomax	tissue
LV8011	Liver disease spectrum (hepatic cancer progression) tissue array, 76 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LV8012	Mid-advanced stage liver cancer tissue array, including TNM and pathology grade, 80 cases 80 cores		231-Eur	US Biomax	tissue
LV8012	Mid-advanced stage liver cancer tissue array, including TNM and pathology grade, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LV8013	Hepatocellular carcinoma tissue array, including TNM, pathology grade, HBV and HCV infection information, 40 cases 80 cores		321-Eur	US Biomax	tissue
LV8013	Hepatocellular carcinoma tissue array, including TNM, pathology grade, HBV and HCV infection information, 40 cases 80 cores		266-Eur	US Biomax	tissue

LV8013	Hepatocellular carcinoma tissue array, including TNM, pathology grade, HBV and HCV infection information, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LV802	Liver carcinoma (multi-tissue combined panel) tissue array, 80 cases 80 cores, no overlaps with LV801		189-Eur	US Biomax	tissue
LV802	Liver carcinoma (multi-tissue combined panel) tissue array, 80 cases 80 cores, no overlaps with LV801; ihc Anti-Proliferating Cell Nuclear Antigen (PCNA) confirmed		185-Eur	US Biomax	tissue
LV803	Liver carcinoma (combination of cancer, cancer adjacent and normal tissue), 53 cases 72 cores, replacing BC03021		231-Eur	US Biomax	tissue
LV803	Liver carcinoma (combination of cancer, cancer adjacent and normal tissue), 53 cases 72 cores, replacing BC03021; ihc Anti-Alpha Fetoprotein (AFP) confirmed		267-Eur	US Biomax	tissue
LV804	Liver cancer tissue array with normal tissue from autopsy, 38 cases 80 cores, replacing BS03011		231-Eur	US Biomax	tissue
LV804	Liver cancer tissue array with normal tissue from autopsy, 38 cases 80 cores, replacing BS03011; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
LV805	Liver cirrhosis and hepatitis tissue array, 80 cases 80 cores, replacing IC03001		231-Eur	US Biomax	tissue
LV805	Liver cirrhosis and hepatitis tissue array, 80 cases 80 cores, replacing IC03001; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
LV806	Liver hemangiomas tissue array with normal tissue control from autopsy, 40 cases 80 cores		231-Eur	US Biomax	tissue
LV806	Liver hemangiomas tissue array with normal tissue control from autopsy, 40 cases 80 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
LV807	Liver cancer and normal tissue array with TNM and grade, 40 cases 80 cores		231-Eur	US Biomax	tissue
LV807	Liver cancer and normal tissue array with TNM and grade, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LV808	Liver cancer and normal tissue array, with stage and grade info, 80 cases 80 cores		231-Eur	US Biomax	tissue
LV808	Liver cancer and normal tissue array, with stage and grade info, 80 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
LV809	Hepatocellular carcinoma and normal tissue array, with stage, TNM and grade, 80 cases 80 cores, replacing BS03014		231-Eur	US Biomax	tissue

LV809	Hepatocellular carcinoma and normal tissue array, with stage, TNM and grade, 80 cases 80 cores, replacing BS03014; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LV961	Hepatocellular carcinoma tissue array, including TNM and pathology grade, 48 cases 96 cores; ihc Anti-Cytokeratin (CK) confirmed		228-Eur	US Biomax	elisa
LV962	Liver cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	elisa
LVC1021	Liver cancer tissue array, 102 cases 102 cores		225-Eur	US Biomax	tissue
LVC1021	Liver cancer tissue array, 102 cases 102 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
LVC1501	Liver cancer mid-density tissue array, non-overlapping with LVC1502 or LVC1503, 75 cases 150 cores		225-Eur	US Biomax	tissue
LVC1501	Liver cancer mid-density tissue array, non-overlapping with LVC1502 or LVC1503, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
LVC1502	Liver cancer mid-density tissue array, non-overlapping with LVC1501 or LVC1503, 75 cases 150 cores		225-Eur	US Biomax	tissue
LVC1502	Liver cancer mid-density tissue array, non-overlapping with LVC1501 or LVC1503, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
LVC1503	Liver cancer mid-density tissue array, non-overlapping with LVC1501 or LVC1502, 75 cases 150 cores		225-Eur	US Biomax	tissue
LVC1503	Liver cancer mid-density tissue array, non-overlapping with LVC1501 or LVC1502, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
LVC2281	Liver cancer high density tissue array, 228 cases 228 cores, replaced by LV2161		403-Eur	US Biomax	tissue
LVC2281	Liver cancer high density tissue array, 228 cases 228 cores, replaced by LV2161; ihc H&E, IHC anti-Cytokeratin		434-Eur	US Biomax	tissue
LVC481	Liver cancer and normal tissue array, non-overlapping with LVC482, 16 cases 48 cores		166-Eur	US Biomax	tissue
LVC481	Liver cancer and normal tissue array, non-overlapping with LVC482, 16 cases 48 cores; ihc H&E, IHC anti-Cytokeratin		205-Eur	US Biomax	tissue
LVC482	Liver cancer and normal tissue array, with TNM and grade info, non-overlapping with LVC481, 16 cases 48 cores		166-Eur	US Biomax	tissue
LVC482	Liver cancer and normal tissue array, with TNM and grade info, non-overlapping with LVC481, 16 cases 48 cores; ihc H&E, IHC anti-Cytokeratin		205-Eur	US Biomax	tissue

LVC961	Liver cancer and normal tissue array, with TNM and grade info, non-overlapping with LVC962, 48 cases 96 cores		189-Eur	US Biomax	elisa
LVC961	Liver cancer and normal tissue array, with TNM and grade info, non-overlapping with LVC962, 48 cases 96 cores, replaced by LV961; ihc H&E, anti-Vimentin Cytokeratin		238-Eur	US Biomax	elisa
LVC962	Liver cancer and normal tissue array, non-overlapping with LVC961, 48 cases 96 cores		189-Eur	US Biomax	elisa
LVC962	Liver cancer and normal tissue array, non-overlapping with LVC961, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	elisa
LVN801	Normal liver and hepatocellular carcinoma tissue array, including TNM, clinical stage and pathology grade, 40 cases 80 cores, replacing BN03011		231-Eur	US Biomax	tissue
LVN801	Normal liver and hepatocellular carcinoma tissue array, including TNM, clinical stage and pathology grade, 40 cases 80 cores, replacing BN03011; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
LY1001	Diffuse large-B cell lymphoma tissue array, 100 cases 100 cores		266-Eur	US Biomax	tissue
LY1001	Diffuse large-B cell lymphoma tissue array, 100 cases 100 cores, replaced by LY1001a; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LY1001a	Diffuse large-B cell lymphoma tissue array, 100 cases 100 cores, replacing LY1001; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
LY121	Diffuse large B-cell lymphoma tissue array, 12 cases 12 cores		189-Eur	US Biomax	tissue
LY121	Diffuse large B-cell lymphoma tissue array, 12 cases 12 cores, replaced by LY121a; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
LY121a	Diffuse large B-cell lymphoma tissue array, 12 cases 12 cores, replacing LY121; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
LY1501	Lymphoma tumor tissue array, 75 cases 150 cores		380-Eur	US Biomax	tissue
LY1501	Lymphoma tumor tissue array, 75 cases 150 cores		314-Eur	US Biomax	tissue
LY1501	Lymphoma tumor tissue array, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
LY2081	Lymphoma tumor survey tissue array (1 of 5), with normal tissue, 104 cases 208 cores		456-Eur	US Biomax	tissue
LY2081	Lymphoma tumor survey tissue array (1 of 5), with normal tissue, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
LY2082	Lymphoma survey tissue array (2 of 5), 104 cases 208 cores		456-Eur	US Biomax	tissue

LY2082	Lymphoma survey tissue array (2 of 5), 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
LY2083	Lymphoma survey tissue array (3 of 5), 104 cases 208 cores		456-Eur	US Biomax	tissue
LY2083	Lymphoma survey tissue array (3 of 5), 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
LY2084	Lymphoma tumor survey tissue array (4 of 5), 104 cases 208 cores		456-Eur	US Biomax	tissue
LY2084	Lymphoma tumor survey tissue array (4 of 5), 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
LY2085	Lymphoma tumor survey tissue array (5 of 5), 104 cases 208 cores		456-Eur	US Biomax	tissue
LY2085	Lymphoma tumor survey tissue array (5 of 5), 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
LY2086	Lymphoma tumor tissue array, 208 cases 208 cores		633-Eur	US Biomax	tissue
LY2086	Lymphoma tumor tissue array, 208 cases 208 cores		516-Eur	US Biomax	tissue
LY2086	Lymphoma tumor tissue array, 208 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
LY2087	Lymphoma tumor survey tissue array (2 of 3), 208 cases 208 cores		456-Eur	US Biomax	tissue
LY2087	Lymphoma tumor survey tissue array (2 of 3), 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LY2088	Lymphoma tumor tissue array, 208 cases 208 cores		558-Eur	US Biomax	tissue
LY2088	Lymphoma tumor tissue array, 208 cases 208 cores		456-Eur	US Biomax	tissue
LY2088	Lymphoma tumor tissue array, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
LY241	Lymphatic tissue array, 12 cases 24 cores		88-Eur	US Biomax	tissue
LY241	Lymphatic tissue array, 12 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
LY481	Lymphatic tissue array, 24 cases 48 cores		160-Eur	US Biomax	tissue
LY481	Lymphatic tissue array, 24 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
LY6161	High-density lymphoma and normal lymph node tissue array, 322 cases 616 cores		753-Eur	US Biomax	tissue
LY6161	High-density lymphoma and normal lymph node tissue array, 322 cases 616 cores; ihc Anti-Actin confirmed		811-Eur	US Biomax	tissue
LY802	Lymph node metastatic squamous cell carcinoma tissue array, 80 cases 80 cores		266-Eur	US Biomax	tissue
LY802	Lymph node metastatic squamous cell carcinoma tissue array, 80 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
LY803	Lymphatic metastatic adenocarcinoma tissue array, 80 cases 80 cores		266-Eur	US Biomax	tissue

LY803	Lymphatic metastatic adenocarcinoma tissue array, 80 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
LYM1501	Lymphoma mid-density tissue array, non-overlapping with LYM1502, 75 cases 150 cores		225-Eur	US Biomax	tissue
LYM1501	Lymphoma mid-density tissue array, non-overlapping with LYM1502, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
LYM1502	Lymphoma mid-density tissue array, non-overlapping with LYM1501, 75 cases 150 cores		225-Eur	US Biomax	tissue
LYM1502	Lymphoma mid-density tissue array, non-overlapping with LYM1501, 75 cases 150 cores; ihc H&E, IHC anti-LCA		238-Eur	US Biomax	tissue
LYM181	Lymphoma tissue array, 18 cases 18 cores		166-Eur	US Biomax	tissue
LYM181	Lymphoma tissue array, 18 cases 18 cores; ihc H&E, IHC anti-LCA		178-Eur	US Biomax	tissue
LYM401	Lymphoma array, together with LYM321, LYM761 and LYM771 forming the lymphoma array set, 39 cases 40 cores		142-Eur	US Biomax	
LYM401	Lymphoma array, together with LYM321, LYM761 and LYM771 forming the lymphoma array set, 39 cases 40 cores; ihc H&E, IHC anti-LCA		151-Eur	US Biomax	
MBN481	Multiple organ normal tissue array, 48 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
MC2081	Top 5 types of cancer (colon, rectum, breast, prostate and lung) 208 core high-density tissue array, 208 cases 208 cores		397-Eur	US Biomax	recombinant
MC2081	Top 5 types of cancer (colon, rectum, breast, prostate and lung) 208 core high-density tissue array, 208 cases 208 cores; ihc Anti-Cytokeratin (CK) confirmed		429-Eur	US Biomax	recombinant
MC2082	Multiple organ tumor tissue array, including TNM, clinical stage and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
MC2082	Multiple organ tumor tissue array, including TNM, clinical stage and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
MC241	Multiple cancer (12 type) tissue array, 12 cases 24 cores, replaced by MC244		88-Eur	US Biomax	tissue
MC241	Multiple cancer (12 type) tissue array, 12 cases 24 cores, replaced by MC244; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	tissue
MC242	Multiple cancer (12 type) tissue array, 16 cases 24 cores, replaced by MC245		88-Eur	US Biomax	tissue

MC242	Multiple cancer (12 type) tissue array, 16 cases 24 cores, replaced by MC245; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	tissue
MC243	Multiple cancer (3 types) tissue array, 24 cases 24 cores, with grade and stage data		100-Eur	US Biomax	tissue
MC243	Multiple cancer (3 types) tissue array, 24 cases 24 cores, with grade and stage data; ihc Anti-Actin confirmed		123-Eur	US Biomax	tissue
MC244	Multiple organ cancer and normal adjacent tissue array, replacing MC241, 12 cases 24 cores		88-Eur	US Biomax	tissue
MC244	Multiple organ cancer and normal adjacent tissue array, replacing MC241, 12 cases 24 cores, replaced by MC246; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
MC245	Multiple cancer (12 type) and adjacent normal tissue array, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing MC242		88-Eur	US Biomax	tissue
MC245	Multiple cancer (12 type) and adjacent normal tissue array, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing MC242; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
MC246	Multiple organ tumor with matched adjacent normal tissue array, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing MC244; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
MC2501	Multiple organs tumor and normal tissue array, with TNM, clinical stage and pathology grade, 250 cases 250 cores		516-Eur	US Biomax	tissue
MC2501	Multiple organs tumor and normal tissue array, with TNM, clinical stage and pathology grade, 250 cases 250 cores; ihc Anti-Actin confirmed		592-Eur	US Biomax	tissue
MC481	Multiple cancer (12 types) tissue microarray, 33 cases 48 cores		160-Eur	US Biomax	tissue
MC481	Multiple cancer (12 types) tissue microarray, 33 cases 48 cores; ihc Anti-Actin confirmed		162-Eur	US Biomax	tissue
MC482	Multiple cancer (12 type) tissue microarray, 40 cases 48 cores, with stage and grade information		160-Eur	US Biomax	tissue
MC482	Multiple cancer (12 type) tissue microarray, 40 cases 48 cores, with stage and grade information; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
MC483	Multiple types of cancer tissue array with normal control, replacing BC00119, 26 cases 48 cores, with stage and grade data		160-Eur	US Biomax	tissue
MC483	Multiple types of cancer tissue array with normal control, replacing BC00119, 26 cases 48 cores, with stage and grade data; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue

MC484	Multiple organs tumor and normal adjacent tissue, replacing BC00113, 44 cases 48 cores		160-Eur	US Biomax	tissue
MC484	Multiple organs tumor and normal adjacent tissue, replacing BC00113, 44 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
MC485	Multiple organ tumor tissue array, including TNM, clinical stage and pathology grade, 24 cases 48 cores		231-Eur	US Biomax	tissue
MC485	Multiple organ tumor tissue array, including TNM, clinical stage and pathology grade, 24 cases 48 cores; ihc Anti-Actin confirmed		228-Eur	US Biomax	tissue
MC5001	High density (495 cases 500 cores) tissue array of multiple organ cancer and normal, with stage and grade information, replaced by MC5002		634-Eur	US Biomax	tissue
MC5001	High density (495 cases 500 cores) tissue array of multiple organ cancer and normal, with stage and grade information, replaced by MC5002; ihc Anti-Cytokeratin (CK) confirmed		592-Eur	US Biomax	tissue
MC5002	High-density multiple organ tumor tissue array, with adjacent normal tissue, information of TNM, stage and grade, 500 cases 500 cores, replacing MC5001		634-Eur	US Biomax	tissue
MC5002	High-density multiple organ tumor tissue array, with adjacent normal tissue, information of TNM, stage and grade, 500 cases 500 cores, replacing MC5001; ihc Anti-Actin confirmed		592-Eur	US Biomax	tissue
MC5003	High-density multiple organ tumor and normal tissue array, with TNM and pathology grade, 500 cases 500 cores, replacing MC5002		634-Eur	US Biomax	tissue
MC5003	High-density multiple organ tumor and normal tissue array, with TNM and pathology grade, 500 cases 500 cores, replacing MC5002; ihc Anti-Actin confirmed		592-Eur	US Biomax	tissue
MC501	Multiple organs tumor and matched adjacent tissue array, 27 cases 50 cores		160-Eur	US Biomax	tissue
MC501	Multiple organs tumor and matched adjacent tissue array, 27 cases 50 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
MC541	Multiple organ, diseased tissue array (54 cases 54 cores, 18 types of cancers), replaced by MC542		160-Eur	US Biomax	tissue
MC541	Multiple organ, diseased tissue array (54 cases 54 cores, 18 types of cancers), replaced by MC542; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
MC542	Multiple organ???diseased tissue array, including TNM and pathology grade, 54 cases 54 cores, replacing MC541		160-Eur	US Biomax	tissue

MC542	Multiple organ???diseased tissue array, including TNM and pathology grade, 54 cases 54 cores, replacing MC541; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
MC601	Multi-organ cancer tissue array, including TNM, clinical stage and pathology grade, 60 cases 60 cores		231-Eur	US Biomax	tissue
MC601	Multi-organ cancer tissue array, including TNM, clinical stage and pathology grade, 60 cases 60 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
MC616	High-density lung, breast, brain and colon cancer array, with stage, grade and normal tissue array, 308 cases 616 cores		753-Eur	US Biomax	tissue
MC616	High-density lung, breast, brain and colon cancer array, with stage, grade and normal tissue array, 308 cases 616 cores; ihc Anti-Actin confirmed		1146-Eur	US Biomax	tissue
MC6162	High-density stomach, colonrectal cancer tissue array, with stage, grade and normal tissue, 616 cases 616 cores		753-Eur	US Biomax	recombinant
MC6162	High-density stomach, colonrectal cancer tissue array, with stage, grade and normal tissue, 616 cases 616 cores; ihc Anti-Actin confirmed		811-Eur	US Biomax	recombinant
MC6163	High-density tissue array of multiple organ tumor and normal tissue, with pathology grade, clinical stage and TNM, 616 cases 616 cores; ihc Anti-Actin confirmed		811-Eur	US Biomax	tissue
MC631	Multiple organ, diseased tissue array (63 cases 63 cores, 20 types of cancer and disease), replacing BC00014		160-Eur	US Biomax	tissue
MC631	Multiple organ, diseased tissue array (63 cases 63 cores, 20 types of cancer and disease), replacing BC00014; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
MC641	Multiple organ cancer and adjacent normal tissue array, including TNM and pathology grade, 59 cases 64 cores, replacing BC00115		----Eur	US Biomax	tissue
MC642	Multiple cancer tissue array - I, 6 common types of cancer and some of matched normal tissues, with TNM data, 58 cases 66 cores		----Eur	US Biomax	tissue
MC643	Multiple cancer tissue array - II, 6 common types of cancer and some of matched normal tissues, with TNM data, 58 cases 66 cores		----Eur	US Biomax	tissue
MC644	Multiple cancer tissue array - III, 6 common types of cancer and some of matched normal tissues, with TNM data, 58 cases 66 cores		----Eur	US Biomax	tissue
MC801	Multiple cancer tissue array, replacing BC00012, 80 cases 80 cores, with grade information		266-Eur	US Biomax	tissue

MC801	Multiple cancer tissue array, replacing BC00012, 80 cases 80 cores, with grade information; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
MC8010	Multiple organ cancer tissue array, including TNM and pathology grade, 80 cases 80 cores		278-Eur	US Biomax	tissue
MC8010	Multiple organ cancer tissue array, including TNM and pathology grade, 80 cases 80 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
MC802	Multiple cancer tissue array with matched or unmatched normal control, replacing BC00115, 44 cases 80 cores, with grade information		266-Eur	US Biomax	tissue
MC802	Multiple cancer tissue array with matched or unmatched normal control, replacing BC00115, 44 cases 80 cores, with grade information; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
MC803	Retinoblastoma, nephroblastoma, neuroblastoma and leukemia tissue array, 40 cases 80 cores		314-Eur	US Biomax	tissue
MC803	Retinoblastoma, nephroblastoma, neuroblastoma and leukemia tissue array, 40 cases 80 cores, replaced by MC803a; ihc Anti-Actin confirmed		320-Eur	US Biomax	tissue
MC803a	Multiple organ tumor tissue array with adjacent normal tissue, including TNM and clinical stage, 40 cases 80 cores, replacing MC803; ihc Anti-Actin confirmed		320-Eur	US Biomax	tissue
MC804	Adamantinoma and hamartoma tissue array, 40 cases 80 cores		266-Eur	US Biomax	tissue
MC804	Adamantinoma and hamartoma tissue array, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
MC805	Synovial sarcoma and cancer sarcomatodes tissue array, 80 cases 80 cores		278-Eur	US Biomax	tissue
MC805	Synovial sarcoma and cancer sarcomatodes tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		382-Eur	US Biomax	tissue
MC806	Gangliocytoma and paraganglioma tissue array, 40 cases 80 cores		278-Eur	US Biomax	tissue
MC806	Gangliocytoma and paraganglioma tissue array, 40 cases 80 cores; ihc Anti-Actin confirmed		382-Eur	US Biomax	tissue
MC807	Multiple types of cancer tissue array, with stage and TNM information, 40 cases 80 cores		278-Eur	US Biomax	tissue
MC807	Multiple types of cancer tissue array, with stage and TNM information, 40 cases 80 cores; ihc Anti-Actin confirmed		382-Eur	US Biomax	tissue
MC808	Multiple tumor tissue array - 58 different tumors and their corresponding normal tissues with TNM data, 58 cases 96 cores		266-Eur	US Biomax	elisa
MC808	Multiple tumor tissue array - 58 different tumors and their corresponding normal tissues with TNM data, 58 cases 96 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	elisa

MC809	Neuroblastoma and retinoblastoma tissue array, with TNM and grade info, 80 cases 80 cores		278-Eur	US Biomax	tissue
MC809	Neuroblastoma and retinoblastoma tissue array, with TNM and grade info, 80 cases 80 cores, replaced by MC809a; ihc Anti-Actin confirmed		382-Eur	US Biomax	tissue
MC809a	Blastoma tissue array with normal tissue as control, including TNM, clinical stage and pathology grade, 80 cases 80 cores, replacing MC809; ihc Anti-Actin confirmed		382-Eur	US Biomax	tissue
MC961	Multiple organ cancer tissue array for testing tumor tissue specificity of therapeutic antibodies, 96 cases 96 cores, replaced by MC964		231-Eur	US Biomax	elisa
MC961	Multiple organ cancer tissue array for testing tumor tissue specificity of therapeutic antibodies, 96 cases 96 cores, replaced by MC964; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	elisa
MC962	Multiple carcinoma tissue array with matched normal organ tissue, 58 cases 96 cores		---Eur	US Biomax	elisa
MC963	Multiple cancer tissue array with four 24 core array squares mounted on glass, 12 cases 96 cores		266-Eur	US Biomax	elisa
MC963	Multiple cancer tissue array with four 24 core array squares mounted on glass, 12 cases 96 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	elisa
MC964	Multiple organ tumor tissue array, including TNM, clinical stage and pathology grade, for testing tumor tissue specificity of therapeutic antibodies, 96 cases 96 cores, replacing MC961		266-Eur	US Biomax	elisa
MC964	Multiple organ tumor tissue array, including TNM, clinical stage and pathology grade, for testing tumor tissue specificity of therapeutic antibodies, 96 cases 96 cores, replacing MC961; ihc Anti-Act		296-Eur	US Biomax	elisa
MCN601	Multiple organ tumor and normal tissue array, 58 cases 60 cores, replaced by MCN602		231-Eur	US Biomax	tissue
MCN601	Multiple organ tumor and normal tissue array, 58 cases 60 cores, replaced by MCN602; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
MCN602	Multiple organ tumor and adjacent normal tissue array, including TNM, clinical stage and pathology grade, 58 cases 60 cores, replacing MCN601		231-Eur	US Biomax	tissue
MCN602	Multiple organ tumor and adjacent normal tissue array, including TNM, clinical stage and pathology grade, 58 cases 60 cores, replacing MCN601; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
ME1001	Malignant melanoma, metastatic malignant melanoma and benign nevus tissue array, replaced by ME1003, 100 cases 100 cores		266-Eur	US Biomax	tissue

ME1001	Malignant melanoma, metastatic malignant melanoma and benign nevus tissue array, replaced by ME1003, 100 cases 100 cores; ihc Anti-HMB45 confirmed		296-Eur	US Biomax	tissue
ME1002	Malignant melanoma and normal tissue array, 50 cases 100 cores		266-Eur	US Biomax	tissue
ME1002	Malignant melanoma and normal tissue array, 50 cases 100 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
ME1003	Malignant melanoma, metastatic malignant melanoma and benign nevus tissue array, including TNM and clinical stage, 100 cases 100 cores, replaced by ME1004		266-Eur	US Biomax	tissue
ME1003	Malignant melanoma, metastatic malignant melanoma and benign nevus tissue array, including TNM and clinical stage, 100 cases 100 cores, replaced by ME1004; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ME1004	Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including TNM, 100 cases 100 cores, replacing ME1003		314-Eur	US Biomax	tissue
ME1004	Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including TNM, 100 cases 100 cores, replaced by ME1004a; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ME1004a	Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including TNM and clinical stage, 100 cases 100 cores, replacing ME1004; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ME207	High-density (69 cases 207 cores), multiple primary melanoma, metastatic and normal tissues array		456-Eur	US Biomax	tissue
ME207	High-density (69 cases 207 cores), multiple primary melanoma, metastatic and normal tissues array; ihc S-100 confirmed		487-Eur	US Biomax	tissue
ME207b	High-density (69 cases 207 cores), multiple primary melanoma, metastatic and normal skin tissue array block		40981-Eur	US Biomax	tissue
ME207b	High-density (69 cases 207 cores), multiple primary melanoma, metastatic and normal skin tissue array block; ihc S-100 confirmed		33112-Eur	US Biomax	tissue
ME2081	Mid-density malignant melanoma and normal tissue array, 104 cases 208 cores		456-Eur	US Biomax	tissue
ME2081	Mid-density malignant melanoma and normal tissue array, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue

ME2082	Malignant melanoma tissue array, including TNM and clinical stage, 208 cases 208 cores		456-Eur	US Biomax	tissue
ME2082	Malignant melanoma tissue array, including TNM and clinical stage, 208 cases 208 cores, replaced by ME2082a; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
ME2082a	Malignant melanoma tissue array, including TNM and clinical stage, 208 cases 208 cores, replacing ME2082; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
ME241	Multiple melanoma tissue array with normal tissues, 12 cases 24 cores		88-Eur	US Biomax	tissue
ME241	Multiple melanoma tissue array with normal tissues, 12 cases 24 cores, replaced by ME241a; ihc Anti-S-100 confirmed		105-Eur	US Biomax	tissue
ME241a	Multiple malignant melanoma tissue array with adjacent normal skin tissue, including TNM and clinical stage, 12 cases 24 cores, replacing ME241; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
ME242	Low-density malignant melanoma array, with stage and grade info, 24 cases 24 cores		88-Eur	US Biomax	
ME242	Low-density malignant melanoma array, with stage and grade info, 24 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	
ME481	Multiple melanoma tissue array with normal skin tissues, 48 cases 48 cores		160-Eur	US Biomax	tissue
ME481	Multiple melanoma tissue array with normal skin tissues, 48 cases 48 cores, replaced by ME481a; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
ME481a	Melanoma tissue array with normal skin tissues, including TNM and clinical stage, 48 cases 48 cores, replacing ME481; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
ME482	Malignant melanoma array with matched normal tissue control, stage and TNM, 48 cases 48 cores		189-Eur	US Biomax	tissue
ME482	Malignant melanoma array with matched normal tissue control, stage and TNM, 48 cases 48 cores; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
ME483	Melanoma tissue array, including TNM and clinical stage, 48 cases 48 cores		231-Eur	US Biomax	tissue
ME483	Melanoma tissue array, including TNM and clinical stage, 48 cases 48 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
ME801	Malignant melanoma tissue array, 80 cases 80 cores, replaced by ME804		231-Eur	US Biomax	tissue
ME801	Malignant melanoma tissue array, 80 cases 80 cores, replaced by ME804; ihc Anti-S-100 antibody confirmed		258-Eur	US Biomax	tissue
ME802	Malignant melanoma with normal skin tissue array, 40 cases 80 cores, replacing BS38011		266-Eur	US Biomax	tissue

ME802	Malignant melanoma with normal skin tissue array, 40 cases 80 cores, replacing BS38011; ihc Anti-S100 confirmed		296-Eur	US Biomax	tissue
ME803	Malignant melanoma array with matched and unmatched normal skin tissue control, with stage and TNM, 80 cases 80 cores		266-Eur	US Biomax	tissue
ME803	Malignant melanoma array with matched and unmatched normal skin tissue control, with stage and TNM, 80 cases 80 cores, replaced by ME803a; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ME803a	Malignant melanoma tissue array with adjacent normal skin tissue, including TNM and clinical stage, 80 cases 80 cores, replacing ME803; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ME804	Malignant melanoma tissue array, including TNM and clinical stage, 80 cases 80 cores, replacing ME801		266-Eur	US Biomax	tissue
ME804	Malignant melanoma tissue array, including TNM and clinical stage, 80 cases 80 cores, replacing ME801; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
MET181	Metastatic cancer tissue array, 18 cases 18 cores		166-Eur	US Biomax	tissue
MET181	Metastatic cancer tissue array, 18 cases 18 cores; ihc H&E, IHC anti- Cytokeratin		178-Eur	US Biomax	tissue
MET961	Metastatic cancer tissue array, 48 cases 96 cores		225-Eur	US Biomax	elisa
MET961	Metastatic cancer tissue array, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	elisa
MG801	Meningioma of central nerve tissue array, 80 cases 80 cores		231-Eur	US Biomax	tissue
MG801	Meningioma of central nerve tissue array, 80 cases 80 cores; ihc Anti-Vimentin confirmed		267-Eur	US Biomax	tissue
MGS801	Male genitourinary system tissue array with normal, inflammation, disease and cancer tissue, including TNM, clinical stage and pathology grade, 80 cases 80 cores		266-Eur	US Biomax	tissue
MGS801	Male genitourinary system tissue array with normal, inflammation, disease and cancer tissue, including TNM, clinical stage and pathology grade, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
MNO341	Antibody cross-reactivity testing tissue array, 33 cases 34 cores		118-Eur	US Biomax	assays
MNO341	Antibody cross-reactivity testing tissue array, 33 cases 34 cores; ihc H&E, IHC anti-Vimentin Cytokeratin		123-Eur	US Biomax	assays
MNO381	Tissue profiling tissue array with 19 types of normal human tissues, 19 cases 38 cores		166-Eur	US Biomax	tissue

MNO381	Tissue profiling tissue array with 19 types of normal human tissues, 19 cases 38 cores; ihc H&E, IHC anti-Vimentin Cytokeratin		178-Eur	US Biomax	tissue
MNO661	Normal organ tissue array of human, 66 cases 66 cores		189-Eur	US Biomax	tissue
MNO661	Normal organ tissue array of human, 66 cases 66 cores; ihc H&E, IHC anti- Cytokeratin		205-Eur	US Biomax	tissue
MNO961	35 types of normal human tissue array, 90 cases 96 cores		225-Eur	US Biomax	elisa
MNO961	35 types of normal human tissue array, 90 cases 96 cores; ihc H&E, IHC anti-Vimentin Cytokeratin		238-Eur	US Biomax	elisa
MNT241	Multiple tumor and normal tissue array for IHC antibody and ISH probe optimization and initial screening, 12 cases 24 cores		77-Eur	US Biomax	tissue
MNT241	Multiple tumor and normal tissue array for IHC antibody and ISH probe optimization and initial screening, 12 cases 24 cores; ihc H&E, IHC Vimentin Cytokeratin		85-Eur	US Biomax	tissue
MO01011	Mouse stomach tissue array, 100 cases 100 cores, 50 from different male, 50 from different female		160-Eur	US Biomax	tissue
MO01011	Mouse stomach tissue array, 100 cases 100 cores, 50 from different male, 50 from different female; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
MO03011	Mouse liver tissue array, 100 cases 100 cores, 50 male and 50 female		160-Eur	US Biomax	tissue
MO03011	Mouse liver tissue array, 100 cases 100 cores, 50 male and 50 female; ihc Anti-EMA confirmed		185-Eur	US Biomax	tissue
MO04011	Mouse lung tissue array, 100 cases 100 cores, 50 male and 50 female		160-Eur	US Biomax	tissue
MO04011	Mouse lung tissue array, 100 cases 100 cores, 50 male and 50 female; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
MO07011	Mouse kidney tissue array, 100 cases 100 cores, 50 male and 50 female		160-Eur	US Biomax	tissue
MO07011	Mouse kidney tissue array, 100 cases 100 cores, 50 male and 50 female; ihc Anti-EMA confirmed		185-Eur	US Biomax	tissue
MO1001	Mouse normal kidney tissue array, 100 cases 100 cores		266-Eur	US Biomax	tissue
MO1001	Mouse normal kidney tissue array, 100 cases 100 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
MO1002	Mouse spleen tissue array, 100 cases 100 cores, 50 male and 50 female, replacing MO32011		189-Eur	US Biomax	tissue
MO1002	Mouse spleen tissue array, 100 cases 100 cores, 50 male and 50 female, replacing MO32011; ihc Anti-CD20 confirmed		185-Eur	US Biomax	tissue

MO1601	Mouse tissue array of liver, kidney, lung, muscle, brain, heart, stomach, spleen, 160 cases 160 cores, replacing BM01011		278-Eur	US Biomax	tissue
MO1601	Mouse tissue array of liver, kidney, lung, muscle, brain, heart, stomach, spleen, 160 cases 160 cores, replacing BM01011; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
MO17011	Mouse brain tissue array, 100 cases 100 cores, 50 male and 50 female		160-Eur	US Biomax	tissue
MO17011	Mouse brain tissue array, 100 cases 100 cores, 50 male and 50 female; ihc Anti-GFAP confirmed		185-Eur	US Biomax	tissue
MO24011	Mouse muscle tissue array, 100 cases 100 cores, 50 male and 50 female		160-Eur	US Biomax	tissue
MO24011	Mouse muscle tissue array, 100 cases 100 cores, 50 male and 50 female; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
MO30011	Mouse heart tissue array, 100 cases 100 cores, 50 male and 50 female		160-Eur	US Biomax	tissue
MO30011	Mouse heart tissue array, 100 cases 100 cores, 50 male and 50 female; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
MO32011	Mouse spleen tissue array, 100 cases 100 cores, 50 male and 50 female, replaced by MO1002		189-Eur	US Biomax	tissue
MO32011	Mouse spleen tissue array, 100 cases 100 cores, 50 male and 50 female, replaced by MO1002; ihc Anti-CD20 confirmed		185-Eur	US Biomax	tissue
MO541	Mouse multiple organ normal tissue array, 24 cases 54 cores; ihc Anti-Actin confirmed		162-Eur	US Biomax	tissue
MS481	Human mesothelioma tissue array, 24 cases 48 cores		314-Eur	US Biomax	tissue
MS481	Human mesothelioma tissue array, 24 cases 48 cores, replaced by MS481a; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
MS481a	Mesothelioma tissue array with normal tissue as control, including TNM and clinical stage, 24 cases 48 cores, replacing MS481; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
MS801	Mesothelioma tissue array with normal mesothelium, with stage and TNM data, 40 cases 80 cores		397-Eur	US Biomax	tissue
MS801	Mesothelioma tissue array with normal mesothelium, with stage and TNM data, 40 cases 80 cores; ihc Anti-Actin confirmed		382-Eur	US Biomax	tissue
MT2081	Multiple organ metastatic cancer tissue array, 19 organ 104 cases 208 cores		456-Eur	US Biomax	tissue
MT2081	Multiple organ metastatic cancer tissue array, 19 organ 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
MT801	Multiple organ cancer metastasis tissue array, 80 cases 80 cores		266-Eur	US Biomax	tissue

MT801	Multiple organ cancer metastasis tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
MTU241	Multiple tumor and normal tissue array, with 12 major types of cancer paired with matched NAT, 12 cases 24 cores		166-Eur	US Biomax	tissue
MTU241	Multiple tumor and normal tissue array, with 12 major types of cancer paired with matched NAT, 12 cases 24 cores; ihc H&E, IHC anti-Vimentin Cytokeratin		178-Eur	US Biomax	tissue
MTU391	Top 10 cancer tissue array (15 major types from Oriental and Western population), 20 cases 39 cores		166-Eur	US Biomax	tissue
MTU391	Top 10 cancer tissue array (15 major types from Oriental and Western population), 20 cases 39 cores; ihc H&E, IHC anti-Cytokeratin		178-Eur	US Biomax	tissue
MTU481	Multiple tumor tissue array, 48 cases 48 cores		142-Eur	US Biomax	tissue
MTU481	Multiple tumor tissue array, 48 cases 48 cores; ihc H&E, IHC anti-Vimentin Cytokeratin		151-Eur	US Biomax	tissue
MTU951	Multiple tumor tissue array covering 40 types of all the common benign, malignant and metastatic entities, 40 cases 95 cores		225-Eur	US Biomax	tissue
MTU951	Multiple tumor tissue array covering 40 types of all the common benign, malignant and metastatic entities, 40 cases 95 cores; ihc H&E, IHC anti-Vimentin Cytokeratin		238-Eur	US Biomax	tissue
NGL481	Nervous system glioma tissue array, 24 cases 48 cores		225-Eur	US Biomax	tissue
NGL481	Nervous system glioma tissue array, 24 cases 48 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
NGL961	Nervous system glioma tissue array, 48 cases 96 cores		261-Eur	US Biomax	elisa
NGL961	Nervous system glioma tissue array, 48 cases 96 cores; ihc H&E, IHC anti-Vimentin		281-Eur	US Biomax	elisa
NH1001	Nasopharynx disease spectrum (nasopharynx cancer progression) tissue array, 49 cases 100 cores		266-Eur	US Biomax	tissue
NH1001	Nasopharynx disease spectrum (nasopharynx cancer progression) tissue array, 49 cases 100 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
NHL401	Lymphoma, multiple myeloma and lymph node tissue array, 40 cases 40 cores		266-Eur	US Biomax	tissue
NHL401	Lymphoma, multiple myeloma and lymph node tissue array, 40 cases 40 cores, replaced by NHL401a; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue

NHL401a	Lymphoma, myeloma and lymph node tissue array, 40 cases 40 cores, replacing NHL401; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
NHL481	Lymphoma tissue array, 48 cases 48 cores, replaced by NHL482		189-Eur	US Biomax	tissue
NHL481	Lymphoma tissue array, 48 cases 48 cores, replaced by NHL482; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
NHL482	Lymphoma tissue array, 48 cases 48 cores, replacing NHL481		189-Eur	US Biomax	tissue
NHL482	Lymphoma tissue array, 48 cases 48 cores, replacing NHL481; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
NHL483	Non-Hodgkin's lymphoma tumor tissue array, 48 cases 48 cores		231-Eur	US Biomax	tissue
NHL483	Non-Hodgkin's lymphoma tumor tissue array, 48 cases 48 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
NHL801	Non-Hodgkin's lymphoma tissue array, 42 cases 80 cores, no overlaps with NHL802		266-Eur	US Biomax	tissue
NHL801	Non-Hodgkin's lymphoma tissue array, 42 cases 80 cores, no overlaps with NHL802; ihc Anti-Leukocyte Common Antigen antibody confirmed		267-Eur	US Biomax	tissue
NHL802	Non-Hodgkin's lymphoma tissue array, 42 cases 80 cores, no overlaps with NHL801, replaced by NHL803		266-Eur	US Biomax	tissue
NHL802	Non-Hodgkin's lymphoma tissue array, 42 cases 80 cores, no overlaps with NHL801, replaced by NHL803a; ihc Anti-Leukocyte Common Antigen antibody confirmed		267-Eur	US Biomax	tissue
NHL802a	Non-Hodgkin's lymphoma tissue array, 42 cases 80 cores, replacing NHL802; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
NHL803	Lymphoma tissue array, 80 cases 80 cores, replacing LM802		266-Eur	US Biomax	tissue
NHL803	Lymphoma tissue array, 80 cases 80 cores, replacing LM802; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
NHL803b	Lymphoma tissue array, 80 cases 80 cores, replacing NHL803		321-Eur	US Biomax	tissue
NHL803b	Lymphoma tissue array, 80 cases 80 cores, replacing NHL803		266-Eur	US Biomax	tissue
NHL803b	Lymphoma tissue array, 80 cases 80 cores, replacing NHL803; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
NPC111	Nasopharyngeal carcinoma tissue array, 11 cases 11 cores		106-Eur	US Biomax	tissue
NPC111	Nasopharyngeal carcinoma tissue array, 11 cases 11 cores; ihc H&E, IHC anti-Cytokeratin		123-Eur	US Biomax	tissue
NPC481	Nasopharyngeal carcinoma tissue array, 48 cases 49 cores		189-Eur	US Biomax	tissue
NPC481	Nasopharyngeal carcinoma tissue array, 48 cases 49 cores; ihc H&E, IHC anti-Cytokeratin		205-Eur	US Biomax	tissue

NPC961	Nasopharyngeal carcinoma tissue array, non-overlapping with NPC962, >50 cases 96 cores		344-Eur	US Biomax	elisa
NPC961	Nasopharyngeal carcinoma tissue array, non-overlapping with NPC962, >50 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		358-Eur	US Biomax	elisa
NPC962	Nasopharyngeal carcinoma tissue array, non-overlapping with NPC961, 96 cases 96 cores		308-Eur	US Biomax	elisa
NPC962	Nasopharyngeal carcinoma tissue array, non-overlapping with NPC961, 96 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		358-Eur	US Biomax	elisa
NST961	Nervous system tumor tissue array, 48 cases 96 cores		225-Eur	US Biomax	elisa
NST961	Nervous system tumor tissue array, 48 cases 96 cores; ihc H&E, IHC anti-Vimentin S100 GFAP		238-Eur	US Biomax	elisa
OM601	Metastatic carcinoma of epiploon tissue array, 60 cases 60 cores		266-Eur	US Biomax	tissue
OM601	Metastatic carcinoma of epiploon tissue array, 60 cases 60 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
ON481	Oncocytoma tissue array, 24 cases 48 cores; ihc Anti-Actin confirmed		162-Eur	US Biomax	tissue
OR1001	Tonsil disease spectrum (tonsil tumor progression) tissue array, 50 cases 100 cores		266-Eur	US Biomax	tissue
OR1001	Tonsil disease spectrum (tonsil tumor progression) tissue array, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
OR208	Oral cavity squamous cell carcinoma and normal tissues high density (69 cases 208 cores) tissue microarray) with grade and stage info		456-Eur	US Biomax	tissue
OR208	Oral cavity squamous cell carcinoma and normal tissues high density (69 cases 208 cores) tissue microarray) with grade and stage info; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
OR2081	Oral cavity disease spectrum (oral cancer progression) tissue array, 98 cases 208 cores		456-Eur	US Biomax	tissue
OR2081	Oral cavity disease spectrum (oral cancer progression) tissue array, 98 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
OR481	Oral cavity (tongue and parotid) cancer tissue array, 48 cases 48 cores.		160-Eur	US Biomax	tissue
OR481	Oral cavity (tongue and parotid) cancer tissue array, 48 cases 48 cores.; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
OR601	Oral squamous cancer tissue array with normal oral control tissue, 60 cases 60 cores		231-Eur	US Biomax	tissue
OR601	Oral squamous cancer tissue array with normal oral control tissue, 60 cases 60 cores, replaced by OR601a; ihc Anti-Cytokeratin (CK) confirmed		258-Eur	US Biomax	tissue

OR601a	Oral squamous cell cancer tissue array with adjacent normal tongue tissue, including TNM, clinical stage and pathology grade, 60 cases 60 cores, replacing OR601; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
OR801	Parotid gland disease spectrum (parotidean cancer progression) tissue array, 80 cases 80 cores		266-Eur	US Biomax	tissue
OR801	Parotid gland disease spectrum (parotidean cancer progression) tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
OR802	Oral cavity disease spectrum (oral cavity cancer progression) tissue array, 79 cases 80 cores		266-Eur	US Biomax	tissue
OR802	Oral cavity disease spectrum (oral cavity cancer progression) tissue array, 79 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
OS208	High density (208 core) tissue microarray of osteosarcoma, chondrosarcoma, giant cell tumor of bone and normal tissue, with TNM data, 69 cases 208 cores		456-Eur	US Biomax	tissue
OS208	High density (208 core) tissue microarray of osteosarcoma, chondrosarcoma, giant cell tumor of bone and normal tissue, with TNM data, 69 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
OS801	Osteosarcoma and chondrosarcoma tissue array, with matched or unmatched adjacent normal tissue, 79 cases 80 cores		266-Eur	US Biomax	tissue
OS801	Osteosarcoma and chondrosarcoma tissue array, with matched or unmatched adjacent normal tissue, 79 cases 80 cores, replaced by OS802; ihc Anti-Proliferating Cell Nuclear Antigen (PCNA) confirmed		258-Eur	US Biomax	tissue
OS802	Osteosarcoma and chondrosarcoma tissue array, with stage, grade and TNM data, 80 cases 80 cores, replacing BC26111		266-Eur	US Biomax	tissue
OS802	Osteosarcoma and chondrosarcoma tissue array, with stage, grade and TNM data, 80 cases 80 cores, replacing OS801 and BC26111; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
OS803	Chondrosarcoma tissue tissue array, 27 cases 80 cores, replacing BS36011		266-Eur	US Biomax	tissue
OS803	Chondrosarcoma tissue tissue array, 27 cases 80 cores, replacing BS36011; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
OS804	Osteosarcoma tissue tissue array, with stage and grade, 40 cases 80 cores, replacing BS26011		266-Eur	US Biomax	tissue
OS804	Osteosarcoma tissue tissue array, with stage and grade, 40 cases 80 cores, replacing BS26011; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue

OV1001	Ovarian disease spectrum (ovarian cancer progression) tissue array, 100 cases 100 cores, replaced by OV1005		231-Eur	US Biomax	tissue
OV1001	Ovarian disease spectrum (ovarian cancer progression) tissue array, 100 cases 100 cores, replaced by OV1005; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
OV1002	Ovarian cancer (multiple types) tissue array, 100 cases 100 cores		231-Eur	US Biomax	tissue
OV1002	Ovarian cancer (multiple types) tissue array, 100 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
OV1003	Ovarian cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases 100 cores		231-Eur	US Biomax	tissue
OV1003	Ovarian cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
OV1004	Ovarian cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases 100 cores		231-Eur	US Biomax	tissue
OV1004	Ovarian cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
OV1005	Ovarian disease spectrum (ovarian cancer progression) tissue array, including TNM, clinical stage and pathology grade, 100 cases 100 cores, replacing OV1001		266-Eur	US Biomax	tissue
OV1005	Ovarian disease spectrum (ovarian cancer progression) tissue array, including TNM, clinical stage and pathology grade, 100 cases 100 cores, replaced by OV1005a; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
OV1005a	Ovary disease spectrum (ovarian cancer progression) tissue array, including TNM, clinical stage and pathology grade, 100 cases 100 cores, replacing OV1005; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
OV1501	Ovarian cancer tissue array, with TNM, clinical stage and pathology grade, 75 cases 150 cores		231-Eur	US Biomax	tissue
OV1501	Ovarian cancer tissue array, with TNM, clinical stage and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
OV1502	Ovary adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		321-Eur	US Biomax	tissue
OV1502	Ovary adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		266-Eur	US Biomax	tissue
OV1502	Ovary adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue

OV1921	Late stage ovarian tumor tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores		456-Eur	US Biomax	elisa
OV1921	Late stage ovarian tumor tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	elisa
OV2001	Ovarian cancer high-density (200 cases 200 cores) tissue array		397-Eur	US Biomax	tissue
OV2001	Ovarian cancer high-density (200 cases 200 cores) tissue array; ihc Anti-Cytokeratin (Low-MW) confirmed		382-Eur	US Biomax	tissue
OV208	Ovarian cancer and normal tissue high density (69 cases 208 cores) tissue microarray, with grade and stage data		456-Eur	US Biomax	tissue
OV208	Ovarian cancer and normal tissue high density (69 cases 208 cores) tissue microarray, with grade and stage data; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
OV20810	Ovary cancer survey tissue array (1 of 4), with normal tissue, including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
OV20810	Ovary cancer survey tissue array (1 of 4), with normal tissue, including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
OV20811	Ovary cancer tissue array (2 of 4), including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
OV20811	Ovary cancer tissue array (2 of 4), including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
OV20812	Ovary cancer tissue array (3 of 4), including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
OV20812	Ovary cancer tissue array (3 of 4), including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
OV20813	Ovary cancer tissue array (4 of 4), including TNM and pathology grade, 208 cases 208 cores		456-Eur	US Biomax	tissue
OV20813	Ovary cancer tissue array (4 of 4), including TNM and pathology grade, 208 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
OV20814	Ovary adenocarcinoma tissue array, including TNM and pathology grade, 208 cases 208 cores, replacing OV2084		558-Eur	US Biomax	tissue
OV20814	Ovary adenocarcinoma tissue array, including TNM and pathology grade, 208 cases 208 cores, replacing OV2084		456-Eur	US Biomax	tissue
OV20814	Ovary adenocarcinoma tissue array, including TNM and pathology grade, 208 cases 208 cores, replacing OV2084; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue

OV2082	Ovary cancer tissue array with normal tissues, with TNM and grade info, 104 cases 208 cores		456-Eur	US Biomax	tissue
OV2082	Ovary cancer tissue array with normal tissues, with TNM and grade info, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
OV2083	High-density ovarian cancer tissue array with normal tissues, with stage and grade info, 69 cases 208 cores		456-Eur	US Biomax	tissue
OV2083	High-density ovarian cancer tissue array with normal tissues, with stage and grade info, 69 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
OV2084	Ovarian cancer tissue array with normal adjacent ovary, TNM, clinical stage and pathology grade, 208 cases 208 cores, replaced by OV20814		456-Eur	US Biomax	tissue
OV2084	Ovarian cancer tissue array with normal adjacent ovary, TNM, clinical stage and pathology grade, 208 cases 208 cores, replaced by OV20814; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
OV2085	Ovary cancer survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
OV2085	Ovary cancer survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
OV2086	Ovary cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
OV2086	Ovary cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
OV2087	Ovary cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
OV2087	Ovary cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Cytokeratin (CK) confirmed		429-Eur	US Biomax	tissue
OV2088	Ovary cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue
OV2088	Ovary cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
OV2089	Ovary cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores		456-Eur	US Biomax	tissue

OV2089	Ovary cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
OV2161	Ovary adenocarcinoma tissue array, including TNM and pathology grade, 216 cases 216 cores		633-Eur	US Biomax	tissue
OV2161	Ovary adenocarcinoma tissue array, including TNM and pathology grade, 216 cases 216 cores		516-Eur	US Biomax	tissue
OV2161	Ovary adenocarcinoma tissue array, including TNM and pathology grade, 216 cases 216 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
OV241	Ovarian cancer test tissue array with self-matching or unmatched normal adjacent tissues, 10 cases 24 cores		88-Eur	US Biomax	assays
OV241	Ovarian cancer test tissue array with self-matching or unmatched normal adjacent tissues, 10 cases 24 cores, replaced by OV241a; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
OV241a	Ovary cancer and adjacent normal tissue array, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing OV241; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
OV242	Multiple ovarian cancer test tissue array with unmatched normal adjacent tissues, 12 cases 24 cores		88-Eur	US Biomax	assays
OV242	Multiple ovarian cancer test tissue array with unmatched normal adjacent tissues, 12 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
OV243	Ovary cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases 48 cores		189-Eur	US Biomax	tissue
OV243	Ovary cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases 48 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
OV481	Ovarian cancer tissue array with unmatched normal adjacent tissues, 24 cases 48 cores, with stage and grade data		160-Eur	US Biomax	tissue
OV481	Ovarian cancer tissue array with unmatched normal adjacent tissues, 24 cases 48 cores, with stage and grade data; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
OV482	Multiple ovarian cancer tissue array with 4 normal tissues control from autopsy, (24 cases 48 cores) with grade and stage info		160-Eur	US Biomax	tissue
OV482	Multiple ovarian cancer tissue array with 4 normal tissues control from autopsy, (24 cases 48 cores) with grade and stage info; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue

OV483	Multiple ovarian cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores, with stage and grade info		160-Eur	US Biomax	tissue
OV483	Multiple ovarian cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores, with stage and grade info; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
OV484	Ovarian cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases 48 cores		231-Eur	US Biomax	tissue
OV484	Ovarian cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases 48 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
OV485	Ovarian cancer tissue array, including TNM, clinical stage and pathology grade, 2 serial sections, 48 cases 96 cores		397-Eur	US Biomax	elisa
OV485	Ovarian cancer tissue array, including TNM, clinical stage and pathology grade, 2 serial sections, 48 cases 96 cores; ihc Anti-Actin confirmed		382-Eur	US Biomax	elisa
OV602	Tissue array of ovarian granulosa-theca cell tumor (GTCT, malignant and benign) and cysts, 60 cases 60 cores		231-Eur	US Biomax	tissue
OV602	Tissue array of ovarian granulosa-theca cell tumor (GTCT, malignant and benign) and cysts, 60 cases 60 cores; ihc Anti-Vimtin confirmed		267-Eur	US Biomax	tissue
OV603	Ovarian serous cystadenoma tissue array, 30 cases 60 cores		231-Eur	US Biomax	tissue
OV603	Ovarian serous cystadenoma tissue array, 30 cases 60 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
OV6161	High-density ovarian cancer array, with stage and grade information, 322 cases 616 cores		753-Eur	US Biomax	
OV6161	High-density ovarian cancer array, with stage and grade information, 322 cases 616 cores; ihc Anti-Actin confirmed		811-Eur	US Biomax	
OV641	Ovary cancer tissue array, 64 cases 66 cores, with TNM data		---Eur	US Biomax	tissue
OV701	Ovary cancer tissue array, with adjacent normal tissue, including TNM, clinical stage and pathology grade, 70 cases 70 cores, replacing BC111110; ihc Anti-Actin confirmed		228-Eur	US Biomax	tissue
OV721	Ovary cancer and normal tissue array, with grade and stage data, 24 cases 72 cores		231-Eur	US Biomax	tissue
OV721	Ovary cancer and normal tissue array, with grade and stage data, 24 cases 72 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
OV801	Ovarian cancer tissue array, with matched or unmatched adjacent normal tissue, 70 cases 80 cores		231-Eur	US Biomax	tissue

OV801	Ovarian cancer tissue array, with matched or unmatched adjacent normal tissue, 70 cases 80 cores; ihc Anti-Cytokeratin (High MW) confirmed		267-Eur	US Biomax	tissue
OV8010	Mid-advanced stage ovary cancer tissue array, with metastasis tissue, including TNM and pathology grade, 80 cases 80 cores		266-Eur	US Biomax	tissue
OV8010	Mid-advanced stage ovary cancer tissue array, with metastasis tissue, including TNM and pathology grade, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
OV802	Multiple ovarian carcinoma and normal tissue array, with stage and TNM info, 78 cases 80 cores, replacing BC11011		231-Eur	US Biomax	tissue
OV802	Multiple ovarian carcinoma and normal tissue array, with stage and TNM info, 78 cases 80 cores, replacing BC11011; ihc Anti-Cytokeratin (CK) confirmed		228-Eur	US Biomax	tissue
OV803	Ovarian adenocarcinoma tissue array, 80 cases 80 cores		231-Eur	US Biomax	tissue
OV803	Ovarian adenocarcinoma tissue array, 80 cases 80 cores, replaced by OV803a; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
OV803a	Ovary cancer tissue array, including TNM, clinical stage and pathology grade, 80 cases 80 cores, replacing OV803; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
OV804	Ovarian metastatic carcinoma tissue array, 80 cases 80 cores		266-Eur	US Biomax	tissue
OV804	Ovarian metastatic carcinoma tissue array, 80 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		258-Eur	US Biomax	tissue
OV805	Ovarian teratoma tissue array, 80 cases 80 cores		231-Eur	US Biomax	tissue
OV805	Ovarian teratoma tissue array, 80 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
OV806	Normal ovarian tissue array, 30 cases 60 cores		231-Eur	US Biomax	tissue
OV806	Normal ovarian tissue array, 30 cases 60 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
OV807	Ovarian cancer tissue array with normal tissue, grade and TNM data, 40 cases 80 cores		231-Eur	US Biomax	tissue
OV807	Ovarian cancer tissue array with normal tissue, grade and TNM data, 40 cases 80 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
OV808	Ovarian cancer metastasis tissue array, 40 cases 80 cores		266-Eur	US Biomax	tissue
OV808	Ovarian cancer metastasis tissue array, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
OV809	Ovary cancer and normal tissue array, with stage and grade info, 80 cases 80 cores		266-Eur	US Biomax	tissue

OV809	Ovary cancer and normal tissue array, with stage and grade info, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
OV811	Ovarian cancer tissue array with normal tissues from autopsy, 35 cases 80 cores, with stage and grade data		231-Eur	US Biomax	tissue
OV811	Ovarian cancer tissue array with normal tissues from autopsy, 35 cases 80 cores, with stage and grade data; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
OV951	Ovary cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 38 cases 95 cores,		456-Eur	US Biomax	tissue
OV951	Ovary cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 38 cases 95 cores,; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
OV961	Ovary tumor tissue array, including TNM, clinical stage and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		228-Eur	US Biomax	elisa
OV962	Ovary tumor tissue array, including TNM, clinical stage and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		228-Eur	US Biomax	elisa
OVC1021	Ovary cancer tissue array, 102 cases 102 cores		225-Eur	US Biomax	tissue
OVC1021	Ovary cancer tissue array, 102 cases 102 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
OVC1501	Ovarian cancer mid-density tissue array, 75 cases 150 cores		225-Eur	US Biomax	tissue
OVC1501	Ovarian cancer mid-density tissue array, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
OVC2281	Hidensity ovarian cancer tissue array containing 8 cases of normal benign conditions and 220 cases of cancers with grading and TNM staging data, 228 cases 228 cores		403-Eur	US Biomax	tissue
OVC2281	Hidensity ovarian cancer tissue array containing 8 cases of normal benign conditions and 220 cases of cancers with grading and TNM staging data, 228 cases 228 cores; ihc H&E, IHC anti-Cytokeratin		434-Eur	US Biomax	tissue
OVC241	Ovary cancer tissue array, 12 cases 24 cores		166-Eur	US Biomax	tissue
OVC241	Ovary cancer tissue array, 12 cases 24 cores; ihc H&E, IHC anti-Cytokeratin		205-Eur	US Biomax	tissue
OVC961	Ovarian cancer and normal tissue array, non-overlapping with OVC962, 48 cases 96 cores		225-Eur	US Biomax	elisa
OVC961	Ovarian cancer and normal tissue array, non-overlapping with OVC962, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	elisa

OVC962	Ovarian cancer and normal tissue array, non-overlapping with OVC961, 48 cases 96 cores		225-Eur	US Biomax	elisa
OVC962	Ovarian cancer and normal tissue array, non-overlapping with OVC961, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	elisa
PA1001	Multiple pancreatic cancer tissue array with unmatched normal adjacent tissues, with TNM data, 50 cases 100 cores		266-Eur	US Biomax	tissue
PA1001	Multiple pancreatic cancer tissue array with unmatched normal adjacent tissues, with TNM data, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PA1002	Pancreas cancer tissue array for antibody screening, with normal tissue, including TNM and pathology grade, 50 cases 100 cores		266-Eur	US Biomax	tissue
PA1002	Pancreas cancer tissue array for antibody screening, with normal tissue, including TNM and pathology grade, 50 cases 100 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
PA1003	Pancreas cancer tissue array for antibody screening, including TNM and pathology grade, 25 cases 100 cores		314-Eur	US Biomax	tissue
PA1003	Pancreas cancer tissue array for antibody screening, including TNM and pathology grade, 25 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PA1921	Mid-advanced stage pancreatic cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores		456-Eur	US Biomax	elisa
PA1921	Mid-advanced stage pancreatic cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	elisa
PA207	High-density (69 cases 207 cores), multiple pancreatic cancer (1-3 grade) and normal pancreatic tissue array, replaced by PA2072		456-Eur	US Biomax	tissue
PA207	High-density (69 cases 207 cores), multiple pancreatic cancer (1-3 grade) and normal pancreatic tissue array, replaced by PA2072; ihc Anti-Cytokeratin (CK) confirmed		487-Eur	US Biomax	tissue
PA2072	Pancreas cancer tissue array, with normal tissue, including TNM and pathology grade, 69 cases 207 cores, replacing PA207		456-Eur	US Biomax	tissue
PA2072	Pancreatic cancer tissue array, with normal tissue, including TNM and pathology grade, 69 cases 207 cores, replacing PA207; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
PA207b	High-density (69 cases 207 cores), multiple pancreatic cancer (I-4 grade) and normal pancreatic tissue array BLOCK		40981-Eur	US Biomax	tissue

PA207b	High-density (69 cases 207 cores), multiple pancreatic cancer (I-4 grade) and normal pancreatic tissue array block; ihc Anti-Cytokeratin (CK) confirmed		19019-Eur	US Biomax	tissue
PA2081	Pancreatic disease spectrum (pancreatic cancer progression) tissue array with pathology grade and TNM information, 101 cases 208 cores		456-Eur	US Biomax	tissue
PA2081	Pancreatic disease spectrum (pancreatic cancer progression) tissue array with pathology grade and TNM information, 101 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
PA2082	High-density pancreatic cancer and normal tissue array, with stage and grade info, 101 cases 208 cores		456-Eur	US Biomax	tissue
PA2082	High-density pancreatic cancer and normal tissue array, with stage and grade info, 101 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
PA241	Pancreatic cancer test tissue array with self-matching normal adjacent tissue, 6 cases 24 cores, replaced by PA241b		100-Eur	US Biomax	assays
PA241	Pancreatic cancer test tissue array with self-matching normal adjacent tissue, 6 cases 24 cores, replaced by PA241b; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
PA241b	Pancreas adenocarcinoma tissue array with matched adjacent normal pancreas tissue, including TNM and pathology grade, 6 cases 24 cores, replacing PA241		99-Eur	US Biomax	tissue
PA241b	Pancreas adenocarcinoma tissue array with matched adjacent normal pancreas tissue, including TNM and pathology grade, 6 cases 24 cores, replacing PA241		88-Eur	US Biomax	tissue
PA241b	Pancreas adenocarcinoma tissue array with matched adjacent normal pancreas tissue, including TNM and pathology grade, 6 cases 24 cores, replacing PA241; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
PA242	Multiple pancreatic cancer tissue array with unmatched normal adjacent tissue, 12 cases 24 cores		88-Eur	US Biomax	tissue
PA242	Multiple pancreatic cancer tissue array with unmatched normal adjacent tissue, 12 cases 24 cores, replaced by PA242a; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	tissue
PA242a	Pancreas cancer tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing PA242; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue

PA243	Pancreas cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases 48 cores		189-Eur	US Biomax	tissue
PA243	Pancreas cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases 48 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
PA481	Multiple pancreatic cancer with 4 normal tissues control from autopsy, 24 cases 48 cores, with grade and stage		160-Eur	US Biomax	tissue
PA481	Multiple pancreatic cancer with 4 normal tissues control from autopsy, 24 cases 48 cores, with grade and stage; ihc Anti-Actin confirmed		162-Eur	US Biomax	tissue
PA482	Multiple pancreatic cancer tissue array with 4 normal tissue control from autopsy, 24 cases 48 cores, with TNM data		160-Eur	US Biomax	tissue
PA482	Multiple pancreatic cancer tissue array with 4 normal tissue control from autopsy, 24 cases 48 cores, with TNM data; ihc Anti-Actin confirmed		162-Eur	US Biomax	tissue
PA483	Multiple pancreatic cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores, with grade and stage data		160-Eur	US Biomax	tissue
PA483	Multiple pancreatic cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores, with grade and stage data, replaced by PA483b; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
PA483a	Pancreatic cancer tissue array, including TNM and pathology grade, 48 cases 48 cores, replacing PA483; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
PA483b	Pancreas cancer tissue array with normal tissue as control, including TNM, clinical stage and pathology grade, 48 cases 48 cores, replacing PA483; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
PA484	Pancreas adenocarcinoma tissue array, including TNM and pathology grade, 24 cases 48 cores		225-Eur	US Biomax	tissue
PA484	Pancreas adenocarcinoma tissue array, including TNM and pathology grade, 24 cases 48 cores		189-Eur	US Biomax	tissue
PA484	Pancreas adenocarcinoma tissue array, including TNM and pathology grade, 24 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
PA721	Pancreatic carcinoma (multi-tissue combined panel), 24 cases 72 cores, replacing BC14012		231-Eur	US Biomax	tissue
PA721	Pancreatic cancer (multi-tissue combined panel), 24 cases 72 cores, replacing BC14012; ihc Anti-Cytokeration (CK) confirmed		228-Eur	US Biomax	tissue
PA722	Pancreatic cancer and normal tissue array, with TNM and pathology grade, 24 cases 72 cores		266-Eur	US Biomax	tissue

PA722	Pancreatic cancer and normal tissue array, with TNM and pathology grade, 24 cases 72 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PA801	Multiple pancreatic cancer tissue array with unmatched normal adjacent tissue, with stage and grade info, 70 cases 80 cores, replaced by PA802		231-Eur	US Biomax	tissue
PA801	Multiple pancreatic cancer tissue array with unmatched normal adjacent tissue, with stage and grade info, 70 cases 80 cores, replaced by PA802; ihc Anti-Cytokeratin (High MW) confirmed		267-Eur	US Biomax	tissue
PA802	Multiple pancreatic cancer tissue array with unmatched normal tissues, with TNM data, 78 cases 80 cores, replacing PA801, to be replaced by PA805		266-Eur	US Biomax	tissue
PA802	Multiple pancreatic cancer tissue array with unmatched normal tissues, with TNM data, 78 cases 80 cores, replacing PA801, to be replaced by PA805; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PA803	Pancreatic duct adenocarcinoma and normal tissue array with TNM and grade info, 40 cases 80 cores		266-Eur	US Biomax	tissue
PA803	Pancreatic duct adenocarcinoma and normal tissue array with TNM and grade info, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PA804	Pancreatic cancer and normal tissue array, with stage and grade info, 80 cases 80 cores		266-Eur	US Biomax	tissue
PA804	Pancreatic cancer and normal tissue array, with stage and grade info, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PA805	Pancreatic cancer tissue array, with adjacent normal tissue and normal tissue, including TNM and pathology grade, 80 cases 80 cores, replacing PA802		266-Eur	US Biomax	tissue
PA805	Pancreatic cancer tissue array, with adjacent normal tissue and normal tissue, including TNM and pathology grade, 80 cases 80 cores, replaced by PA805a; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PA805a	Pancreas cancer tissue array with adjacent normal tissue as control, including TNM, clinical stage and pathology grade, 80 cases 80 cores, replacing PA805; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PA961	Pancreatic cancer and normal tissue array, including TNM, clinical stage and pathology grade, 96 cases 96 cores		278-Eur	US Biomax	elisa
PA961	Pancreatic cancer and normal tissue array, including TNM, clinical stage and pathology grade, 96 cases 96 cores; ihc Anti-Actin confirmed		320-Eur	US Biomax	elisa

PA961a	Pancreatic cancer tissue array with normal pancreatic tissue, including TNM, clinical stage and pathology grade, 96 cases 96 cores, replacing PA961; ihc Anti-Actin confirmed		258-Eur	US Biomax	elisa
PAC481	Pancreatic cancer tissue array, 24 cases 48 cores		225-Eur	US Biomax	tissue
PAC481	Pancreatic cancer tissue array, 24 cases 48 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	tissue
PE241	Penis cancer tissue array with unmatched normal adjacent tissues, 12 cases 24 cores		88-Eur	US Biomax	tissue
PE241	Penis cancer tissue array with unmatched normal adjacent tissues, 12 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	tissue
PE601	Penis disease spectrum (penis tumor progression) tissue array, 59 cases 60 cores		266-Eur	US Biomax	tissue
PE601	Penis disease spectrum (penis tumor progression) tissue array, 59 cases 60 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PE801	Penile (penis) carcinoma tissue array, 80 cases 80 cores		266-Eur	US Biomax	tissue
PE801	Penile (penis) carcinoma tissue array, 80 cases 80 cores; ihc IHC confirmed		296-Eur	US Biomax	tissue
PIT501	Normal pituitary gland tissue array, 25 cases 50 cores		261-Eur	US Biomax	tissue
PIT501	Normal pituitary gland tissue array, 25 cases 50 cores; ihc H&E, IHC anti-Vimentin		281-Eur	US Biomax	tissue
PM2-ER	ER Immunohistochemistry control tissue array, including TNM and pathology grade of breast cancer and IHC results of ER Ki67 PR Her-2, 10 cases 10 cores; ihc Anti-Actin confirmed		114-Eur	US Biomax	tissue
PM2-PR	PR Immunohistochemistry control tissue array, including TNM and pathology grade of breast cancer, 11 cases 11 cores; ihc Anti-Actin confirmed		114-Eur	US Biomax	tissue
PR1001	Prostate cancer tissue array, including TNM and pathology grade, 25 cases 100 cores		266-Eur	US Biomax	tissue
PR1001	Prostate cancer tissue array, including TNM and pathology grade, 25 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PR207b	High-density prostate cancer (1-4 grade) and normal prostate tissue array, 70 cases 208 cores		456-Eur	US Biomax	tissue
PR207b	High-density prostate cancer (1-4 grade) and normal prostate tissue array, 70 cases 208 cores, replaced by PR208; ihc P504S confirmed		487-Eur	US Biomax	tissue
PR208	High-density (70 cases 208 cores), multiple prostate cancer (1-4 grade), normal prostate and placenta tissue array		456-Eur	US Biomax	tissue

PR208	High-density prostate cancer tissue array(1-4 grade), normal prostate and placenta (as control), 70 cases 208 cores, replacing PR207b; ihc P504S confirmed		487-Eur	US Biomax	tissue
PR2085a	High-density (114 cases 208 cores) prostate adenocarcinoma (I-4 grade) and normal prostate (from autopsy and cancer adjacent) tissue array		456-Eur	US Biomax	tissue
PR2085a	High-density (114 cases 208 cores) prostate adenocarcinoma (grade 1-4) and normal prostate (from autopsy and cancer adjacent) tissue array, replaced by PR2085b; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
PR2085b	High-density (208 core) prostate adenocarcinoma (I-4 grade) and normal prostate (from autopsy and cancer adjacent) tissue BLOCK		46914-Eur	US Biomax	tissue
PR2085b	High-density prostate cancer tissue array, including TNM, pathology grade, Gleason grade and Gleason scores, 114 cases 208 cores, replacing PR2085a; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
PR241	Prostate cancer test tissue array with unmatched normal adjacent tissue, 12 cases 24 cores, replaced by PR243		88-Eur	US Biomax	assays
PR241	Prostate cancer test tissue array with unmatched normal adjacent tissue, 12 cases 24 cores, replaced by PR243; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
PR242	Multiple prostate cancer test tissue array with unmatched normal adjacent tissue, 12 cases 24 cores		88-Eur	US Biomax	assays
PR242	Multiple prostate cancer test tissue array with unmatched normal adjacent tissue, 12 cases 24 cores, replaced by PR242a; ihc Anti-Proliferating Cell Nuclear Antigen (PCNA) confirmed		105-Eur	US Biomax	assays
PR242a	Prostate cancer tissue array with adjacent normal prostate tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing PR242; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
PR243	Prostate cancer and normal tissue array, with stage and grade info, 12 cases 24 cores, replacing PR241		88-Eur	US Biomax	tissue
PR243	Prostate cancer and normal tissue array, with stage and grade info, 12 cases 24 cores, replaced by PR243a; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
PR243a	Prostate cancer tissue array with adjacent normal prostate tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing PR243; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
PR481	Prostate cancer tissue array with unmatched normal prostate tissues, 24 cases 48 cores, with grades, stages and Gleason scores		160-Eur	US Biomax	tissue

PR481	Prostate cancer tissue array with unmatched normal prostate tissues, 24 cases 48 cores, with grades, stages and Gleason scores; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
PR482	Multiple prostate cancer tissue array with 4 normal tissue control from autopsy, with TNM and Gleason Scores, 24 cases 48 cores		160-Eur	US Biomax	tissue
PR482	Multiple prostate cancer tissue array with 4 normal tissue control from autopsy, with TNM and Gleason Scores, 24 cases 48 cores; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
PR483	Multiple prostate cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores, with stage, grade and Gleason score info		160-Eur	US Biomax	tissue
PR483	Multiple prostate cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores, with stage, grade and Gleason score info, replaced by PR483a; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
PR483a	Prostate cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases 48 cores, replacing PR483; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
PR484	Prostate cancer tissue array, including TNM, clinical stage and pathology grade, 24 cases 48 cores; ihc Anti-Actin confirmed		162-Eur	US Biomax	tissue
PR631	Prostatic carcinoma tissue array with 3 cases of normal prostate tissue from autopsy, 33 cases 63 cores, with grade and Gleason scores		266-Eur	US Biomax	tissue
PR631	Prostatic carcinoma tissue array with 3 cases of normal prostate tissue from autopsy, 33 cases 63 cores, with grade and Gleason scores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PR632	Prostate cancer, hyperplasia with normal tissue array, with Gleason scores and stage information, 21cases 63 cores		266-Eur	US Biomax	tissue
PR632	Prostate cancer, hyperplasia with normal tissue array, with Gleason scores and stage information, 21cases 63 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PR633	Prostate cancer tissue array, including TNM, clinical stage and pathology grade, 63 cases 63 cores, replacing PR8010; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PR721	Prostate cancer normal prostate tissue array with TNM, grade and Gleason scores, 24 cases 72 cores		266-Eur	US Biomax	tissue
PR721	Prostate cancer normal prostate tissue array with TNM, grade and Gleason scores, 24 cases 72 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue

PR751	Prostate cancer, PIN (prostatic intraepithelial neoplasia) and hyperplasia tissue array, 75 cases 75 cores, with grade and Gleason's Score data		266-Eur	US Biomax	tissue
PR751	Prostate cancer, PIN (prostatic intraepithelial neoplasia) and hyperplasia tissue array, 75 cases 75 cores, with grade and Gleason's Score data; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PR752	Prostate cancer and hyperplasia tissue array, including TNM and pathology grade, 75 cases 75 cores		266-Eur	US Biomax	tissue
PR752	Prostate cancer and hyperplasia tissue array, including TNM and pathology grade, 75 cases 75 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PR753	Prostate cancer and hyperplasia tissue array, including TNM and pathology grade, 75 cases 75 cores		266-Eur	US Biomax	tissue
PR753	Prostate cancer and hyperplasia tissue array, including TNM and pathology grade, 75 cases 75 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PR801	Prostate cancer tissue array with unmatched normal prostate tissue, 78 cases 80 cores, replaced by PR803		231-Eur	US Biomax	tissue
PR801	Prostate cancer tissue array with unmatched normal prostate tissue, 78 cases 80 cores, replaced by PR803; ihc Anti-Proliferating Cell Nuclear Antigen antibody confirmed		296-Eur	US Biomax	tissue
PR8010	Prostate cancer tissue array, including TNM and pathology grade, 80 cases 80 cores, replacing PR802		266-Eur	US Biomax	tissue
PR8010	Prostate cancer tissue array, including TNM and pathology grade, 80 cases 80 cores, replaced by PR633; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PR8011	Prostate disease spectrum tissue array, including TNM and pathology grade, 80 cases 80 cores, replacing PR805		314-Eur	US Biomax	tissue
PR8011	Prostate disease spectrum tissue array, including TNM and pathology grade, 80 cases 80 cores, replacing PR805; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PR802	Prostate carcinoma tissue array, 80 cases 80 cores, no overlaps with PR801, replaced by PR8010		231-Eur	US Biomax	tissue
PR802	Prostate carcinoma tissue array, 80 cases 80 cores, no overlaps with PR801, replaced by PR8010; ihc Anti-Proliferating Cell Nuclear Antigen (PCNA) confirmed		296-Eur	US Biomax	tissue

PR803	Prostate cancer tissue array with unmatched normal prostate tissue, 80 cases 80 cores, replacing PR801		231-Eur	US Biomax	tissue
PR803	Prostate cancer tissue array with unmatched normal prostate tissue, 80 cases 80 cores, replacing PR801, replaced by PR803a; ihc Anti-Proliferating Cell Nuclear Antigen (PCNA) confirmed		296-Eur	US Biomax	tissue
PR803a	Prostate cancer tissue array, including TNM, clinical stage and pathology grade, 80 cases 80 cores, replacing PR803; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PR804	Hyperplasia and carcinoma of prostate tissue array, 80 cases 80 cores, with grade and Gleason score information		266-Eur	US Biomax	tissue
PR804	Hyperplasia and carcinoma of prostate tissue array, 80 cases 80 cores, with grade and Gleason score information; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PR805	Prostate disease spectrum (prostatic cancer progression) tissue array, 80 cases 80 cores		266-Eur	US Biomax	tissue
PR805	Prostate disease spectrum (prostatic cancer progression) tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PR806	Prostate adenocarcinoma and normal tissue array with stage and Gleason Scores, 40 cases 80 cores		266-Eur	US Biomax	tissue
PR806	Prostate adenocarcinoma and normal tissue array with stage and Gleason Scores, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PR807	Prostate cancer, hyperplasia and normal tissue array, with stage (Gleason Scores) and grade info, 79 cases 80 cores		266-Eur	US Biomax	tissue
PR807	Prostate cancer, hyperplasia and normal tissue array, with stage (Gleason Scores) and grade info, 79 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PR807a	Prostate cancer, hyperplasia and normal tissue array, including TNM and pathology grade, 79 cases 80 cores, replacing PR807; ihc Anti-Prostate Specific Antigen (PSA) confirmed		296-Eur	US Biomax	tissue
PR808	Prostate cancer and normal tissue array, with TNM, stage, Gleason's score and grade info, 40 cases 80 cores, replacing BC19012		266-Eur	US Biomax	tissue
PR808	Prostate cancer and normal tissue array, with TNM, stage, Gleason's score and grade info, 40 cases 80 cores, replacing BC19012; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PR809	Prostate cancer and hyperplasia tissue array, with stage and grade, 40 cases 80 cores, replacing BC19019		266-Eur	US Biomax	tissue

PR809	Prostate cancer and hyperplasia tissue array, with stage and grade, 40 cases 80 cores, replacing BC19019; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
PR951	Prostate adenocarcinoma tissue array with matched normal adjacent tissue and metastatic bones, 40 cases 95 cores, with TNM and Gleason scores, replaced by PR952; ihc Anti-PCNA confirmed		487-Eur	US Biomax	tissue
PR952	Prostate adenocarcinoma tissue array with matched normal adjacent tissue and metastatic bones, 40 cases 95 cores, with TNM and Gleason scores, replaced by PR953		314-Eur	US Biomax	tissue
PR952	Prostate adenocarcinoma tissue array with matched normal adjacent tissue and metastatic bones, 40 cases 95 cores, with TNM and Gleason scores, replaced by PR953; ihc Anti-PCNA confirmed		296-Eur	US Biomax	tissue
PR953	Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replaced by PR954		456-Eur	US Biomax	tissue
PR953	Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replaced by PR954; ihc Anti-Actin conf		487-Eur	US Biomax	tissue
PR954	Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replaced by PR955		456-Eur	US Biomax	tissue
PR954	Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replaced by PR955; ihc Anti-Actin conf		487-Eur	US Biomax	tissue
PR955	Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replacing PR954		558-Eur	US Biomax	tissue
PR955	Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replacing PR954		456-Eur	US Biomax	tissue

PR955	Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replaced by PR956; ihc Anti-Actin conf		487-Eur	US Biomax	tissue
PR956	Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replacing PR955; ihc Anti-Actin confir		487-Eur	US Biomax	tissue
PRC481	Prostate cancer tissue array, 24 cases 48 cores		225-Eur	US Biomax	tissue
PRC481	Prostate cancer tissue array, 24 cases 48 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	tissue
PRC961	Prostate cancer tissue array, 48 cases 96 cores		261-Eur	US Biomax	elisa
PRC961	Prostate cancer tissue array, 48 cases 96 cores; ihc H&E, IHC anti- Cytokeratin		281-Eur	US Biomax	elisa
PRF281	Prostate cancer frozen tissue array, with grade and Gleason scores and normal prostate tissue control, 28 cases 28 cores; ihc H&E and Anti-Actin confirmed		742-Eur	US Biomax	tissue
RA161	Multiple organs normal tissue array of rat, 8 cases 16 cores		189-Eur	US Biomax	tissue
RA161	Multiple organs normal tissue array of rat, 8 cases 16 cores; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
RA162	Multiple organs normal tissue array of rat, 8 cases 16 cores		189-Eur	US Biomax	tissue
RA162	Multiple organs normal tissue array of rat, 8 cases 16 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
RAT901	Rat multiple organs, normal tissue array, 22 cases 90 cores, replacing BR01013		231-Eur	US Biomax	tissue
RAT901	Rat multiple organs, normal tissue array, 22 cases 90 cores, replacing BR01013; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
RE1021	Rectum cancer tissue array, including TNM, clinical stage and pathology grade, 102 cases 102 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	recom binant
RE1501	Rectum adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		321-Eur	US Biomax	recom binant
RE1501	Rectum adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		266-Eur	US Biomax	recom binant
RE1501	Rectum adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	recom binant

RE1502	Rectum adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		321-Eur	US Biomax	recom binant
RE1502	Rectum adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		266-Eur	US Biomax	recom binant
RE1502	Rectum adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	recom binant
RE1503	Rectum cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	recom binant
RE2001	Rectum cancer high-density (200 core) tissue array, 192 cases 208 cores		397-Eur	US Biomax	recom binant
RE2001	Rectum cancer high-density (200 core) tissue array, 192 cases 208 cores; ihc Anti-Cytokeratin (Low-MW) confirmed		382-Eur	US Biomax	recom binant
RE2081	Rectum disease spectrum (rectal cancer progression) tissue array, 98 cases 208 cores		456-Eur	US Biomax	recom binant
RE2081	Rectum disease spectrum (rectal cancer progression) tissue array, 98 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	recom binant
RE2161	Rectum adenocarcinoma tissue array, including TNM and pathology grade, 216 cases 216 cores		558-Eur	US Biomax	recom binant
RE2161	Rectum adenocarcinoma tissue array, including TNM and pathology grade, 216 cases 216 cores		456-Eur	US Biomax	recom binant
RE2161	Rectum adenocarcinoma tissue array, including TNM and pathology grade, 216 cases 216 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	recom binant
RE241	Rectal cancer test tissue array with unmatched normal adjacent tissues, 12 cases 24 cores		88-Eur	US Biomax	recom binant
RE241	Rectal cancer test tissue array with unmatched normal adjacent tissues, 12 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	recom binant
RE242	Multiple rectal cancer tissue array with unmatched normal adjacent tissues, 12 cases 24 cores		88-Eur	US Biomax	recom binant
RE242	Multiple rectal cancer tissue array with unmatched normal adjacent tissues, 12 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	recom binant
RE481	Tissue array of rectal adenocarcinoma and matched adjacent tissue, 12 cases 48 cores		160-Eur	US Biomax	recom binant
RE481	Tissue array of rectal adenocarcinoma and matched adjacent tissue, 12 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	recom binant
RE482	Multiple rectal cancer tissue array with normal tissue, stage and grade data, 48 cases 48 cores		160-Eur	US Biomax	recom binant

RE482	Multiple rectal cancer tissue array with normal tissue, stage and grade data, 48 cases 48 cores; ihc Anti-Actin confirmed		162-Eur	US Biomax	recombinant
RE483	Rectum adenocarcinoma tissue array with matched adjacent rectum tissue, including TNM and pathology grade, 16 cases 48 cores		188-Eur	US Biomax	recombinant
RE483	Rectum adenocarcinoma tissue array with matched adjacent rectum tissue, including TNM and pathology grade, 16 cases 48 cores		160-Eur	US Biomax	recombinant
RE483	Rectum adenocarcinoma tissue array with matched adjacent rectum tissue, including TNM and pathology grade, 16 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	recombinant
RE601	Colon and rectum cancer tissue array, including TNM, clinical stage and pathology grade, 60 cases 60 cores		231-Eur	US Biomax	recombinant
RE601	Colon and rectum cancer tissue array, including TNM, clinical stage and pathology grade, 60 cases 60 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	recombinant
RE641	Rectum cancer tissue array, 64 cases 66 cores, with TNM data		---Eur	US Biomax	recombinant
RE721	Normal rectum and cancer tissue array, 22 cases 72 cores		231-Eur	US Biomax	recombinant
RE721	Normal rectum and cancer tissue array, 22 cases 72 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	recombinant
RE722	Rectal cancer tissue array with matched adjacent normal tissue, including stage and grade info, 24 cases 72 cores, replacing BC06022		231-Eur	US Biomax	recombinant
RE722	Rectal cancer tissue array with matched adjacent normal tissue, including stage and grade info, 24 cases 72 cores, replacing BC06022; ihc Anti-Actin confirmed		267-Eur	US Biomax	recombinant
RE723	Rectal adenocarcinoma (grade 2) tissue array, with stage, TNM and grade, 24 cases 72 cores, replacing BS06031		231-Eur	US Biomax	recombinant
RE723	Rectal adenocarcinoma (grade 2) tissue array, with stage, TNM and grade, 24 cases 72 cores, replacing BS06031; ihc Anti-Actin confirmed		267-Eur	US Biomax	recombinant
RE724	Rectal adenocarcinoma (grade 3) tissue array, with stage, TNM and grade info, 24 cases 72 cores, replacing BS06041		231-Eur	US Biomax	recombinant
RE724	Rectal adenocarcinoma (grade 3) tissue array, with stage, TNM and grade info, 24 cases 72 cores, replacing BS06041; ihc Anti-Actin confirmed		267-Eur	US Biomax	recombinant
RE801	Rectal cancer tissue array, with matched adjacent normal tissue, 40 cases 80 cores		231-Eur	US Biomax	recombinant

RE801	Rectal cancer tissue array, with matched adjacent normal tissue, 40 cases 80 cores; ihc Anti-Cytokeratin (High MW) confirmed		267-Eur	US Biomax	recom binant
RE802	Rectal normal adjacent tissue and cancer tissue array, 74 cases 80 cores		231-Eur	US Biomax	recom binant
RE802	Rectal normal adjacent tissue and cancer tissue array, 74 cases 80 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	recom binant
RE803	Rectal cancer and normal tissue array, with TNM and grade info, 73 cases 80 cores		231-Eur	US Biomax	recom binant
RE803	Rectal cancer and normal tissue array, with TNM and grade info, 73 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	recom binant
RE804	Rectal disease spectrum (rectum cancer progression) tissue array, 75 cases 80 cores		231-Eur	US Biomax	recom binant
RE804	Rectal disease spectrum (rectum cancer progression) tissue array, 75 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	recom binant
RE811	Rectal cancer tissue array with normal tissues from autopsy, with TNM and grade data, 80 cases 80 cores		231-Eur	US Biomax	recom binant
RE811	Rectal cancer tissue array with normal tissues from autopsy, with TNM and grade data, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	recom binant
RE812	Rectal cancer tissue array with normal tissue from autopsy, 40 cases 80 cores, with grade and stage data		231-Eur	US Biomax	recom binant
RE812	Rectal cancer tissue array with normal tissue from autopsy, 40 cases 80 cores, with grade and stage data; ihc Anti-Actin confirmed		296-Eur	US Biomax	recom binant
RE961	Rectum adenocarcinoma tissue array, including TNM and pathology grade, 48 cases 96 cores		321-Eur	US Biomax	elisa
RE961	Rectum adenocarcinoma tissue array, including TNM and pathology grade, 48 cases 96 cores		266-Eur	US Biomax	elisa
RE961	Rectum adenocarcinoma tissue array, including TNM and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	elisa
RE962	Rectum adenocarcinoma tissue array, including TNM and pathology grade, 48 cases 96 cores		321-Eur	US Biomax	elisa
RE962	Rectum adenocarcinoma tissue array, including TNM and pathology grade, 48 cases 96 cores		266-Eur	US Biomax	elisa
RE962	Rectum adenocarcinoma tissue array, including TNM and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	elisa
REC1021	Rectum cancer tissue array, 102 cases 102 cores		---Eur	US Biomax	recom binant

REC1021	Rectum cancer tissue array, 102 cases 102 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	recom binant
REC1501	Rectal cancer mid-density tissue array, non-overlapping with REC1502 or REC1503, 75 cases 150 cores		---Eur	US Biomax	recom binant
REC1501	Rectal cancer mid-density tissue array, non-overlapping with REC1502 or REC1503, 75 cases 150 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	recom binant
REC1502	Rectal cancer mid-density tissue array, non-overlapping with REC1501 or REC1503, 75 cases 150 cores		---Eur	US Biomax	recom binant
REC1502	Rectal cancer mid-density tissue array, non-overlapping with REC1501 or REC1503, 75 cases 150 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	recom binant
REC1503	Rectum cancer mid-density tissue array, non-overlapping with REC1501 or REC1502, 75 cases 150 cores		---Eur	US Biomax	recom binant
REC1503	Rectum cancer mid-density tissue array, non-overlapping with REC1501 or REC1502, 75 cases 150 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	recom binant
REC2281	Rectum cancer high density tissue array, 228 cases 228 cores		---Eur	US Biomax	recom binant
REC481	Rectum cancer and normal tissue array, 16 cases 48 cores		---Eur	US Biomax	recom binant
REC481	Rectum cancer and normal tissue array, 16 cases 48 cores; ihc H&E, IHC anti- Cytokeratin		205-Eur	US Biomax	recom binant
REC961	Rectum cancer and normal tissue array, non-overlapping with REC962, 48 cases 96 cores		---Eur	US Biomax	elisa
REC961	Rectum cancer and normal tissue array, non-overlapping with REC962, 48 cases 96 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	elisa
REC962	Rectal cancer and normal tissue array, non-overlapping with REC961, 48 cases 96 cores		---Eur	US Biomax	elisa
REC962	Rectal cancer and normal tissue array, non-overlapping with REC961, 48 cases 96 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	elisa
RhFDA1	FDA normal organ tissue array of rhesus monkey, 99 cases 99 cores		278-Eur	US Biomax	tissue
RhFDA1	FDA normal organ tissue array of rhesus monkey, 99 cases 99 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
RhFDA2	FDA normal organ tissue array (TMA) block of rhesus monkey, 99 cases 99 cores		23184-Eur	US Biomax	tissue
RhFDA2	FDA normal organ tissue array (TMA) block of rhesus monkey, 99 cases 99 cores; ihc Anti-Actin confirmed		18780-Eur	US Biomax	tissue

RS321	Tissue microarray of normal human respiratory tract, 32 cases 32 cores		266-Eur	US Biomax	tissue
RS321	Tissue microarray of normal human respiratory tract, 32 cases 32 cores; ihc Anti-Cytokeratin (CK) confirmed		296-Eur	US Biomax	tissue
SF961	Soft tissue tumor tissue array, including TNM and clinical stage, 48 cases 96 cores; ihc Anti-Actin confirmed		228-Eur	US Biomax	elisa
SFD241	Human soft tissue disease tissue array, 24 cases 24 cores		166-Eur	US Biomax	tissue
SFD241	Human soft tissue disease tissue array, 24 cases 24 cores; ihc H&E, IHC anti- Cytokeratin		178-Eur	US Biomax	tissue
SFT961	Soft tissue tumor tissue array, 48 cases 96 cores		225-Eur	US Biomax	elisa
SFT961	Soft tissue tumor tissue array, 48 cases 96 cores; ihc H&E, IHC anti-vimentin		238-Eur	US Biomax	elisa
SK208	Skin cancer and normal tissue high density (69 cases 208 core) tissue microarray		456-Eur	US Biomax	tissue
SK208	Skin cancer and normal tissue high density (69 cases 208 core) tissue microarray; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
SK2081	Skin disease spectrum (dermatic cancer progression) tissue array, 102 cases 208 cores		456-Eur	US Biomax	tissue
SK2081	Skin disease spectrum (dermatic cancer progression) tissue array, 102 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
SK241	Skin cancer test tissue array with unmatched normal adjacent tissues, 12 cases 24 cores		88-Eur	US Biomax	assays
SK241	Skin cancer test tissue array with unmatched normal adjacent tissues, 12 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
SK242	Multiple skin cancer test tissue array with unmatched normal adjacent tissues, 12 cases 24 cores		88-Eur	US Biomax	assays
SK242	Multiple skin cancer test tissue array with unmatched normal adjacent tissues, 12 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
SK243	Age grouped female skin tissue array, 12 cases 24 cores, replaced by SK244		231-Eur	US Biomax	tissue
SK243	Age grouped female skin tissue array, 12 cases 24 cores, replaced by SK244; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
SK244	Age grouped female skin tissue array, 12 cases 24 cores, replacing SK243		99-Eur	US Biomax	tissue
SK244	Age grouped female skin tissue array, 12 cases 24 cores, replacing SK243		88-Eur	US Biomax	tissue
SK244	Age grouped female skin tissue array, 12 cases 24 cores, replacing SK243; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue

SK245	Skin disease tissue array, including TNM, clinical stage and pathology grade, 24 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
SK481	Skin cancer tissue array with corresponding (unmatched) normal adjacent tissues, 24 cases 48 cores		160-Eur	US Biomax	tissue
SK481	Skin cancer tissue array with corresponding (unmatched) normal adjacent tissues, 24 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
SK482	Multiple skin cancer tissue array with 4 normal tissue control from autopsy, 24 cases 48 cores		160-Eur	US Biomax	tissue
SK482	Multiple skin cancer tissue array with 4 normal tissue control from autopsy, 24 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
SK483	Multiple skin squamous cell carcinoma tissue array with normal tissues control from autopsy, 48 cases 48 cores		160-Eur	US Biomax	tissue
SK483	Multiple skin squamous cell carcinoma tissue array with normal tissues control from autopsy, 48 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
SK484	Skin basal cell cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores		160-Eur	US Biomax	tissue
SK484	Skin basal cell cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
SK721	Skin cancer and normal tissue array, with stage and grade info, 24 cases 72 cores		266-Eur	US Biomax	tissue
SK721	Skin cancer and normal tissue array, with stage and grade info, 24 cases 72 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
SK801	Skin cancer tissue array, with matched or unmatched adjacent normal tissue, 80 cases 73 cores, replaced by SK801b		278-Eur	US Biomax	tissue
SK801	Skin cancer tissue array, with matched or unmatched adjacent normal tissue, 80 cases 73 cores, replaced by SK801b; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
SK801b	Skin squamous cell carcinoma tissue array, including TNM and pathology grade, 80 cases 80 cores, replacing SK801		321-Eur	US Biomax	tissue
SK801b	Skin squamous cell carcinoma tissue array, including TNM and pathology grade, 80 cases 80 cores, replacing SK801		266-Eur	US Biomax	tissue
SK801b	Skin squamous cell carcinoma tissue array, including TNM and pathology grade, 80 cases 80 cores, replacing SK801; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue

SK802	Skin squamous cell carcinoma (SCC) tissue array, 80 cases 80 cores, no overlaps with SK801		231-Eur	US Biomax	tissue
SK802	Skin squamous cell carcinoma (SCC) tissue array, with pathology grade and clinical stage, 80 cases 80 cores, no overlaps with SK801; ihc Anti-Cytokeratin (High MW) confirmed		267-Eur	US Biomax	tissue
SK803	Skin basal cell cancer (BCC) and benign nevus tissue array, 52 cases 100 cores		231-Eur	US Biomax	tissue
SK803	Skin basal cell cancer (BCC) and benign nevus tissue array, 52 cases 100 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
SK804	Skin cancerous and normal tissue array, with stage and grade info, 40 cases 80 cores		266-Eur	US Biomax	tissue
SK804	Skin cancerous and normal tissue array, with stage and grade info, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
SK805	Skin disease spectrum (dermatic cancer progression) tissue array, 79 cases 80 cores		266-Eur	US Biomax	tissue
SK805	Skin disease spectrum (dermatic cancer progression) tissue array, 79 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
SK961	Skin tumor tissue array, including TNM, clinical stage and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	elisa
SKD241	Skin disease tissue array, 24 cases 24 cores		166-Eur	US Biomax	tissue
SKD241	Skin disease tissue array, 24 cases 24 cores; ihc H&E, IHC anti-Cytokeratin		178-Eur	US Biomax	tissue
SKT1501	Skin cancer mid-density tissue array, 75 cases 150 cores		225-Eur	US Biomax	tissue
SKT1501	Skin cancer mid-density tissue array, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
SKT961	Skin cancer and normal tissue array, 48 cases 96 cores		225-Eur	US Biomax	elisa
SKT961	Skin cancer and normal tissue array, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	elisa
SLC601	Stomach cancer and lung cancer tissue array, including TNM and pathology grade, 60 cases 60 cores		266-Eur	US Biomax	tissue
SLC601	Stomach cancer and lung cancer tissue array, including TNM and pathology grade, 60 cases 60 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
SM208	Small intestine cancer, metastatic lymph nodes and normal tissue high density tissue microarray, 69 cases 208 core, with stage and grade data		456-Eur	US Biomax	assays

SM208	Small intestine cancer, metastatic lymph nodes and normal tissue high density tissue microarray, 69 cases 208 core, with stage and grade data; ihc Anti-Actin confirmed		487-Eur	US Biomax	assays
SM2081	Small intestine disease (cancer progression) spectrum tissue array, 95 cases 208 cores		456-Eur	US Biomax	assays
SM2081	Small intestine disease (cancer progression) spectrum tissue array, 95 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	assays
SM241	Small intestine adenocarcinoma tissue array (including normal adjacent tissue), 6 cases 24 cores		88-Eur	US Biomax	assays
SM241	Small intestine adenocarcinoma tissue array (including normal adjacent tissue), 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
SM242	Small intestine adenocarcinoma with normal tissue array, 12 cases 24 cores		88-Eur	US Biomax	assays
SM242	Small intestine adenocarcinoma with normal tissue array, 12 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
SM801	Small intestine carcinoma and normal tissue array, 77 cases 80 cores		266-Eur	US Biomax	assays
SM801	Small intestine carcinoma and normal tissue array, 77 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	assays
SM802	Small intestine disease spectrum (small intestine cancer progression) tissue array, with grade, stage and TNM data, 72 cases 80 cores		266-Eur	US Biomax	assays
SM802	Small intestine disease spectrum (small intestine cancer progression) tissue array, with grade, stage and TNM data, 72 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	assays
SO1001	Peripheral nerve disease spectrum (peripheroneural cancer progression) tissue array, 50 cases 100 cores		266-Eur	US Biomax	tissue
SO1001	Peripheral nerve disease spectrum (peripheroneural cancer progression) tissue array, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
SO208	Soft tissue sarcoma high density tissue array with normal controls, 69 cases 208 cores, with grade and stage data		456-Eur	US Biomax	tissue
SO208	Soft tissue sarcoma high density tissue array with normal controls, 69 cases 208 cores, with grade and stage data; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
SO2081	Muscle disease spectrum (smooth muscle and striated muscle cancer progression) tissue array, 104 cases 208 cores		456-Eur	US Biomax	tissue

SO2081	Muscle disease spectrum (smooth muscle and striated muscle cancer progression) tissue array, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
SO2083	Adipose tissue disease spectrum (adipose tumor progression) tissue array, 104 cases 208 cores		456-Eur	US Biomax	tissue
SO2083	Adipose tissue disease spectrum (adipose tumor progression) tissue array, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
SO2084	Fibrous tissue disease spectrum (fibrous tissue cancer progression) tissue array, 104 cases 208 cores		456-Eur	US Biomax	tissue
SO2084	Fibrous tissue disease spectrum (fibrous tissue cancer progression) tissue array, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
SO241	Soft tissue cancer tissue array with unmatched normal adjacent tissues, 12 cases 24 cores		88-Eur	US Biomax	tissue
SO241	Soft tissue cancer tissue array with unmatched normal adjacent tissues, 12 cases 24 cores; ihc Anti-Vimentin (Vim) confirmed		105-Eur	US Biomax	tissue
SO481	Soft tissue cancer tissue array with unmatched normal adjacent tissues, 48 cases 48 cores, with TNM information		160-Eur	US Biomax	tissue
SO481	Soft tissue cancer tissue array with unmatched normal adjacent tissues, 48 cases 48 cores, with TNM information; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
SO482	Soft tissue cancer tissue array, with normal tissue, including TNM and pathology grade, 48 cases 48 cores		189-Eur	US Biomax	tissue
SO482	Soft tissue cancer tissue array, with normal tissue, including TNM and pathology grade, 48 cases 48 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
SO751	Leiomyosarcoma and rhabdomyosarcoma tissue array, including TNM and clinical stage, 39 cases 75 cores, replacing BC24021; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
SO801	Soft tissue cancer tissue array, with matched or unmatched adjacent normal tissue, 78 cases 80 cores		231-Eur	US Biomax	tissue
SO801	Soft tissue cancer tissue array, with matched or unmatched adjacent normal tissue, 78 cases 80 cores; ihc Anti-Vimentin (Vim) confirmed		267-Eur	US Biomax	tissue
SO8010	Blood vessel disease spectrum (blood vessel cancer progression) tissue array, 80 cases 80 cores		266-Eur	US Biomax	tissue
SO8010	Blood vessel disease spectrum (blood vessel cancer progression) tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue

SO8011	Smooth muscle and striated muscle disease spectrum (cancer progression) tissue array, 80 cases 80 cores		278-Eur	US Biomax	tissue
SO8011	Smooth muscle and striated muscle disease spectrum (cancer progression) tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		382-Eur	US Biomax	tissue
SO8012	Soft tissue cancer tissue array, with normal tissue, including TNM and pathology grade, 40 cases 80 cores		278-Eur	US Biomax	tissue
SO8012	Soft tissue cancer tissue array, with normal tissue, including TNM and pathology grade, 40 cases 80 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
SO802	Malignant fibrohistiocytoma tissue array, 80 cases 80 cores; ihc CD68 confirmed		267-Eur	US Biomax	tissue
SO803	Liparomphalus and liposarcoma tissue array, 80 cases 80 cores		278-Eur	US Biomax	tissue
SO803	Liparomphalus and liposarcoma tissue array, 80 cases 80 cores; ihc Vim confirmed		267-Eur	US Biomax	tissue
SO804	Leiomyosarcoma tissue array, 80 cases 80 cores		231-Eur	US Biomax	tissue
SO804	Leiomyosarcoma tissue array, 80 cases 80 cores; ihc SMA confirmed		267-Eur	US Biomax	tissue
SO805	Neurilemmoma of peripheral nerve tissue array, 80 cases 80 cores		231-Eur	US Biomax	tissue
SO805	Neurilemmoma of peripheral nerve tissue array, 80 cases 80 cores; ihc Anti-S-100 confirmed		267-Eur	US Biomax	tissue
SO806	Leiomyoma of uterus tissue array, 80 cases 80 cores		231-Eur	US Biomax	tissue
SO806	Leiomyoma of uterus tissue array, 80 cases 80 cores; ihc Smooth muscle actin (SMA) confirmed		267-Eur	US Biomax	tissue
SO807	Interstitialoma of gastrointestinal tract tissue array, 80 cases 80 cores		231-Eur	US Biomax	assays
SO807	Interstitialoma of gastrointestinal tract tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	assays
SO808	Schwannoma (neurilemmoma or neurinoma) of central nerve tissue array, 30 cases 60 cores		266-Eur	US Biomax	tissue
SO808	Schwannoma (neurilemmoma or neurinoma) of central nerve tissue array, 30 cases 60 cores; ihc Anti-S100 confirmed		267-Eur	US Biomax	tissue
SO809	Sarcoma tissue array of soft tissue (adipose, fibrous tissue, smooth muscles and striated muscles), 80 cases 80 cores		231-Eur	US Biomax	tissue
SO809	Sarcoma tissue array of soft tissue (adipose, fibrous tissue, smooth muscle and skeletal muscle), 80 cases 80 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue

SP1001	Spleen disease spectrum (splenic cancer progression) tissue array, 50 cases 100 cores		266-Eur	US Biomax	tissue
SP1001	Spleen disease spectrum (splenic cancer progression) tissue array, 50 cases 100 cores; ihc Anti-actin confirmed		401-Eur	US Biomax	tissue
SP241	Spleen cancer tissue array with unmatched normal adjacent tissues, 12 cases 24 cores		88-Eur	US Biomax	tissue
SP241	Spleen cancer tissue array with unmatched normal adjacent tissues, 12 cases 24 cores; ihc Anti-Leukocyte Common Antigen (LCA) confirmed		105-Eur	US Biomax	tissue
SP242	Multiple spleen cancer tissue array with unmatched normal adjacent tissues, 12 cases 24 cores		88-Eur	US Biomax	tissue
SP242	Multiple spleen cancer tissue array with unmatched normal adjacent tissues, 12 cases 24 cores; ihc Anti-Leukocyte Common Antigen (LCA) confirmed		105-Eur	US Biomax	tissue
SP481	Spleen cancer tissue array with unmatched normal adjacent tissues, 12 cases 48 cores		160-Eur	US Biomax	tissue
SP481	Spleen cancer tissue array with unmatched normal adjacent tissues, 12 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
SP482	Multiple spleen cancer tissue array with unmatched normal adjacent tissues, 28 cases 48 cores		160-Eur	US Biomax	tissue
SP482	Multiple spleen cancer tissue array with unmatched normal adjacent tissues, 28 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue
ST1001	Stomach disease spectrum (stomach cancer progression) tissue array, 100 cases 100 cores		266-Eur	US Biomax	tissue
ST1001	Stomach disease spectrum (stomach cancer progression) tissue array, 100 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ST1002	Stomach carcinoma for antibody screening array, including TNM, clinical stage and pathology grade, 25 cases 100 cores		231-Eur	US Biomax	
ST1002	Stomach carcinoma for antibody screening array, including TNM, clinical stage and pathology grade, 25 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	
ST1003	Stomach cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases 100 cores		231-Eur	US Biomax	tissue
ST1003	Stomach cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue

ST1004	Stomach adenocarcinoma with matched adjacent tissue array, including TNM and pathology grade, 55 cases 100 cores, replacing BC01114; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
ST1501	Stomach adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		321-Eur	US Biomax	tissue
ST1501	Stomach adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		266-Eur	US Biomax	tissue
ST1501	Stomach adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
ST1502	Stomach adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		321-Eur	US Biomax	tissue
ST1502	Stomach adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores		266-Eur	US Biomax	tissue
ST1502	Stomach adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
ST1503	Stomach adenocarcinoma tissue array, including TNM and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
ST1921	Middle-advanced stage stomach cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores		456-Eur	US Biomax	elisa
ST1921	Middle-advanced stage stomach cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases 192 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	elisa
ST2001	Stomach cancer high density (200 cases 200 cores) tissue array, including TNM and pathology grade		397-Eur	US Biomax	tissue
ST2001	Stomach cancer high density (200 cases 200 cores) tissue array, including TNM and pathology grade, replaced by ST2091; ihc Anti-Cytokeratin (CK) confirmed		429-Eur	US Biomax	tissue
ST208	Stomach cancer and normal tissue high density (70 cases 208 core) tissue microarray		456-Eur	US Biomax	tissue
ST208	Stomach cancer and normal tissue high density (70 cases 208 core) tissue microarray; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
ST2082	High-density stomach cancer tissue array with normal tissues, with stage and grade info, 104 cases 208 cores		456-Eur	US Biomax	tissue
ST2082	High-density stomach cancer tissue array with normal tissues, with stage and grade info, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
ST2083	Stomach cancer and normal stomach tissue array with stage and grade, 69 cases 208 cores		456-Eur	US Biomax	tissue

ST2083	Stomach cancer and normal stomach tissue array with stage and grade, 69 cases 208 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
ST2091	Stomach cancer tissue array with adjacent normal stomach tissue, including TNM and clinical stage, 208 cases 208 cores, replacing ST2001; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
ST2161	Stomach cancer tissue array, including TNM and pathology grade, 216 cases 216 cores		456-Eur	US Biomax	tissue
ST2161	Stomach cancer tissue array, including TNM and pathology grade, 216 cases 216 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
ST241	Stomach cancer test tissue array with self-matching normal adjacent tissues, 6 cases 24 cores		88-Eur	US Biomax	assays
ST241	Stomach cancer test tissue array with self-matching normal adjacent tissues, 6 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
ST242	Multiple stomach cancer tissue array with self-matching normal adjacent tissues, 10 cases 24 cores		88-Eur	US Biomax	tissue
ST242	Multiple stomach cancer tissue array with self-matching normal adjacent tissues, 10 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	tissue
ST481	Stomach cancer tissue array with corresponding (self-matching) normal adjacent tissues (12 cases 48 cores), with stage and grade info		160-Eur	US Biomax	tissue
ST481	Stomach cancer tissue array with corresponding (self-matching) normal adjacent tissues (12 cases 48 cores), with stage and grade info; ihc Anti-Actin confirmed		162-Eur	US Biomax	tissue
ST482	Multiple stomach cancer tissue array with 4 normal tissues control from autopsy (24 caeas 48 cores), with stage and grade info		160-Eur	US Biomax	tissue
ST482	Multiple stomach cancer tissue array with 4 normal tissues control from autopsy (24 caeas 48 cores), with stage and grade info; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
ST483	Multiple stomach cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores, with stage and grade info		160-Eur	US Biomax	tissue
ST483	Multiple stomach cancer tissue array with normal tissue control from autopsy, 48 cases 48 cores, with stage and grade info, replaced by ST483b; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
ST483a	Stomach cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases 48 cores, replacing ST483; ihc Anti-Actin confirmed		185-Eur	US Biomax	tissue

ST483b	Stomach cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases 48 cores, replacing ST483; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
ST484	Stomach cancer tissue array, including TNM and pathology grade, 48 cases 48 cores		189-Eur	US Biomax	tissue
ST484	Stomach cancer tissue array, including TNM and pathology grade, 48 cases 48 cores; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
ST485	Stomach cancer and matched adjacent tissue array, including TNM and pathology grade, 16 cases 48 cores		189-Eur	US Biomax	tissue
ST485	Stomach cancer and matched adjacent tissue array, including TNM and pathology grade, 16 cases 48 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ST721	Stomach adenocarcinoma and normal tissue array with TNM and pathology grade data, 24 cases 72 cores, replacing BC01011		231-Eur	US Biomax	tissue
ST721	Stomach adenocarcinoma and normal tissue array with TNM and pathology grade data, 24 cases 72 cores, replacing BC01011; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ST722	Stomach adenocarcinoma with self-matched adjacent and normal tissue array, with stage and grade info, 24 cases 72 cores		231-Eur	US Biomax	tissue
ST722	Stomach adenocarcinoma with self-matched adjacent and normal tissue array, with stage and grade info, 24 cases 72 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ST723	Stomach poorly differentiated adenocarcinoma tissue array with adjacent normal control, stage and grade info, 24 cases 72 cores, replacing BS01042		231-Eur	US Biomax	tissue
ST723	Stomach poorly differentiated adenocarcinoma tissue array with adjacent normal control, stage and grade info, 24 cases 72 cores, replacing BS01042; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
ST781	Stomach adenocarcinoma (grade I-III) tissue array with self-matched adjacent and normal tissues, 26 cases 78 cores		231-Eur	US Biomax	tissue
ST781	Stomach adenocarcinoma (grade I-III) tissue array with self-matched adjacent and normal tissues, 26 cases 78 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
ST801	Stomach cancer tissue array, with matched adjacent normal tissue, 40 cases 80 cores		231-Eur	US Biomax	tissue

ST801	Stomach cancer tissue array, with matched adjacent normal tissue, 40 cases 80 cores, replaced by ST801a; ihc Anti-Cytokeratin (High MW) confirmed		267-Eur	US Biomax	tissue
ST8011	Gastric cardia disease spectrum (cardia cancer progression) tissue array, 80 cases 80 cores		266-Eur	US Biomax	tissue
ST8011	Gastric cardia disease spectrum (cardia cancer progression) tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ST8012	Stomach adenocarcinoma and normal tissue array, with stage and grade information, 40 cases 80 cores		231-Eur	US Biomax	tissue
ST8012	Stomach adenocarcinoma and normal tissue array, with stage and grade information, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ST8013	Stomach cancer metastatic tissue array, 40 cases 80 cores		231-Eur	US Biomax	tissue
ST8013	Stomach cancer metastatic tissue array, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ST8014	Stomach cancer and normal tissue array, with stage and grade info, 80 cases 80 cores		231-Eur	US Biomax	tissue
ST8014	Stomach cancer and normal tissue array, with stage and grade info, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ST8015	Stomach cancer and adjacent normal tissue array, including TNM and pathology grade, 80 cases 80 cores		231-Eur	US Biomax	tissue
ST8015	Stomach cancer and adjacent normal tissue array, including TNM and pathology grade, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ST801a	Stomach cancer tissue array with matched adjacent normal stomach tissue, including TNM and clinical stage, 40 cases 80 cores, replacing ST801; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
ST802	Stomach carcinoma (multi-tissue combined panel) tissue array, 78 cases 80 cores		231-Eur	US Biomax	tissue
ST802	Stomach carcinoma (multi-tissue combined panel) tissue array, 78 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
ST803	Stomach adenocarcinoma tissue array, in various type, 40 cases 80 cores		231-Eur	US Biomax	tissue
ST803	Stomach adenocarcinoma tissue array, in various type, 40 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
ST804	Stomach adenocarcinoma tissue array, mucous type, 40 cases 80 cores		231-Eur	US Biomax	tissue

ST804	Stomach adenocarcinoma tissue array, mucous type, 40 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
ST805	Stomach cancer progression tissue array (containing normal, inflammation, hyperplasia and adenocarcinoma), 80 cases 80 cores		231-Eur	US Biomax	tissue
ST805	Stomach cancer progression tissue array (containing normal, inflammation, hyperplasia and adenocarcinoma), 80 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
ST806	Gastritis, stomach hyperplasia and dysplasia, 80 cases 80 cores		231-Eur	US Biomax	
ST806	Gastritis, stomach hyperplasia and dysplasia, 80 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	rat
ST807	Stomach carcinoma (multi-tissue combined panel) tissue array (replacing BC01014), 80 cases 80 cores		231-Eur	US Biomax	tissue
ST807	Stomach carcinoma (multi-tissue combined panel) tissue array (replacing BC01014), 80 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
ST808	Stomach adenocarcinoma and normal tissue array, 80 cases 80 cores, replacing BS01032		231-Eur	US Biomax	tissue
ST808	Stomach adenocarcinoma and normal tissue array, 80 cases 80 cores, replacing BS01032; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ST810	Stomach cancer with matched lymph node metastasis tissue array, 40 cases 80 cores		231-Eur	US Biomax	tissue
ST810	Stomach cancer with matched lymph node metastasis tissue array, 40 cases 80 cores; ihc Anti-Cytokeratin (Low-MW) confirmed		228-Eur	US Biomax	tissue
ST811	Stomach cancer tissue array with normal tissues from autopsy, 80 cases 80 cores, with grade and stage data		231-Eur	US Biomax	tissue
ST811	Stomach cancer tissue array with normal tissues from autopsy, 80 cases 80 cores, with grade and stage data; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ST812	Stomach cancer tissue array with normal tissues from autopsy, with clinical stage (TNM) and pathology grade info, 40 cases 80 cores		231-Eur	US Biomax	tissue
ST812	Stomach cancer tissue array with normal tissues from autopsy, with clinical stage (TNM) and pathology grade info, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
ST961	Stomach adenocarcinoma tissue array, including TNM and pathology grade, 48 cases 96 cores		321-Eur	US Biomax	elisa
ST961	Stomach adenocarcinoma tissue array, including TNM and pathology grade, 48 cases 96 cores		266-Eur	US Biomax	elisa

ST961	Stomach adenocarcinoma tissue array, including TNM and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	elisa
ST962	Stomach cancer tissue array, including clinical stage, TNM and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		228-Eur	US Biomax	elisa
ST991	Stomach adenocarcinoma (combination of margin and normal tissue) tissue array, 33 cases 99 cores		231-Eur	US Biomax	tissue
ST991	Stomach adenocarcinoma (combination of margin and normal tissue) tissue array, 33 cases 99 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
STC1021	Stomach cancer tissue array with normal and gastritis tissue control, having grade and stage info, 102 cases 102 cores		225-Eur	US Biomax	tissue
STC1021	Stomach cancer tissue array with normal and gastritis tissue control, having grade and stage info, 102 cases 102 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	tissue
STC1501	Stomach cancer mid-density tissue array, non-overlapping with STC1502 or STC1503, 75 cases 150 cores		225-Eur	US Biomax	tissue
STC1501	Stomach cancer mid-density tissue array, non-overlapping with STC1502 or STC1503, 75 cases 150 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	tissue
STC1502	Human stomach cancer mid-density tissue array, non-overlapping with STC1501 or STC1503, 75 cases 150 cores		225-Eur	US Biomax	tissue
STC1502	Human stomach cancer mid-density tissue array, non-overlapping with STC1501 or STC1503, 75 cases 150 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	tissue
STC1503	Stomach cancer mid-density tissue array, non-overlapping with STC1501 or STC1502, 75 cases 150 cores		225-Eur	US Biomax	tissue
STC1503	Stomach cancer mid-density tissue array, non-overlapping with STC1501 or STC1502, 75 cases 150 cores; ihc H&E, IHC anti-Vimentin Cytokeratin		238-Eur	US Biomax	tissue
STC2281	Stomach cancer high density tissue array, 228 cases 228 cores		----Eur	US Biomax	tissue
STC481	Stomach cancer and normal tissue array, 16 cases 48 cores		166-Eur	US Biomax	tissue
STC481	Stomach cancer and normal tissue array, 16 cases 48 cores; ihc H&E, IHC anti-Cytokeratin		205-Eur	US Biomax	tissue
STC961	Stomach cancer and normal tissue array, non-overlapping with STC962, 48 cases 96 cores		189-Eur	US Biomax	elisa
STC961	Stomach cancer and normal tissue array, non-overlapping with STC962, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	elisa

STC962	Human stomach cancer and normal tissue array, non-overlapping with STC962, 48 cases 96 cores		189-Eur	US Biomax	elisa
STC962	Human stomach cancer and normal tissue array, non-overlapping with STC962, 48 cases 96 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	elisa
T001	Embryonal tumor test tissue array, with normal tissue as control, including TNM and clinical stage, 6 cases 24 cores		88-Eur	US Biomax	assays
T001	Embryonal tumor test tissue array, with normal tissue as control, including TNM and clinical stage, 6 cases 24 cores, replaced by T001a; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T0010	Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T0010	Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T0011	Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T0011	Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T0012	Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T0012	Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T0013	Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T0013	Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T0014	Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T0014	Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T001a	Embryonal tumor test tissue array, with normal tissue as control, including TNM and clinical stage, 6 cases 24 cores, replacing T001; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays

T002	Endocrine organ cancer test tissue array, with normal tissue as control, including TNM and clinical stage, 6 cases 24 cores		88-Eur	US Biomax	assays
T002	Endocrine organ cancer test tissue array, with normal tissue as control, including TNM and clinical stage, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T003	Multiple organ cancer and normal tissue array, including TNM and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	tissue
T003	Multiple organ cancer and normal tissue array, including TNM and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
T004	Multiple organ cancer and normal tissue array, including TNM and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	tissue
T004	Multiple organ cancer and normal tissue array, including TNM and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
T005	Multiple organ cancer and normal tissue array, including TNM and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	tissue
T005	Multiple organ cancer and normal tissue array, including TNM and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
T006	Multiple organ cancer and normal tissue array, including TNM and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	tissue
T006	Multiple organ cancer and normal tissue array, including TNM and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
T007	Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T007	Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T008	Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T008	Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T009	Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays

T009	Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T011	Stomach cancer test tissue array, with TNM and grade info, 6 cases 24 cores		88-Eur	US Biomax	assays
T011	Stomach cancer test tissue array, with TNM and grade info, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T012	Stomach cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores		88-Eur	US Biomax	assays
T012	Stomach cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T013	Stomach cancer test tissue array, with normal stomach tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T013	Stomach cancer test tissue array, with normal stomach tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T014	Stomach cancer test tissue array (4x (2x3)array), including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T021	Esophageal cancer tissue array, with normal tissues, TNM and grade info, 6 cases 24 cores		88-Eur	US Biomax	tissue
T021	Esophageal cancer tissue array, with normal tissues, TNM and grade info, 6 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		90-Eur	US Biomax	tissue
T022	Esophageal cancer test tissue array, with normal tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores		88-Eur	US Biomax	assays
T022	Esophageal cancer test tissue array, with normal tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
T023	Esophagus cancer test tissue array, with normal esophagus tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T023	Esophagus cancer test tissue array, with normal esophagus tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays

T024	Esophageal cancer test tissue array (4x (2x3)array), including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T031	Liver cancer test tissue array with normal liver tissues, with TNM, stage and grade info, 6 cases 24 cores		88-Eur	US Biomax	assays
T031	Liver cancer test tissue array with normal liver tissues, with TNM, stage and grade info, 6 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		90-Eur	US Biomax	assays
T032	Liver cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores		88-Eur	US Biomax	assays
T032	Liver cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replaced by T032a; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T032a	Liver tumor tissue array, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing T032; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
T033	Liver cancer test tissue array, with normal liver tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T033	Liver cancer test tissue array, with normal liver tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
T034	Liver cancer test tissue array (4x (2x3) array)???including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T041	Lung cancer test tissue array, with normal lung control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T041	Lung cancer test tissue array, with normal lung control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		90-Eur	US Biomax	assays
T042	Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replaced by T044		88-Eur	US Biomax	assays
T042	Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replaced by T044; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
T043	Lung cancer test tissue array, with normal lung tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays

T043	Lung cancer test tissue array, with normal lung tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
T044	Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replaced by T045		88-Eur	US Biomax	assays
T044	Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replaced by T045; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T045	Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replaced by T045b		88-Eur	US Biomax	assays
T045	Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replaced by T045c; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T045b	Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing T045		99-Eur	US Biomax	assays
T045b	Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing T045		88-Eur	US Biomax	assays
T045b	Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing T045; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T045c	Lung cancer test tissue array, with normal control tissue, including TNM and pathology grade, 12 cases 24 cores, replacing T045; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T046	Lung cancer test tissue array (4x (2x3)array)???including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T047	Non-small cell lung cancer test tissue array (4x (2x3)array)???including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T051	Colon cancer test tissue array, with normal colon tissues as control, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T051	Colon cancer test tissue array, with normal colon tissues as control, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		90-Eur	US Biomax	assays

T052	Colon cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases 24 cores		88-Eur	US Biomax	assays
T052	Colon cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
T053	Colon cancer test tissue array, with normal colon tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T053	Colon cancer test tissue array, with normal colon tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T054	Colon tumor test tissue array, with normal control tissue, including TNM and pathology grade, 12 cases 24 cores, replacing T052		88-Eur	US Biomax	assays
T054	Colon tumor test tissue array, with normal control tissue, including TNM and pathology grade, 12 cases 24 cores, replaced by T054a; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T054a	Colon cancer tissue array with normal colon tissue as control, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing T054; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
T055	Colon cancer test tissue array (4x (2x3) array)???including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T061	Rectal cancer test tissue array, with normal rectal control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	recombinant
T061	Rectal cancer test tissue array, with normal rectal control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	recombinant
T063	Rectum cancer test tissue array, with normal rectum tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	recombinant
T063	Rectum cancer test tissue array, with normal rectum tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	recombinant
T071	Kidney cancer test tissue array, with normal renal tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays

T071	Kidney cancer test tissue array, with normal renal tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T072	Kidney cancer test tissue array, with normal tissue, TNM, clinical stage and pathology grade, 12 cases 24 cores		88-Eur	US Biomax	assays
T072	Kidney cancer test tissue array, with normal tissue, TNM, clinical stage and pathology grade, 12 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T073	Kidney cancer test tissue array, with normal kidney tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T073	Kidney cancer test tissue array, with normal kidney tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T074	Kidney cancer test tissue array (4x (2x3)array), including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T081	Breast cancer test tissue array, with normal breast tissues as control, including TNM, clinical stage and pathology grade, 6 cases 24 cores, replaced by T085		88-Eur	US Biomax	assays
T081	Breast cancer test tissue array, with normal breast tissues as control, including TNM, clinical stage and pathology grade, 6 cases 24 cores, replaced by T085; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T082	Breast cancer test tissue array, with normal tissue as control, including TNM, stage and grade, 12 cases 24 cores, replaced by T084		88-Eur	US Biomax	assays
T082	Breast cancer test tissue array, with normal tissue as control, including TNM, stage and grade, 12 cases 24 cores, replaced by T084; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T083	Breast cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T083	Breast cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores, replaced by T087; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T084	Breast cancer test tissue array, with normal control tissue, with TNM, Grade and Stage, 12 cases 24 cores, replacing T082		88-Eur	US Biomax	assays

T084	Breast cancer test tissue array, with normal control tissue, with TNM, Grade and Stage, 12 cases 24 cores, replaced by T086a; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T085	Breast cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 6 cases 24 cores, replaced by T088		88-Eur	US Biomax	assays
T085	Breast cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 6 cases 24 cores, replaced by T088; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T086	Breast cancer test tissue array, with normal tissue, including TNM and pathology grade, 12 cases 24 cores, replacing T084		88-Eur	US Biomax	assays
T086	Breast cancer test tissue array, with normal tissue, including TNM and pathology grade, 12 cases 24 cores, replacing T084, replaced by T086a; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T086a	Breast invasive ductal carcinoma test tissue array, with normal tissue, including TNM and pathology grade, 12 cases 24 cores, replaced by T086b; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T086b	Breast cancer test tissue array, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing T086a; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T087	Breast cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores, replaced by T087a; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T087a	Breast cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores, replacing T087; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T088	Breast cancer tissue array, with normal tissue as control, including TNM and pathology grade, 6 cases 24 cores, replacing T085		88-Eur	US Biomax	tissue
T088	Breast cancer tissue array, with normal tissue as control, including TNM and pathology grade, 6 cases 24 cores, replacing T085; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
T089	Breast cancer test tissue array (4x (2x3)array), including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T091	Endometrial cancer test tissue array, with normal endometriual tissue as control, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays

T091	Endometrial cancer test tissue array, with normal endometriual tissue as control, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T092	Endometrium cancer test tissue array, with normal tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores		88-Eur	US Biomax	assays
T092	Endometrium cancer test tissue array, with normal tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T093	Uterus cancer test tissue array, with normal endometrial tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T093	Uterus cancer test tissue array, with normal endometrial tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T095	Endometrium cancer test tissue array (4x (2x3)array), including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T101	Cervix cancer test tissue array, with normal cervix control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T101	Cervix cancer test tissue array, with normal cervix control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T102	Cervix cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases 24 cores		88-Eur	US Biomax	assays
T102	Cervix cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T103	Cervical cancer test tissue array, with normal tissue as control, including TNM and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T103	Cervical cancer test tissue array, with normal tissue as control, including TNM and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T104	Cervical cancer tissue array, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue

T111	Ovary cancer test tissue array, with normal ovary control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T111	Ovary cancer test tissue array, with normal ovary control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T112	Ovary cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores		88-Eur	US Biomax	assays
T112	Ovary cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replaced by T112a; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T112a	Ovary cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing T112; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T113	Ovarian cancer test tissue array, with normal ovary tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T113	Ovarian cancer test tissue array, with normal ovary tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T113a	Ovary cancer test tissue array with normal ovary tissue, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores, replacing T113; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T114	Ovary cancer tissue array, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
T121	Bladder cancer test tissue array, with normal bladder tissue as control, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T121	Bladder cancer test tissue array, with normal bladder tissue as control, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T122	Bladder cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases 24 cores		88-Eur	US Biomax	assays
T122	Bladder cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replaced by T124; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays

T123	Bladder cancer test tissue array, with normal bladder tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T123	Bladder cancer test tissue array, with normal bladder tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T124	Bladder cancer test tissue array, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing T122; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T125	Bladder cancer tissue array, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
T141	Pancreatic cancer test tissue array, with normal pancreas control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T141	Pancreatic cancer test tissue array, with normal pancreas control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores, replaced by T141a; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T141a	Pancreas cancer test tissue array, including TNM and pathology grade, 6 cases 24 cores, replacing T141; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T142	Pancreatic cancer test tissue array, with normal tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores		88-Eur	US Biomax	assays
T142	Pancreatic cancer test tissue array, with normal tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replaced by T142a; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T142a	Pancreas tumor test tissue array, including TNM and pathology grade, 12 cases 24 cores, replacing T142; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T143	Pancreatic cancer test tissue array, with normal pancreatic tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T143	Pancreatic cancer test tissue array, with normal pancreatic tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T144	Pancreas cancer tissue array, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue

T151	Thyroid cancer test tissue array, with normal thyroid control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T151	Thyroid cancer test tissue array, with normal thyroid control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T153	Thyroid cancer test tissue array, with normal thyroid gland tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T153	Thyroid cancer test tissue array, with normal thyroid gland tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T161	Nasopharyngeal and laryngeal cancer test tissue array, 6 cases 24 cores		88-Eur	US Biomax	assays
T161	Nasopharyngeal and laryngeal cancer test tissue array, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T163	Nose, pharyngeal and laryngeal cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T163	Nose, pharyngeal and laryngeal cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T171	Brain glioma test tissue array, with normal brain tissues as control, including pathology grade, 6 cases 24 cores, replaced by T174		88-Eur	US Biomax	assays
T171	Brain glioma test tissue array, with normal brain tissues as control, including pathology grade, 6 cases 24 cores, replaced by T174a; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T172	Brain cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases 24 cores		88-Eur	US Biomax	assays
T172	Brain cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replaced by T175; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T173	Brain cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays

T173	Brain cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores, replaced by T173a; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T173a	Brain cancer test tissue array, with normal tissue as control, including TNM and pathology grade, 2 serial sections, 6 cases 24 cores, replacing T173; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T174	Brain tumor test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores, replacing T171		88-Eur	US Biomax	assays
T174	Brain tumor test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores, replacing T171; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T174a	Brain tumor tissue array with normal brain tissue as control, including pathology grade, 6 cases 24 cores, replacing T171; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
T175	Brain tumor tissue array with normal brain tissue as control, including pathology grade, 12 cases 24 cores, replacing T172; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
T176	Brain tumor tissue array, including pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
T191	Prostate cancer test tissue array, with normal prostate control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T191	Prostate cancer test tissue array, with normal prostate control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T192	Prostate cancer test tissue array, with normal control tissue, including TNM, clinical stage, pathology grade, gleason grade and gleason score, 12 cases 24 cores, replaced by T195		88-Eur	US Biomax	assays
T192	Prostate cancer test tissue array, with normal control tissue, including TNM, clinical stage, pathology grade, gleason grade and gleason score, 12 cases 24 cores, replaced by T195; ihc Anti-Actin con		105-Eur	US Biomax	assays
T193	Prostate cancer test tissue array, with normal prostate tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T193	Prostate cancer test tissue array, with normal prostate tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays

T194	Prostate cancer test tissue array, with normal control tissue, including TNM and pathology grade, 12 cases 24 cores, replaced by T195		88-Eur	US Biomax	assays
T194	Prostate cancer test tissue array, with normal control tissue, including TNM and pathology grade, 12 cases 24 cores, replaced by T195; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T195	Prostate adenocarcinoma tissue array, including TNM and pathology grade, 12 cases 24 cores, 2 serial sections, replacing T192		113-Eur	US Biomax	tissue
T195	Prostate adenocarcinoma tissue array, including TNM and pathology grade, 12 cases 24 cores, 2 serial sections, replacing T192		100-Eur	US Biomax	tissue
T195	Prostate adenocarcinoma tissue array, including TNM and pathology grade, 12 cases 24 cores, 2 serial sections, replaced by T195a; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
T195a	Prostate cancer test tissue array, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing T195; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T196	Prostate cancer test tissue array (4x (2x3) array)???including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T201	Lymphoma test tissue array, with normal lymph node control tissues, 6 cases 24 cores		88-Eur	US Biomax	assays
T201	Lymphoma test tissue array, with normal lymph node control tissues, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T203	Lymphatic tissue tumor test tissue array, with normal tissue, 12 cases 24 cores		88-Eur	US Biomax	assays
T203	Lymphatic tissue tumor test tissue array, with normal tissue, 12 cases 24 cores, replaced by T203a; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T203a	Lymphatic tissue tumor test tissue array, with normal control tissue, 12 cases 24 cores, replacing T203; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T204	Lymphoma test tissue array, with normal tissue as control, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T204	Lymphoma test tissue array, with normal tissue as control, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T205	Lymphoma tissue array, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
T211	Skin cancer test tissue array, with normal skin control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays

T211	Skin cancer test tissue array, with normal skin control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T212	Skin cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases 24 cores		88-Eur	US Biomax	assays
T212	Skin cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replaced by T212a; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T212a	Skin tumor tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases 24 cores, replacing T212; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
T213	Skin cancer test tissue array, with normal tissue as control, including TNM and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T213	Skin cancer test tissue array, with normal tissue as control, including TNM and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T214	Skin tumor tissue array, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
T221	Penis cancer test tissue array, with normal penis control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T221	Penis cancer test tissue array, with normal penis control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T223	Penis cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T223	Penis cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T231	Testis cancer test tissue array, with normal testis control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T231	Testis cancer test tissue array, with normal testis control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores, replaced by T231a; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays

T231a	Testis tumor tissue array with normal tissue as control, including TNM and clinical stage, 6 cases 24 cores, replacing T231; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T233	Testis cancer test tissue array, with normal tissue as control, including TNM and clinical stage, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T233	Testis cancer test tissue array, with normal tissue as control, including TNM and clinical stage, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T241	Soft tissue cancer test tissue array, with normal soft tissue control tissue, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T241	Soft tissue cancer test tissue array, with normal soft tissue control tissue, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T242	Soft tissue cancer test tissue array, with normal tissue, including TNM and clinical stage, 12 cases 24 cores		88-Eur	US Biomax	assays
T242	Soft tissue cancer test tissue array, with normal tissue, including TNM and clinical stage, 12 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T243	Soft tissue tumor test tissue array, with normal tissue as control, including TNM and clinical stage, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T243	Soft tissue tumor test tissue array, with normal tissue as control, including TNM and clinical stage, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T244	Soft tissue malignant tumor tissue array, including TNM and clinical stage, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
T261	Bone and cartilage cancer test tissue array, with normal bone and cartilage tissue as control, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T261	Bone and cartilage cancer test tissue array, with normal bone and cartilage tissue as control, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T262	Bone cancer test tissue array, with normal control tissue, including TNM and clinical stage, 12 cases 24 cores		88-Eur	US Biomax	assays

T262	Bone cancer test tissue array, with normal control tissue, including TNM and clinical stage, 12 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T263	Bone and cartilage tumor tissue array, with normal tissue, including TNM, 6 cases 24 cores		88-Eur	US Biomax	tissue
T263	Bone and cartilage tumor tissue array, with normal tissue, including TNM, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
T271	Oral cavity tumor test tissue array, with normal oral cavity control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T271	Oral cavity tumor test tissue array, with normal oral cavity control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T273	Oral cavity cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T273	Oral cavity cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T291	Multiple myeloma test tissue array, with normal bone marrow tissue as control, 6 cases 24 cores		100-Eur	US Biomax	assays
T291	Multiple myeloma test tissue array, with normal bone marrow tissue as control, 6 cases 24 cores, replaced by T291a; ihc Anti-Actin confirmed		114-Eur	US Biomax	assays
T291a	Myeloma tissue array with normal tissue as control, 6 cases 24 cores, replacing T291; ihc Anti-actin		114-Eur	US Biomax	tissue
T293	Bone marrow tumor and normal tissue array, including TNM, 6 cases 24 cores		100-Eur	US Biomax	tissue
T293	Bone marrow tumor and normal tissue array, including TNM, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
T301	Heart tumor test tissue array, with normal heart tissue, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T301	Heart tumor test tissue array, with normal heart tissue, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T303	Heart tumor test tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays

T303	Heart tumor test tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T321	Spleen tumor test tissue array, with normal spleen control tissue, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T321	Spleen tumor test tissue array, with normal spleen control tissue, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T323	Spleen tumor tissue array, with normal tissue, including TNM, 6 cases 24 cores		88-Eur	US Biomax	tissue
T323	Spleen tumor tissue array, with normal tissue, including TNM, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
T342	Head & Neck cancer test tissue array, with normal tongue and epiglottis control tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores		88-Eur	US Biomax	assays
T342	Head & Neck cancer test tissue array, with normal tongue and epiglottis control tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
T343	Head & Neck cancer tissue array, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
T381	Malignant melanoma test tissue array, with normal skin control tissue, including TNM and clinical stage, 6 cases 24 cores, replaced by T385		88-Eur	US Biomax	assays
T381	Malignant melanoma test tissue array, with normal skin control tissue, including TNM and clinical stage, 6 cases 24 cores, replaced by T385; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T382	Malignant melanoma test tissue array, with normal skin control tissue, including TNM and clinical stage, 12 cases 24 cores		88-Eur	US Biomax	assays
T382	Malignant melanoma test tissue array, with normal skin control tissue, including TNM and clinical stage, 12 cases 24 cores; ihc Anti-HMB45 confirmed		105-Eur	US Biomax	assays
T383	Malignant melanoma test tissue array, with normal skin tissue, including TNM and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays

T383	Malignant melanoma test tissue array, with normal skin tissue, including TNM and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T385	Malignant melanoma test tissue array, with normal skin tissue as control, including TNM and clinical stage, 6 cases 24 cores, replaced by T386		88-Eur	US Biomax	assays
T385	Malignant melanoma test tissue array, with normal skin tissue as control, including TNM and clinical stage, 6 cases 24 cores, replaced by T385a; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T385a	Malignant melanoma test tissue array, including TNM and clinical stage, 6 cases 24 cores, replacing T385; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T386	Malignant melanoma test tissue array, with normal skin tissue, including TNM and clinical stage, 6 cases 24 cores, replacing T385		88-Eur	US Biomax	assays
T386	Malignant melanoma test tissue array, with normal skin tissue, including TNM and clinical stage, 6 cases 24 cores, replacing T385; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T388	Malignant melanoma test tissue array (4x (2x3)array), including TNM and clinical stage, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T391	Mesothelioma test tissue array, with normal mesothelium tissue as control, including TNM and clinical stage, 6 cases 24 cores, replaced by T392		88-Eur	US Biomax	assays
T391	Mesothelioma test tissue array, with normal mesothelium tissue as control, including TNM and clinical stage, 6 cases 24 cores, replaced by T392; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T392	Mesothelioma test tissue array, with normal mesothelial control tissue, including TNM and clinical stage, 6 cases 24 cores, replacing T391		88-Eur	US Biomax	assays
T392	Mesothelioma test tissue array, with normal mesothelial control tissue, including TNM and clinical stage, 6 cases 24 cores, replacing T391; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T413	Appendix cancer test tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T413	Appendix cancer test tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T421	Small intestine cancer test tissue array, with normal small intestine tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays

T421	Small intestine cancer test tissue array, with normal small intestine tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T423	Small intestine cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T423	Small intestine cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	assays
T433	Adrenal gland cancer test tissue array, with normal tissue, 2 serial sections, 6 cases 24 cores		88-Eur	US Biomax	assays
T433	Adrenal gland cancer test tissue array, with normal tissue, 2 serial sections, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
T461	Thymus cancer test tissue array, with normal control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores		88-Eur	US Biomax	assays
T461	Thymus cancer test tissue array, with normal control tissues, including TNM, clinical stage and pathology grade, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
TE2081	Testis disease spectrum (testicular cancer progression) tissue array, with TNM data, 104 cases 208 cores		456-Eur	US Biomax	assays
TE2081	Testis disease spectrum (testicular cancer progression) tissue array, with TNM data, 104 cases 208 cores; ihc Anti-Actin confirmed		429-Eur	US Biomax	assays
TE241	Testis cancer tissue array with unmatched normal adjacent tissues, 12 cases 24 cores		88-Eur	US Biomax	assays
TE241	Testis cancer tissue array with unmatched normal adjacent tissues, 12 cases 24 cores; ihc Anti-leukocyte common antigen confirmed		105-Eur	US Biomax	assays
TE242	Testis cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 12 cases 24 cores, replacing TE241		88-Eur	US Biomax	assays
TE242	Testis cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 12 cases 24 cores, replacing TE241; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
TE481	Testis cancer tissue array with unmatched normal adjacent tissues, 48 cases 48 cores, with stage data		160-Eur	US Biomax	assays
TE481	Testis cancer tissue array with unmatched normal adjacent tissues, 48 cases 48 cores, with stage data; ihc Anti-Actin confirmed		210-Eur	US Biomax	assays
TE482	Testis tumor tissue array, including TNM, 24 cases 48 cores		225-Eur	US Biomax	assays

TE482	Testis tumor tissue array, including TNM, 24 cases 48 cores		189-Eur	US Biomax	assays
TE482	Testis tumor tissue array, including TNM, 24 cases 48 cores; ihc Anti-Actin confirmed		185-Eur	US Biomax	assays
TE802	Testis seminoma and lymphoma tissue array, 80 cases 80 cores		266-Eur	US Biomax	assays
TE802	Testis seminoma and lymphoma tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	assays
TE803	Testis disease spectrum (testicular cancer progression) tissue array, 80 cases 80 cores		266-Eur	US Biomax	assays
TE803	Testis disease spectrum (testicular cancer progression) tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	assays
TET481	Human testis cancer tissue array, 24 cases 48 cores		225-Eur	US Biomax	assays
TET481	Human testis cancer tissue array, 24 cases 48 cores; ihc H&E, IHC anti- Cytokeratin		238-Eur	US Biomax	assays
TH208	Thyroid cancer tissue microarray with normal tissue control, high density (60 cases 208 cores), with clinical stage data		456-Eur	US Biomax	tissue
TH208	Thyroid cancer tissue microarray with normal tissue control, high density (60 cases 208 cores), with clinical stage data; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
TH241	Thyroid cancer tissue array with self-matching normal adjacent tissues, 10 cases 24 cores		88-Eur	US Biomax	tissue
TH241	Thyroid cancer tissue array with self-matching normal adjacent tissues, 10 cases 24 cores; ihc Anti-Thyroglobulin (TG) antibody confirmed		105-Eur	US Biomax	tissue
TH242	Thyroid cancer tissue array with matched adjacent thyroid tissue, including TNM and clinical stage, 12 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
TH481	Thyroid cancer tissue array with unmatched normal adjacent tissues, 48 cases 48 cores, with grade and stage info		160-Eur	US Biomax	tissue
TH481	Thyroid cancer tissue array with unmatched normal adjacent tissues, 48 cases 48 cores, with grade and stage info; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
TH721	Thyroid cancer and normal tissue array with clinical stage and grade info, 24 cases 72 cores		266-Eur	US Biomax	tissue
TH721	Thyroid cancer and normal tissue array with clinical stage and grade info, 24 cases 72 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
TH801	Thyroid cancer tissue array, with matched or unmatched adjacent normal tissue, 68 cases 80 cores, no overlaps with TH802		231-Eur	US Biomax	tissue

TH801	Thyroid cancer tissue array, with matched or unmatched adjacent normal tissue, 68 cases 80 cores, no overlaps with TH802; ihc Anti-Thyroglobulin (TG) antibody confirmed		267-Eur	US Biomax	tissue
TH8010	Thyroid cancer and normal tissue array, with stage and grade info, 80 cases 80 cores		266-Eur	US Biomax	tissue
TH8010	Thyroid cancer and normal tissue array, with stage and grade info, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
TH802	Thyroid cancer and adenoma tissue array, 80 cases 80 cores, no overlaps with TH801		231-Eur	US Biomax	tissue
TH802	Thyroid cancer and adenoma tissue array, 80 cases 80 cores, no overlaps with TH801, replaced by TH802a; ihc Anti-Thyroglobulin (TG) confirmed		267-Eur	US Biomax	tissue
TH802a	Thyroid cancer and adenoma tissue array, including TNM and clinical stage, 80 cases 80 cores, replacing TH802; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
TH803	Thyroid papillary cancer tissue array, 80 cases 80 cores		231-Eur	US Biomax	tissue
TH803	Thyroid papillary cancer tissue array, 80 cases 80 cores; ihc Anti-Thyroglobulin (Tg) confirmed		267-Eur	US Biomax	tissue
TH804	Normal thyroid gland tissue array, 80 cases 80 cores		266-Eur	US Biomax	tissue
TH804	Normal thyroid gland tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
TH805	Goiter and thyroiditis tissue array, 80 cases 80 cores		231-Eur	US Biomax	tissue
TH805	Goiter and thyroiditis tissue array, 80 cases 80 cores; ihc Anti-Cytokeratin (CK) confirmed		267-Eur	US Biomax	tissue
TH806	Thyroid medullary cancer tissue array and normal tissues, 40 cases 80 cores, with grade and stage data		266-Eur	US Biomax	tissue
TH806	Thyroid medullary cancer tissue array and normal tissues, 40 cases 80 cores, with grade and stage data; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
TH807	Thyroid disease spectrum tissue array, 75 cases 80 cores		266-Eur	US Biomax	tissue
TH807	Thyroid disease spectrum tissue array, 75 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
TH808	Thyroid cancer and normal tissue array, with grade and stage data, 40 cases 80 cores		266-Eur	US Biomax	tissue
TH808	Thyroid cancer and normal tissue array, with grade and stage data, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
TH809	Thyroid cancer metastasis tissue array, 40 cases 80 cores		266-Eur	US Biomax	tissue

TH809	Thyroid cancer metastasis tissue array, 40 cases 80 cores, replaced by TH809a; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
TH809a	Thyroid metastatic carcinoma tissue array with normal thyroid tissue as control, 40 cases 80 cores, replacing TH809; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
THC241	Thyroid cancer array, 12 cases 24 cores		189-Eur	US Biomax	
THC241	Thyroid cancer array, 12 cases 24 cores; ihc H&E, IHC Cytokeratin		205-Eur	US Biomax	rat
THC961	Thyroid cancer tissue array, 48 cases 96 cores		225-Eur	US Biomax	elisa
THC961	Thyroid cancer tissue array, 48 cases 96 cores; ihc H&E, IHC anti-Cytokeratin		238-Eur	US Biomax	elisa
THD181	Thyroid disease tissue array, 18 cases 18 cores		142-Eur	US Biomax	tissue
THD181	Multiple organ, normal fetus tissue array, 50 cases 50 cores; ihc Anti-Actin confirmed		138-Eur	US Biomax	tissue
THY761	Thymus disease spectrum (thymic cancer progression) tissue array, 76 cases 76 cores		266-Eur	US Biomax	tissue
THY761	Thymus disease spectrum (thymic cancer progression) tissue array, 76 cases 76 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
TMA2001	Multiple organ cancer with normal tissue array, with TNM data, 180 cases 200 cores		397-Eur	US Biomax	tissue
TMA2001	Multiple organ cancer with normal tissue array, with TNM data, 180 cases 200 cores; ihc Anti-Actin confirmed		382-Eur	US Biomax	tissue
TMA2081	High density (156 cases 208 cores) tissue array of normal colon, prostate and breast tissue		456-Eur	US Biomax	tissue
TMA2081	High density (156 cases 208 cores) tissue array of normal colon, prostate and breast tissue; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
TMA2401	High density multiple organ (top 4) cancer tissue array (240 cores)		456-Eur	US Biomax	tissue
TMA2401	High density multiple organ (top 4) cancer tissue array (240 cores); ihc Anti-Actin confirmed		429-Eur	US Biomax	tissue
TOP4-240	High density tissue array of top 4 types of cancers with normal tissue control, 220 cases 240 cores		456-Eur	US Biomax	tissue
TOP4-240	High density tissue array of top 4 types of cancers with normal tissue control, 220 cases 240 cores; ihc Anti-Actin confirmed		487-Eur	US Biomax	tissue
TP241	Top 4 types of cancer (colon, breast, lung and prostate) tissue array, including TNM and pathology grade, 12 cases 24 cores		99-Eur	US Biomax	tissue
TP241	Top 4 types of cancer (colon, breast, lung and prostate) tissue array, including TNM and pathology grade, 12 cases 24 cores		88-Eur	US Biomax	tissue

TP241	Top 4 types of cancer (colon, breast, lung and prostate) tissue array, including TNM and pathology grade, 12 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
TP242	Top 4 types of cancer (colon, breast, prostate and lung) 24 core test tissue array, 24 cases 24 cores		88-Eur	US Biomax	assays
TP242	Top 4 types of cancer (colon, breast, prostate and lung) 24 core test tissue array, 24 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	assays
TP481	Top 4 types of cancer (colon, breast, prostate and lung) 48 core tissue array, 48 cases 48 cores		160-Eur	US Biomax	tissue
TP481	Top 4 types of cancer (colon, breast, prostate and lung) 48 core tissue array, 48 cases 48 cores; ihc Anti-Cytokeratin (CK) confirmed		185-Eur	US Biomax	tissue
TP482	Top 4 types of cancer (colon, breast, lung and prostate) tissue microarray, 22 cases 48 cores, plus grade, stage and Gleason Score information		160-Eur	US Biomax	tissue
TP482	Top 4 types of cancer (colon, breast, lung and prostate) tissue microarray, 22 cases 48 cores, plus grade, stage and Gleason Score information; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
TP483	Top 4 types of cancer (colon, breast, prostate and lung) tissue microarray, 48 case 48 cores, with grade, Gleason score and stage data		160-Eur	US Biomax	tissue
TP483	Top 4 types of cancer (colon, breast, prostate and lung) tissue microarray, 48 case 48 cores, with grade, Gleason score and stage data; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
TP484	Tissue microarray of top 4 types of cancer (colon, breast, prostate and lung) and normal tissue, 24 cases 48 cores		160-Eur	US Biomax	tissue
TP484	Tissue microarray of top 4 types of cancer (colon, breast, prostate and lung) and normal tissue, 24 cases 48 cores; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
TR011	Rat normal stomach test tissue array, 6 cases 24 cores		88-Eur	US Biomax	assays
TR011	Rat normal stomach test tissue array, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
TR031	Rat normal liver test tissue array, 6 cases 24 cores		88-Eur	US Biomax	assays
TR031	Rat normal liver test tissue array, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
TR041	Rat normal lung test tissue array, 6 cases 24 cores		88-Eur	US Biomax	assays
TR041	Rat normal lung test tissue array, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
TR071	Rat normal kidney test tissue array, 6 cases 24 cores		88-Eur	US Biomax	assays

TR071	Rat normal kidney test tissue array, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
TR301	Rat normal heart test tissue array, 6 cases 24 cores		88-Eur	US Biomax	assays
TR301	Rat normal heart test tissue array, 6 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	assays
UGD381	Urinary genital system disease tissue array, 38 cases 38 cores		166-Eur	US Biomax	tissue
UGD381	Urinary genital system disease tissue array, 38 cases 38 cores; ihc H&E, IHC anti- Cytokeratin		178-Eur	US Biomax	tissue
UNC241	Universal control tissue array, used for screening of more than 90% routine IHC markers, 12 cases 24 cores		77-Eur	US Biomax	tissue
UNC241	Universal control tissue array, used for screening of more than 90% routine IHC markers, 12 cases 24 cores; ihc H&E, IHC anti-Vimentin Cytokeratin		85-Eur	US Biomax	tissue
UR1001	Ureter and urethra disease spectrum tissue array, with stage, grade and TNM data, 50 cases 100 cores		199-Eur	US Biomax	tissue
UR1001	Ureter and urethra disease spectrum tissue array, with stage, grade and TNM data, 50 cases 100 cores; ihc Anti-Actin confirmed		382-Eur	US Biomax	tissue
UT1001	Endometrial cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases 100 cores		266-Eur	US Biomax	tissue
UT1001	Endometrial cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
UT1002	Endometrium cancer tissue array for antibody screening, including TNM and pathology grade, 50 cases 100 cores		266-Eur	US Biomax	tissue
UT1002	Endometrium cancer tissue array for antibody screening, including TNM and pathology grade, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
UT1501	Uterus cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases 150 cores; ihc Anti-Actin confirmed		258-Eur	US Biomax	tissue
UT241	Uterine endometrial cancer tissue array with normal tissue from autopsy, 12 cases 24 cores, with TNM data		100-Eur	US Biomax	tissue
UT241	Uterine endometrial cancer tissue array with normal tissue from autopsy, 12 cases 24 cores, with TNM data; ihc Anti-Actin confirmed		114-Eur	US Biomax	tissue
UT242	Endometrium cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases 48 cores		189-Eur	US Biomax	tissue

UT242	Endometrium cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases 48 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
UT242a	Endometrium cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases 24 cores		100-Eur	US Biomax	tissue
UT242a	Endometrium cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases 24 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
UT243	Endometrium cancer tissue array with matched adjacent endometrium tissue, including TNM, clinical stage and pathology grade, 12 cases 24 cores; ihc Anti-Actin confirmed		90-Eur	US Biomax	tissue
UT481	Endometrium cancer tissue array, including TNM and pathology grade, 48 cases 48 cores		278-Eur	US Biomax	tissue
UT481	Endometrium cancer tissue array, including TNM and pathology grade, 48 cases 48 cores; ihc Anti-Actin confirmed		267-Eur	US Biomax	tissue
UT501	Endometrioid adenocarcinoma and normal tissue array with TNM and grade, 50 cases 50 cores		160-Eur	US Biomax	tissue
UT501	Endometrioid adenocarcinoma and normal tissue array with TNM and grade, 50 cases 50 cores; ihc Anti-Actin confirmed		210-Eur	US Biomax	tissue
UT721	Endometrioid adenocarcinoma and normal tissue array with clinical stage and grade information, 24 cases 72 cores		266-Eur	US Biomax	tissue
UT721	Endometrioid adenocarcinoma and normal tissue array with clinical stage and grade information, 24 cases 72 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
UT801	Endometrial disease spectrum (endometrial cancer progression) tissue array, 80 cases 80 cores		278-Eur	US Biomax	tissue
UT801	Endometrial disease spectrum (endometrial cancer progression) tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		382-Eur	US Biomax	tissue
UT802	Uteral cancer (multi-types of uterine carcinomas and diseases) tissue array, 80 cases 80 cores		278-Eur	US Biomax	tissue
UT802	Uteral cancer (multi-types of uterine carcinomas and diseases) tissue array, 80 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
UT803	Endometrioid carcinoma, adjacent and normal tissue array, with grade and stage information, 40 cases 80 cores		266-Eur	US Biomax	tissue
UT803	Endometrioid carcinoma, adjacent and normal tissue array, with grade and stage information, 40 cases 80 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue

UT961	Endometrium cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases 96 cores; ihc Anti-Actin confirmed		228-Eur	US Biomax	elisa
UTE601	Fallopian tube disease spectrum (fallopian tube cancer progression) tissue array, 30 cases 60 cores		266-Eur	US Biomax	tissue
UTE601	Fallopian tube disease spectrum (fallopian tube cancer progression) tissue array, 30 cases 60 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
UV1001	Vulval disease spectrum (vulva cancer progression) tissue array, 46 cases 100 cores		266-Eur	US Biomax	tissue
UV1001	Vulval disease spectrum (vulva cancer progression) tissue array, 46 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
UV241	Vulvar (vulva) cancer tissue array with unmatched normal adjacent tissues, 12 cases 24 cores		88-Eur	US Biomax	tissue
UV241	Vulvar (vulva) cancer tissue array with unmatched normal adjacent tissues, 12 cases 24 cores; ihc Anti-Cytokeratin (CK) confirmed		105-Eur	US Biomax	tissue
UV801	Vulva malignant tumor tissue array, 39 cases 78 cores		266-Eur	US Biomax	tissue
UV801	Vulva malignant tumor tissue array, 39 cases 78 cores; ihc Anti-Cytokeratin (CK) confirmed		258-Eur	US Biomax	tissue
VA1001	Vermiform appendix disease spectrum (vermiform appendix tumor progression) tissue array, 50 cases 100 cores		266-Eur	US Biomax	tissue
VA1001	Vermiform appendix disease spectrum (vermiform appendix tumor progression) tissue array, 50 cases 100 cores; ihc Anti-Actin confirmed		296-Eur	US Biomax	tissue
VLC11	Lung cancer tissue array, with TNM and grade info, 11 cases 11 cores		88-Eur	US Biomax	tissue
VLC11	Lung cancer tissue array, with TNM and grade info, 11 cases 11 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue
VLC12	Lung cancer tissue array, with TNM and grade info, 12 cases 12 cores		88-Eur	US Biomax	tissue
VLC12	Lung cancer tissue array, with TNM and grade info, 12 cases 12 cores; ihc Anti-Actin confirmed		105-Eur	US Biomax	tissue